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General introduction and study objectives
1. Introduction
The targeting of  drugs to the brain is a major problem in drug delivery
research. The tight construction of  the brain capillary endothelial cells
that form the blood-brain barrier (BBB), is the main obstacle that needs
to be overcome before drugs can enter the central nervous system (CNS).
Only small lipophilic compounds (M
w
 < 600 Da) and nutrients and
peptides which have a carrier-mediated transport system in the BBB can
be transported from the systemic circulation into the brain (108, 132). To
enhance the uptake into the CNS of  drugs that do not meet these crite-
ria, several strategies have been investigated to manipulate the barrier
function of  the brain capillary endothelial cells. However, there is still no
satisfactory method to target drugs across the BBB.
At the beginning of  the previous century the direct connection between
the brain and the open air was discovered: the olfactory neurons. Injec-
tion of  dyes in the ventricles of  rabbits and monkeys showed that the
cerebrospinal fluid (CSF) is drained via the olfactory neurones into the
lymphatic vessels and the nasal mucosa (80, 159). The olfactory neurons,
originating from the olfactory bulb, connect the brain with the nasal cav-
ity by penetrating the cribriform plate, which brings the neurons into the
nasal mucosa. This coined the idea that this transport route could also
exist in the opposite direction, which would imply direct access from the
nasal cavity to the brain, thus circumventing the BBB. This opened up a
new perspective in the research field of  drug targeting to the CNS. Since
the last decades extensive research has been performed on the feasibility
of  this nose-brain/CSF pathway for brain targeting of  drugs (78, 99). A
problem in these investigations is the fact that researchers have to deal
with delicate materials like brain tissue and/or CSF, which is difficult to
sample and very scarce in small laboratory animals like rats and mice.
This can affect the used study design, and therefore the interpretation of
the results. Several research groups have used different methods to study
drug transport via the nasal route to the CNS. These methods will be
compared and discussed. In order to get a better understanding of  this
possible transport route, first the nose and neuronal connection with the
brain and CSF will be described in more detail.
8
1 General introduction and study objectives
2. The nose
The inhaled air is warmed and humidified in the nasal cavities. The mu-
cus filters the air by clearing dust particles, bacteria and other inhaled
substances from the nasal cavity by the mucociliary clearance. Other na-
sal functions are vocalisation and olfaction.
The nasal cavity is split into two symmetrical halves by the nasal septum.
The structure of  each cavity is further determined by the shape of  three
turbinates: the inferior, middle and superior one. The two halves are sub-
divided in the vestibule, lined with skin-like epithelium, the respiratory
and the olfactory area (Figure 1).
2.1. The respiratory and olfactory epithelium
The respiratory epithelium, covering the main part of  the nasal cavity (~
160 cm2 in humans (142)), consists of four main cell types: ciliated and
non-ciliated columnar cells, goblet cells and basal cells (Figure 2). The
epithelial cell layer is covered with mucus, which is produced by the gob-
let cells and cleared by the beating of  the cilia, the so-called mucociliary
clearance. This clearance mechanism protects the respiratory tract in-
cluding the lungs from bacteria and other harmful exogenous compounds.
The respiratory mucus layer contains several isoforms of  the metabolis-
ing enzyme family P-450. The olfactory mucus layer has even a higher
capability to degrade xenobiotics than the respiratory one. However, be-
cause of  the high vascularisation of  the latter mucus layer nasally admin-
istered drugs are quickly absorbed and hardly metabolised by the en-
zymes. Secondly, the small amount of  specific cytochrome P-450 en-
zymes decreases the risk on degradation compared to other P-450 con-
taining organs like the liver (131).
The olfactory epithelium is located at the top of  the nose between the
superior turbinate and the roof  of  the nasal cavity and covers only 10 –
20 cm2 in humans. This is about 8 % of  the total nasal surface area,
whereas in rats the olfactory area comprises 50 % of  the nasal cavity (41).
The olfactory epithelium is build up by three main cells. The olfactory
receptor neurons (ORN) are bipolar cells connecting the olfactory bulb
with the nasal cavity. The axons of  the ORNs extend from the cell body




Figure 1 Anatomic representation of  the human nasal cavity; a olfactory area and super
conchae; b respiratory area comprising the middle (c) and inferior (d) conchae; e
vestibular region; f palate.
Figure 2 Schematic presentation of  the respiratory mucosa; a mucus layer; b cilia and
microvilli; c cilliated columnar cell; d goblet cell; e basal cell; f non-cilliated columnar















1 General introduction and study objectives
tory bulb and synaps with juxtaglomerular neurons and with tufted and
mitral cells in the glomeruli (139). The other end of  the ORN, a dendritic
knob containing several dendritic cilia, terminates in the olfactory epi-
thelium (Figure 3). The ORNs are located in between the supporting or
sustentacular cells. These are large columnar cells covered with microvilli
at the apical side (103). The functions of  these cells are unclear, but prob-
ably include the secretion of  mucus, insulation of  ORNs and guidance
of  developing basal cells (103). It is also suggested that the supporting
cells are a source of  xenobiotic-metabolising enzymes (68). Adjacent to
the basal lamina of  the olfactory epithelium a layer of  basal cells is lo-
cated, which is covered with a second layer of  these cells (104). The latter
one contains the so-called globose basal cells, which undergo continuous
mitotic activity and replace ORNs under normal conditions and follow-
ing injury (103). Other structures located in the olfactory mucosa are
Bowman’s glands and blood and lymphatic vessels (99).
2.2. Nasal transport routes
After nasal delivery, drugs will at first reach the respiratory epithelium,
from where compounds can be absorbed into the systemic circulation.
When a nasal drug formulation is delivered deep and high enough into
the nasal cavity, the olfactory area may be reached and drug transport via
the ORNs might occur. Two possible routes exist by which molecules
can be transported from the olfactory epithelium into the brain and/or
CSF. First the epithelial pathway, considered as a fast route (passage takes <
2 hours (10, 58)), where compounds pass paracellularly across the olfac-
tory epithelium into the perineural spaces, crossing the cribriform plate
and ending up in the subarachnoid space filled with CSF. Then the mol-
ecules can diffuse into the brain tissue or will be cleared by the CSF flow
into the lymphatic vessels and subsequently into the systemic circulation.
The second possibility is the olfactory nerve pathway, which is a very slow
route (passage takes > 1 day (10, 18, 138)). Compounds may be internal-
ised into the ORN and pass inside the neuron through the cribriform
plate into the olfactory bulb. From here further transport into the brain
can occur by bridging the synapses between the neurons. Once a drug is
in the brain, it can be further influenced by BBB efflux transporter sys-
tems like P-glycoprotein (67, 134). All possible transport routes after na-
sal drug administration are depicted in Figure 3 and 4.
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Figure 3 Schematic presentation of  the olfactory mucosa; a olfactory receptor neuron;
b supporting cell; c basal cell; d Bowman’s gland; e lymphatic capilaries; f fila olfactoria;
g Schwann’s cells; h perineural cells; i dura mater; j arachnoid mater; A olfactory mucosa;
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3. The neuronal connection
The ORN’s connect the nasal cavity with the brain and the CSF. For
years it is known that substances injected into the CSF or brain tissue are
transported into the nasal mucosa and lymphatic vessels (15, 30). This is
in agreement with the physiological CSF drain, which starts at the choroid
plexi where it is produced. From the ventricles inside the brain the CSF
flows towards the spinal cord and back into the subarachnoid space sur-
rounding the outer brain surface. Subsequently it is drained into the su-
perior sagittal sinus across the arachnoid granulations. The CSF is drained
away from the CNS by movement into blood vessels  within the sagittal
sinus and by flow into the deep cervical lymphatics (15). The drainage of
dyes and micro-organisms from the CSF and/or brain to the lymphatics
and nasal mucosa has already been reviewed by Yoffey (159) and Jackson
et al. (80), although the exact mechanism was still unknown to these au-
thors. This mechanism was further elucidated by Erlich et al. (49), who
injected ferritin into the lateral ventricle in rabbits and found that this
substance was transported by the CSF drain along the olfactory pathway
into the nasal mucosa. Microscopic studies showed that ferritin was trans-
ported from the ventricles into the nasal mucosa via an open pathway
between the subarachnoid space and the olfactory epithelium.
By nasal application of  several dyes, the transport route in the opposite
direction was demonstrated (6, 53, 154). This observation was supported
by experiments with viruses and metals (98, 112, 146, 149). However, the
entrance of  viruses and metals may cause toxic effects in the CNS, which
have to be avoided (17, 63, 70, 72, 97, 160).
Some studies describing the nose-CSF/brain transport of  dyes, viruses
and metals show that these compounds are directly transported from the
nasal cavity into the CSF and/or brain. However, for several other sub-
stances like small molecular weight drugs, peptides and high molecular
weight compounds there is not a consistent answer to this transport route.
As mentioned in the Introduction, the used experimental set-up and the
methodology of  data analysis can influence the interpretation of  the re-
sults obtained. Therefore, the different methodologies used in this re-
search area will be discussed below.
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4. How to study nose-to-CSF/brain drug transport?
First, the question of  possible direct drug transport from the nasal cavity
to the brain/CSF will be discussed by a theoretical approach keeping in
mind the possible transport routes of  a drug after nasal delivery as de-
picted in Figure 4. Subsequently, the experimental models published in
the literature will be described.
4.1. Theoretical study design
The actual question is whether a compound is transported from the nasal
cavity, via the systemic circulation into the brain and/or CSF after cross-
ing the respective blood-brain and blood-CSF barriers, or from the nasal
cavity via the olfactory neurons directly into the CSF and/or brain tissue.
Both routes have to be examined when investigating this transport phe-
nomenon. This implies that intranasal drug administration should be
compared with intravenous delivery. The actual route of  drug transport
can be determined by calculating the relative distribution of  a drug over















Figure 4 Schematic overview of  the in vivo fate of  drugs following nasal administration.





ratioplasmaCSF =/ Equation 1
The CSF/plasma ratio of  a compound is expressed by the area under the
CSF concentration-time curve (AUC
CSF
) divided by the area under the
plasma concentration-time curve (AUC
plasma
) following the same admin-
istration route (75, 153). The AUC value of  a drug, determined in plasma
or CSF, is a quantitative measure that reflects the complete uptake profile
of  the compound in the specified biocompartment. Therefore, it is pre-
ferred to relate AUC values rather than drug concentrations at specific
time points because such time points give limited information on the
total uptake profile. Instead of  AUC
CSF
, it is also possible to investigate
AUC
brain 
values. However, since the AUC values are more often calcu-
lated for CSF drug concentrations than for brain drug concentrations,
the term AUC
CSF
 is used in this Thesis.
In case of  direct drug transport from the nasal cavity, it is expected that
the CSF/plasma ratio following intranasal delivery will be significantly
higher than that after intravenous administration. When this ratio is equal
or lower than the intravenous one, the observed drug transport can be
considered as systemically and not via the ORNs.
Besides a pharmacokinetic analysis, nose-brain/CSF transport can also
be investigated on the level of  pharmacodynamics (56). However, it is
still necessary to monitor plasma levels when studying drug effects, be-
cause a larger change in pharmacodynamic effect can be due to higher
drug plasma levels and not necessarily to a direct drug uptake from the
nasal cavity into the CNS.  Because it is difficult to relate a pharmacody-
namic effect to plasma levels following different administration routes,
the drug plasma profile after nasal delivery should be mimicked by intra-
venous administration of  the same drug. In this way it is possible to
compare drug effects after nasal and intravenous administration without
relating them to the obtained plasma levels (119). When investigating
pharmacodynamics, a control treatment is generally included, as the change
in effect is the actual point of measurement.
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In conclusion: Using the pharmacokinetic approach the nasal route of
drug administration should be compared with intravenous delivery, if
possible resulting in similar plasma levels as following nasal administra-
tion. The drug distribution over CSF and plasma or brain tissue and plasma
can be expressed in terms of  CSF/plasma ratios based on the obtained
AUCs. Only when the CSF/plasma ratio after nasal delivery
 
significantly
exceeds the one after intravenous delivery, the drug transport route can
be considered as directly from the nasal cavity into the CSF and/or brain
tissue. In pharmacodynamic studies it is necessary to achieve similar drug
plasma levels after intranasal and intravenous administration, in order to
compare the pharmacological effect after different administration routes.
4.2. Study designs used in the literature
The investigation of  drug transport from the nasal cavity into the CSF or
brain requires animal experiments. Rats and mice are used most often in
such studies, although the anatomy of  the nasal cavity of  rodents is dif-
ferent from that in humans. Rats are widely used in nasal drug absorption
studies (77) and therefore it is obvious that this species is frequently used
for nose-brain transport studies as well. The advantage of  mice is that
Table I References of the used publications per research category 




9-13, 17, 18, 27-29, 32, 43-46, 48, 50, 51, 53, 55, 
58, 59, 61-64, 69-71, 76, 79, 81, 82, 86, 87, 89, 
91, 94, 98, 100, 102, 109, 111, 112, 115-117, 121, 
122, 135-138, 140, 143-145, 147, 148, 150, 151, 




Nose-CSF 1-5, 7, 8, 14, 23, 25, 31, 33, 34, 36, 73, 84, 90, 96, 
101, 107, 125-128, 133, 134, 153, 158  
 
28 
Nose-brain and CSF 22, 24, 35, 54, 97, 129, 130 
 
7 
Pharmacodynamics 19-21, 38-40, 42, 47, 52, 57, 60, 65, 66, 72, 74, 
83, 85, 88, 92, 93, 95, 105, 110, 113, 114, 118-
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large numbers of  animals can be used easily, which is necessary when
sampling brain tissue. The most striking anatomical difference between
the human and rat nose is the distribution of  the respiratory and olfac-
tory epithelium over the nasal cavity as mentioned above in paragraph
2.1.  The literature about nose-to-brain/CSF drug transport can be di-
vided into four categories: nose-brain, nose-CSF, nose-brain and CSF,
and pharmacodynamic (PD) research. These categories will be further
discussed with respect to the study designs that are used in this research
field.
4.2.1. Nose-brain research
In 64 publications (Table I) of  the investigated literature (134 papers),
brain tissue was sampled for examining the nasal pathway to reach the
CNS. The most commonly used species are rats and mice, but only a few
studies are known using rabbits (29, 53, 106, 111), pigs (87, 89, 143),
monkeys (10, 13, 51, 64), dogs (154) and hamsters (100). Only a few of
these studies compared nasal with intravenous drug administration. In
most papers intranasal administration was compared with a control ad-
ministration like placebo, vehicle or no treatment, and a delivery route
other than the intravenous one.
In the majority of  the nose-brain studies, brain tissue is sampled only,
without monitoring the drug plasma levels. Generally, the brain tissue is
sampled by dissection or by slicing the brain tissues. The dissected tis-
sues are analysed by determining radioactivity or, after extracting the drug
of  investigation, by HPLC or radioimmunoassay. The brain slices are
analysed either by autoradiography or by staining techniques using
microscopy. Investigating the drug transport via the ORNs using
microscopy still needs comparison with intravenous injection, as intrave-
nously administered substances can reach the ORNs via transport from
the blood into the CSF, which fills the perineural spaces between the
ORNs (16, 80).
The majority of  the studies using brain tissue sampling investigated the
possibility of  direct nose-brain transport in a qualitative way using auto-
radiography or microscopic analysis. There are only 3 publications show-
ing quantitative data on nose to brain transport (27, 28, 76). Chow et al.
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(28) calculated the brain/plasma ratio for three different brain areas fol-
lowing intranasal administration of  cocaine, and did not found any direct
transport. This is supported by Hussain et al. (76) in their study with a
cognition enhancer. The observed brain/plasma ratios after intranasal
and intravenous delivery appeared to be similar. In another report by
Chow et al. (27) the brain/plasma ratio was higher after intranasal admin-
istration of  benzoylecgonine compared to that after intravenous injec-
tion.
The reason for the very few number of  kinetic studies sampling brain
tissue, is the large number of  required animals, which makes it also labo-
rious and expensive. When sampling brain tissue only, one sample per
animal per time point has to be taken. This also increases the variability
in the obtained data.
In summary, microscopic analysis of  brain tissue gives a qualitative an-
swer whether or not there is direct drug transport. A disadvantage is that
microscopy does not give an indication about the proportion of  the ad-
ministered drug that is transported from the nasal cavity into the brain.
Direct transport may be concluded after spotting only a few molecules in
or along the olfactory tract. However, this is probably not satisfactory for
achieving pharmacologically relevant drug concentrations in the brain.
4.2.2. Nose-CSF research
Twenty-eight of  the publications used for this review (Table I) examined
CSF and plasma to investigate the nasal pathway to the CNS. The major-
ity of  these studies are performed in rats, some in monkeys (1-4, 36, 107,
133) and only a few in humans (14, 101), rabbits (31, 96) and dogs (5, 73).
In most of  the papers the intranasal route is compared with intravenous
administration. Blood is sampled either from a vein or an artery, and no
preference has been shown.  The CSF is mainly sampled by puncturing
the cisterna magna. This is the largest CSF-containing cavity in the brain
in mammals, easily accessible and therefore commonly used as CSF sam-
pling site. In general, CSF is sampled in rats from the cisterna magna by
entering a needle into the cistern and collecting 75 - 150 µl CSF as de-
scribed by Waynfort and Flecknel (156) and Chou and Levy (26). In this
way relatively large CSF samples can be obtained from rats. However, the
obvious disadvantage of  these methods is that only one sample per ani-
18
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mal can be collected. This increases the number of  animals needed to
obtain a complete drug uptake profile in CSF and/or limits the data on
drug uptake in CSF. Subsequently, the variability between data will in-
crease compared to the results obtained from one animal. Secondly, there
is a high risk on contamination of  the CSF with blood. This can be the
reason of  measuring enhanced drug levels in CSF, as blood contaminat-
ing the CSF will contribute considerably to these drug concentrations.
Several papers reported that CSF sampling was stopped as soon as blood
appeared and that this last fraction was discarded. However, this can still
be too late to stop the CSF collection because it may already be contami-
nated with blood, even if  not visible with the eye.
Only a few papers describe serial CSF sampling in rats in this field of
research (7, 23, 25). Chou and Donovan investigated the CSF penetra-
tion of intranasally administered antihistamines (23) and local anaesthet-
ics (25) using serial CSF sampling by cisternal puncture, but with replace-
ment of  CSF via a needle positioned in the lateral ventricle. The advan-
tage of  this CSF sampling method is that CSF and blood samples can be
collected serially from one animal. The collected CSF samples are small
(about 30 µl), which may be disadvantageous for drug analysis, but ex-
cludes possible blood contamination. Bagger and Bechgaard (7) devel-
oped a microdialysis method to sample extracellular fluid (ECF) in the
left and right striatum in rats. The sampled ECF is replaced with artificial
CSF and sampling from the second half  of  the brain serves as a negative
control in case of  direct nose-brain drug transport. Another advantage
of  the model is the ability to insert the microdialysis probe in the brain
area of  interest in order to monitor the drug concentration at the site
where the pharmacological effect will take place. A disadvantage of  this
model and the previous one is the invasive character and the risk on
blockage of  the implanted cannula and probe, which makes it difficult to
use the rats for both intranasal and intravenous treatment. This would
allow using the rats as their own control and therefore reducing the number
of animals needed.
In about half  of  the nose-CSF transport studies the drug transport route
from the nasal cavity to the CSF compartment is not determined by com-
paring CSF/plasma ratios after nasal and intravenous delivery.
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In some reports the CSF/plasma ratio is calculated for concentrations at
particular time points. (4, 127, 128, 133, 134, 158). Other reports based
their conclusion of  direct nose-CSF transport only on increased drug
uptake into CSF after nasal drug delivery compared to intravenous ad-
ministration at one time point only, regardless from the observed plasma
levels (3, 14, 31, 35, 36, 126). The information given by these concentra-
tion ratios is not satisfactory to draw clear-cut conclusions on the uptake
route of  the drug after nasal delivery, but can only serve as an indication.
Taking together, studying nose-CSF drug transport requires drug absorp-
tion and uptake profiles in plasma and CSF, respectively, after both intra-
nasal and intravenous delivery. A serious drawback in this type of  experi-
ments is the serial collection of  CSF, which in small laboratory animals
like rats is difficult to perform due to their small CSF volume (about 300
µl (37)). In humans the sampling of CSF is also rather difficult because
of  the invasive character. In healthy volunteers CSF was sampled by us-
ing an interspinal catheter (14). Merkus et al. (101) obtained CSF from
neurosurgery patients provided with a CSF drain necessary for their treat-
ment. If  it is not possible to collect CSF in a serial way because of  meth-
odological reasons, the results obtained should be used as an indication
only.
4.2.3. Nose-brain and CSF research
Only 7 publications (Table I) of  the selected literature describe experi-
ments investigating plasma, CSF and brain tissue following nasal drug
delivery. Four of  these studies were carried out in rats (22, 24, 35, 129),
whereas monkey (54), rabbit (130) and mice studies (97) were noticed
only once. Also in these studies intravenous drug administration is the
reference treatment used most often.
The sampling characteristics are similar to those mentioned in the previ-
ous two paragraphs. Despite of  the fact that about half  of  these papers
report drug plasma levels following delivery, no CSF/plasma ratios are
given in these studies.
20
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In the rat study by Chou and Donovan (24) CSF and brain tissue AUC
values after nasal and intra-arterial delivery of  lidocaine in rats were com-
pared. The reported nasal/intra-arterial AUC ratios suggest direct trans-
port to the CSF when sampling by cisternal puncture, but not when us-
ing microdialysis as sampling technique at different brain areas. Never-
theless, these results are difficult to interpret, because nasal plasma ab-
sorption data of  lidocaine are not available.
In another rat study, the direct transport of  tritiated dopamine was claimed
(35). Comparable blood levels were found after nasal and intravenous
administration. However, in blood, CSF and brain tissue total radioactiv-
ity was measured, which does not distinguish between the intact com-
pound and possibly formed metabolites.
The uptake of  5-fluorouracil into CSF and brain tissue was studied by
Sakane et al. (129) following nasal instillation, nasal perfusion or intrave-
nous administration in rats. After nasal perfusion enhanced drug trans-
port to the cortex was found compared to intravenous administration.
However, a volume of  8 ml was perfused through the rat’s nasal cavity
for 30 min, which is a very aggressive method for nasal administration.
Firstly, to prevent swallowing of  a nasal formulation, no more than 20 µl
per nostril should be applied to rats. Secondly, the residence time of  the
administered drug is not restricted by the mucociliary clearance, thereby
prolonging the drug absorption phase. The distribution of  5-fluorour-
acil over the cerebral cortex and plasma was expressed as the cortex/
plasma concentration ratios against time. This method of  data analysis is





for each delivery, making the interpretation of  the results easier and more
clear-cut.
In summary, to obtain both CSF and brain tissue samples requires a large
number of  experimental animals, but on the other hand it provides more
information on the CNS distribution of  the nasally administered drug.
4.2.4. Nasal drug delivery and pharmacodynamics
In the three previous sections the discussed experimental methods were
focused on determining the drug concentration in CSF and/or brain
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tissue and plasma following nasal administration. This section will de-
scribe methods monitoring the pharmacodynamic effect of  the adminis-
tered drug as the main parameter. Humans are the most investigated spe-
cies in studies describing the relation between intranasal drug delivery
and the obtained CNS effects. This is explained by the fact that in hu-
mans pharmacological effects can be monitored more easily than CSF
drug concentrations. The majority determined CNS effects by monitor-
ing the change in event-related brain potentials at one or more brain
sites. One study investigating the nose-to-brain transport of  the peptide
drug angiotensin II measured the effects at peripheral sites: vasopressin
and norepinephrine release was determined by measuring their plasma
concentrations and the systemic vascular resistance was monitored (40).
In animal studies, rats and mice are the most frequently used species,
whereas monkeys were studied twice (52, 124) and dogs (20), rabbits (92)
and pigs (105) only once. The effects studied in animals are mainly of
neurochemical, histological or behavioural type of  studies. For instance,
the uptake of  cocaine, L-DOPA methylester and amphetamine into the
neostriatum in rats was determined by monitoring the neurochemical
effects of  these drugs on the dopamine, DOPAC and HVA levels in that
brain area using microdialysis (38). Gozes et al. (65) studied the effect of
a vasoactive intestinal peptide (VIP) analogue in rats on learning and
memory behaviour. The development of  neurons, plaques, astrocyte tox-
icity, lesions, tissue degeneration and neuron staining are examples of
histological effects monitored after nasal drug delivery. It is obvious that
such effects are easier to monitor in laboratory animals than for example
event-related brain potentials in humans.
In these pharmacodynamic investigations a control treatment seems to
be more important than comparison of  the intranasal and intravenous
routes of  drug administration. Other administrations used as reference
in these pharmacodynamic investigations differ in nasal delivery condi-
tions like dose, formulation composition or drug and therefore can hardly
be used as control treatment.
With respect to the sampling characteristics, it is remarkable that in more
than half  of  the pharmacodynamic studies drug blood levels were not
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monitored and in most of  these papers no CSF levels.  This means that
the majority of  these pharmacodynamic studies bases the drug transport
route to the brain after nasal delivery on effect monitoring only, without
taking into account the drug distribution over plasma and CSF or brain
tissue. Considering the pharmacokinetically based CSF/plasma ratio as a
key parameter necessary to determine whether or not the drug is directly
transported from the nasal cavity into the CNS, gives these pharmacody-
namic studies a weak basis for clear-cut conclusions.
From the discussion above it is evident that the majority of  the studies in
the area of  nose-brain/CSF research do not meet the criteria as outlined
in the theoretical study design (see 4.1.). Therefore, the results obtained
in these studies will be evaluated in the General discussion and conclusions
(Chapter 8) for their relevance and conclusions if  direct drug transport
from the nasal cavity to the CNS is justified or not.
5. Study objectives
The main objective of  this Thesis was to investigate the relevance of
drug transport from the nasal cavity directly into the CSF in rats. This
was accomplished by fulfilling the following aims. Firstly, a rat model was
developed in order to take serial CSF and blood samples from one ani-
mal after nasal or intravenous drug administration. The intravenous de-
livery device was set-up in order to simulate the drug plasma profile ob-
tained after nasal administration to create similar experimental condi-
tions for both delivery routes.
The developed rat model was subsequently used to examine the direct
nose-to-CSF transport of  the lipophilic compounds hydrocortisone,
estradiol, progesterone and melatonin and the hydrophilic compounds
hydroxocobalamin (M
w
 = 1.3 kDa) and fluorescein isothiocyanate-labelled
dextran (M
w
 = 3.0 kDa). In addition, for the compound melatonin and
the hydrophilic substance hydroxocobalamin the obtained results in rats
were compared with those of  two clinical studies in order to investigate
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Serial cerebrospinal fluid sampling in a rat
model to study drug uptake from the nasal
cavity
M.P. van den Berg, S.G. Romeijn, J.C. Verhoef  and F.W.H.M. Merkus
Journal of  Neuroscience Methods (2002) 116 99-107.
Abstract
Drug transport from the nasal cavity to the brain has gained high interest
in the last decade. In the present study a model was developed to deter-
mine the uptake of  drugs into the cerebrospinal fluid (CSF) after nasal
delivery in rats. CSF samples were taken using a cisternal puncture method.
In this method a needle is advanced through the skin and muscles over-
lying the atlanto-occipital membrane into the cisterna magna, while the
rat is fixed in a stereotaxic frame. This method appeared to be superior
over cannulation of  the atlanto-occipital membrane for CSF sampling.
The major advantages of  the puncture method are the ability of  serial
and simultaneous CSF and blood sampling for over two hours in the
same rat.
To obtain maximal drug absorption from the nasal cavity and uptake into
CSF, different positions of  the rat’s head (upright-90° angle, supine-90°
angle, supine-45° angle and supine-70° angle) were tested in nasal deliv-
ery studies using hydrocortisone (HC) as model drug. Putting the rat in
the supine-90° angle position increased the absorption of  HC into plasma
and CSF two-fold compared to the upright-90° angle position. The su-
pine-70° angle position did not change the HC plasma and CSF levels
compared to the supine-90° angle position. However, the supine-70° angle
position showed the fastest CSF sampling rate, enabling more accurate
CSF sampling and therefore preferred for further studies.
In conclusion, the cisternal puncture method using the supine-70° and
90° angle position is a suitable method to study drug transport from the
nasal cavity into the CSF, with the ability of  multiple CSF sampling.
Keywords
intranasal delivery, cisternal puncture method, serial CSF sampling, nose-
to-brain transport, hydrocortisone, rat
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1. Introduction
Drug transport from the nasal cavity to the brain has been extensively
investigated in the last decade (15, 19). This route gained much interest
because it has major advantages over conventionally used delivery routes
as the oral and intravenous ones, especially with regard to brain targeting
of  drugs. Firstly, the nose-brain route is not obstructed by the blood-
brain barrier, which is one of  the major problems in delivery of  drugs to
the central nervous system. A direct route from the nasal cavity to the
brain also circumvents the first-pass elimination by the liver and
gastrointestinal tract. For drugs that are currently administered by
parenteral injections, the nose-brain route will enhance the patient com-
pliance.
To study nose-to-brain transport of  drugs properly it is important to
choose a good model. To investigate whether a drug is delivered to the
brain and/or cerebrospinal fluid (CSF) rather than to the systemic circu-
lation, the drug uptake in brain tissue and/or CSF and blood needs to be
monitored. For studying drug uptake into biological tissues and fluids
requires an animal model, since the use of  cell cultures represents only
one body compartment at the time and can not simulate absorption and
elimination of  a compound. The choice of  the species to be used should
be made in such a way, that it could be related to the human situation.
On guidance of  these considerations an animal model to study drug up-
take from the nasal cavity into the CSF should ideally meet the following
conditions: 1) serial blood sampling over a certain period of  time, 2)
serial CSF sampling over that same period, 3) use of  a species that has a
close analogy to the human nose-brain transport route, and because of
working with laboratory animals: 4) act according to the three R’s of
Russell and Burch: Replacement, Reduction and Refinement (23).
With respect to the third condition, a few studies concerning drug up-
take into the brain after nasal delivery were performed in monkeys (1, 11)
which have a nasal cavity showing close homology to humans (10). How-
ever, most studies investigating nose-to-CSF drug delivery were done in
rats (4, 6, 24, 26). Therefore, in the present studies the rat was chosen to
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set-up as an experimental animal model. This rat model can be used to
screen for potential nose-to-CSF transport of  drugs. Subsequently, these
drugs should be tested in species with closer analogy to humans, like
rabbits or monkeys (10). The last condition (i.e. the three R’s) requires
that the experimental set-up should have the least possible degree of
discomfort for the animals. This has important implications for choos-
ing the sampling methods needed for the first two conditions (i.e. serial
blood and CSF sampling).
A blood sampling method, which is animal friendly and useful for serial
sampling in rats, is the tail incision method described by Fluttert et al. (8).
In this method a small incision in the tail vein is made at the end of  the
tail, from which blood samples can be taken easily without using a can-
nula. The CSF sampling methods reported until now do not answer all
above-mentioned requirements. The two CSF sampling methods used
most often are the cisternal puncture (4, 5, 29) and the cisternal cannula-
tion method (2, 16, 17, 25, 27, 30), which are both invasive methods. In
the first method an incision is made in the skin overlying the atlanto-
occipital (a-o) membrane and in most cases also in the first muscle layer.
Then a needle is put through the a-o membrane into the cisterna magna
and CSF is sampled often until blood appears. In the second method a
cannula is put through the roof  of  the skull along the cerebellum into the
cisterna magna. Both approaches sample CSF from the cisterna magna,
the largest CSF compartment lying between the cerebellum and the up-
per vertebral. The former method is terminal for the animal, while the
second one has the advantage that anaesthesia is not required for CSF
sampling. However, the cannulation method is highly susceptible to in-
fections and cannulas are blocked easily. Another disadvantage of  both
methods is the high risk of contamination of the CSF samples with red
blood cells. Chou and Donovan (4) used a microdialysis procedure to
obtain serial CSF samples from rats after nasal administration. Although
this technique eliminates the removal of  significant CSF volumes during
the experiment, the implantation of  microdialysis probes is very invasive
and the surgery needed is complicated. Huang et al. (13) described a can-
nulation method, which they claimed to be non-traumatic and minimally
inflammatory, allowing multiple CSF sampling with unblocked cannulas
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for at least one week. Another CSF sampling method that meets the above
mentioned criteria is the cisternal puncture method using a stereotaxic
frame as described by Frankmann (9). In this method CSF samples are
taken from the cisterna magna by putting a needle through the muscle
layer overlying the a-o membrane and finally into the cisternal compart-
ment while the anaesthetised rat is fixed in a stereotaxic frame, which is
not invasive like the first mentioned cisternal puncture procedure. These
two CSF sampling methods are already a refinement of  the earlier men-
tioned cisternal cannulation (2, 16, 17, 25, 27, 30) and puncture (4, 5, 29)
methods.
The aim of  the present study was to develop a suitable rat model for
investigating drug transport from the nasal cavity to the CSF, which ful-
fils all four above-mentioned criteria. To that purpose, the cannulation
of  the a-o membrane and the cisternal puncture using a stereotaxic frame
were compared with each other, using the steroid hormone hydrocorti-
sone (HC) as a model drug. Corticosteroids are involved in brain proc-
esses like learning and memory, and may also be useful in the treatment
of  neurodegenerative diseases (18), making these compounds very inter-
esting for studying drug targeting from the nasal cavity to the CSF.
2. Materials and methods
2.1 Materials
Hydrocortisone (HC) (at least 98 % purity) was from Sigma Chemical (St.
Louis, MO, USA) and randomly methylated beta-cyclodextrin (RAMEB;
degree of  substitution 1.8) was from Wacker-Chemie (Krommenie, The
Netherlands). Ethanol (96 %) of  analytical grade was from Merck
(Darmstadt, Germany) and sterile saline (0.9 % NaCl) was from the Hos-
pital Pharmacy of  Leiden University Medical Centre (Leiden, The Neth-
erlands). Hypnorm® (fentanyl citrate 0.315 mg/ml, fluanisone 10 mg/
ml) was supplied by Janssen Pharmaceutica (Beerse, Belgium). Midazolam
(5 mg/ml) was from Genthon B.V. (Nijmegen, the Netherlands). Nemb-
utal® (pentobarbital sodium, 60 mg/ml) was purchased from Sanofi Sante
Nutrition Animale (Libourne, France) and Temgesic® (buprenorfine, 0.3
mg/ml) from Schering-Plough (Maarssen, The Netherlands). Collagenase
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(455 U/mg digestion activity) was obtained from Sigma (St. Louis, MO,
USA) and the tissue glue Histoacryl blue® was from B Braun (Melsungen,
Germany). All other reagents were of  analytical grade.
2.2 Hydrocortisone formulations
HC and RAMEB were dissolved in ethanol in a molar ratio of  1:1.2 to
generate inclusion complexes. RAMEB was used as solubiliser to en-
hance the solubility of  HC by inclusion complex formation. After evapo-
ration of  ethanol at 35°C under a mild nitrogen stream, the residues were
dissolved in sterile saline to obtain two formulations with the following
concentrations HC (mg/ml) and RAMEB (%, w/v), respectively: 7.0 mg/
ml and 3.0 %; 14.0 mg/ml and 6.0 %.
2.3 Animals
Male Wistar rats (Charles River, Someren, The Netherlands) were used,
weighing 250 – 400 g at the start of  the experiments. The animals were
housed separately with free access to food and water with a 12-h light/
dark cycle. At the end of  the experiments the animals were euthanised
with an overdose of  Nembutal® (1 – 2 ml, intraperitoneally).
2.4 Cannulation of the atlanto-occipital membrane for CSF sampling
The surgery was performed according to Huang et al. (13) with some
adaptations. Briefly, rats were anaesthetised with Hypnorm® (0.5 ml/kg)
and midazolam (2.5 mg/kg) and body temperature was maintained at
37°C by placing the rats on a heating blanket. The skin overlying the
occipital bone was incised and the underlying tissue was prepared as such
that the a-o membrane in between the occipital bone and the upper cer-
vical vertebral was exposed. The remaining tissue on the a-o membrane
was removed using a collagenase solution (10 %, w/v). A cannula was
attached to the middle of  the membrane with Histoacryl blue®. The can-
nula was made of  polyethylene tubing (ID 1.13 mm, OD 1.57 mm), which
had a length of  1 mm shorter than the perforation needle which was
inserted into a ring of  Raumedic tubing (ID 1.5 mm, OD 3.2 mm) of  1.0
mm thickness. After hardening of  the tissue-glue, the membrane was
perforated by putting a double needle (a 26 G needle in an 22 G needle)
through the cannula. Since CSF entered the cannula, it was occluded with
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a lid (silicon tubing (ID 1.5 mm, OD 2.1 mm) closed at one end with a
drop of  silicon rubber) to prevent infections or other contaminants from
entering the CSF. The cannula was further attached to the skull using
dental cement (Ketac-Cem®, ESPE, Seefeld, Germany), and thereafter
the muscles and the skin were sutured separately. As post-operative care
Temgesic® was given (0.1 mg/kg, intramuscularly).
2.5 Cisternal puncture method using a stereotaxic frame
2.5.1 Upright-90° angle position
The cisternal puncture was carried out using a stereotaxic frame (model
51600, Stoelting, Wood Dale, IL, USA) with self-made swivel mounts (15
cm). The procedure as described by Frankmann (9) was followed with
some adaptations. Briefly, the rats were anaesthetised as described above
and the skin overlying the neck was shaven. The rats were fixed in the
stereotaxic frame, where the U-frame and the ear bars were held 15 cm
above the base plate (for position of  the rat’s head: see Figure 1a). The
needle at the end of  the CSF collection tubing (Figure 2) was attached to
a holder of  the stereotaxic frame. The other end of  the CSF collection
tubing was attached to a 30 cm polyethylene tubing (ID 0.28 mm, OD
0.61 mm) which was connected to 1 ml syringe filled with sterile filtered
(0.22 µm) milliQ water. Using the anterior/posterior (A/P) and dorsal/
ventral (D/V) drives, the needle was brought to the centre of  the occipi-
tal crest, which point was used as reference point for determining the
puncture position. The A/P and D/V co-ordinates of  the reference point
were monitored. From this point the a-o membrane is situated 6.8 – 8.5
mm ventrally, dependent on the weight of  the rat. According to Table I,
the D/V co-ordinates of  the puncture point were calculated and the nee-
dle was brought into position to carry out the puncture. Before punctur-
ing, an air bubble was drawn into the needle with the 1 ml syringe at the
other end of  the collection tubing. For puncturing, the needle was gently
moved through the skin and muscles towards the cisterna magna using
the A/P drive. If  necessary, the skin was pulled over the needle with a
pair of  tweezers. During advancement of  the needle through the mus-
cles the syringe plunger was pulled back to create negative pressure. Ad-
vancement of  the needle was continued until the air bubble moved into
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Figure 1 Different positions of  the rat’s head in the stereotaxic frame used for intranasal
delivery of  HC. a upright-90° angle, b supine-90° angle, c supine-45° angle, and d
supine-70° angle.
Figure 2 Schematic drawing of  the developed cisternal puncture system and CSF
collection tubing.
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the tubing followed by CSF. When CSF entered the tubing, the syringe
and the 30 cm piece of  polyethylene tubing were disconnected from the
CSF collection system. By connecting a Hamilton syringe to the CSF
collection tubing, CSF samples could be easily withdrawn. After sam-
pling, the Hamilton syringe was disconnected and the tubing was closed
with a clamp. Subsequent samples were taken by removing the clamp
from the tubing, followed by attachment of  the Hamilton syringe. After
taking the last CSF sample, the puncture needle was carefully drawn out
of  the rat’s head using the A/P drive. The puncture needle together with
the collection tubing (Figure 2) had a volume of  6 µl. The obtained CSF
samples (15 – 25 µl) were stored in Eppendorf  tubes at – 20°C until
analysis. After the experiment the rats were allowed to recover for 7 days,
and during this week they were monitored daily on body weight and well-
being.
2.5.2 Supine-90° angle position
Performing the cisternal puncture while the rat was lying in the supine-
90° angle position was almost the same as described above, but the fol-
lowing adaptations were required. When fixing the head between the ear
bars, the back of  the head was facing the U-frame of  the stereotaxic
frame, instead of  the eyes and nose. Therefore, after fixing the head be-
tween the ear bars, the rat was carefully turned on its back by moving the
animal to the other side of  the ear bars. The back was supported with a
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Table I Calculation of cisternal puncture points 








 (D/V) (A/P) (A/P) (A/P) 
250 – 300 6.8 6.8 2.9 5.2 
300 – 360 7.0 7.0 3.0 5.4 
360 – 380 7.5 7.5 3.2 5.7 
380 – 425 7.7 7.7 3.3 5.9 
425 – 470 8.0 8.0 3.4 6.1 
554 8.5 8.5 3.6 6.5 
For each position used (see Figure 1) the movement (mm) of the needle from the 
centre of the occipital crest towards the point of puncture, dependent on the rat’s 
weight and the use of the right drive, are given. D/V, dorsal/ventral drive; A/P, 
anterior/posterior drive. 
lab-jack to keep the rat in a horizontal position. The position of  the nose
was fixed by putting the tooth bar against the head. When determining
the puncture point, the functions of  the A/P and D/V drives were
switched around in this set-up. For taking a CSF sample (2 – 3 drops; 30
– 50 µl), the clamp was removed from the tubing and then CSF dripped
out from the tubing by means of  gravitation only. The CSF samples were
directly collected in pre-weighed antibody-coated radioimmunoassay tubes
and stored at 4°C until further analysis.
The methods for the supine-45°- and supine-70°- angle positions were
the same, except for the position of  the head (see Figure 1). In these
cases the movement of  the needle from the centre of  the occipital crest
to achieve the puncture point was performed as indicated in Table I.
2.6 Intranasal drug delivery
For intranasal administration of  the HC formulations, a polyvinylchloride
(PVC) tube (ID 0.5 mm, OD 1.0 mm) attached to a Hamilton syringe was
inserted into the left nostril of  the rat for about 2 cm, while the animal
was fixed in the stereotaxic frame. A volume of  20 µl (7 mg/ml formula-
tion: 140 µg HC/20 µl; 14 mg/ml formulation: 280 µg HC/20 µl) was
delivered by gently pushing the plunger of  the syringe. After delivery of
the formulation the PVC tube was removed. Before and after nasal HC
delivery, blood and CSF samples (8 – 11 samples) were taken until 120
min after administration.
2.7 Blood sampling
Blood samples (200 µl) were taken from the tail vein according to Fluttert
et al. (8) using heparinised tubes (Microvette® CB 100/200, Sarstedt,
Nümbrecht, Germany). Samples were centrifuged (15 min at 14.000 rpm;
ambient temperature) and plasma obtained was stored at – 20°C until
analysis.
2.8 Hydrocortisone analysis
Plasma and CSF samples were analysed on HC by radioimmunoassay
(Coat-A-Count® Cortisol RIA kit, DPC, Los Angeles, CA, USA) with a
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detection limit of  2 ng/ml. The analysis was performed according to the
manufacturer’s protocol. When calculating the HC concentration for the
CSF samples, the different sample volumes were taken into account.
3. Results
3.1 Cannulation a-o membrane versus cisternal puncture using a stereotaxic frame: practical
considerations
To cannulate the a-o membrane successfully advanced surgery techniques
were needed, which require great expertise from the surgeons. A major
problem met during surgery was to clean the a-o membrane from re-
maining tissue without damaging the membrane. Due to this problem
less than half  of  the surgeries succeeded. If  the cleaning of  this mem-
brane did succeed, the surgery was successful. However, within 5 – 9
days the cannula was blocked. Blood clotting occurred inside the can-
nula, which made CSF sampling impossible.
The cisternal puncture method described by Frankmann (9) was rela-
tively easy compared to the cannulation of  the a-o membrane. The main
problem with this method was to make an airtight CSF collection tubing,
so negative pressure could be created when pulling the syringe plunger
during advancement of  the needle through the muscles. The CSF collec-
tion tubing, as shown in Figure 2, has proven to be an airtight system
during advancement of  the needle through the skin and muscles. The
movement of  the needle from the centre of  the occipital crest to the
point of  puncture has been given already by Frankmann (6.8 mm) for
rats weighing 225 – 350 g. During the present experiments this observa-
tion was confirmed and complemented as given in Table I.
The CSF samples collected using the puncture method were virtually
blood free. Before and during the experiment several CSF samples (10
µl) were taken for microscopic examination using a Bürker counting cham-
ber. The CSF samples (n = 120) were checked for the number of  red
blood cells/µl. The majority of  the obtained CSF samples (76 %) had an
erythrocyte contamination of  less than 90 cells/µl (< 0.001 % of  normal
blood content), similar to that previously reported for the cannulation
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method (13). The remaining 24 % had a contamination exceeding 90
cells/µl (16 %: 90 – 900 cells/µl, 7 %: 900 – 9000 cells/µl and 1 %: >
9000 cells/µl), which was mainly observed in CSF samples taken imme-
diately after the cisternal puncture. Compared to other published studies
(17, 30, 32), these values are very low and therefore acceptable. In the
nasal delivery studies with HC (see below), CSF samples containing an
erythrocyte contamination > 0.01 % were discarded.
After performing the cisternal puncture in upright-90° angle position,
the animals appeared to develop scratching wounds around their shoul-
ders, probably caused by muscular pain as a consequence of  hanging in
the stereotaxic frame for more than 2 hours. Therefore, the supine-90°
angle position was also studied (Figure 1b). By putting the rat on a lab-
jack during the experiment, the animal was not hanging in the stereotaxic
frame but was completely supported. With these animals no wounds were
observed after the experiment. During the recovery period the animals
gained normal weighed again and showed normal behaviour.
The cisternal puncture method in supine-90° angle position was found
to be more suitable for CSF sampling than the cannulation method de-
scribed here. The major advantage of  the puncture method using a stere-
otaxic frame was the possibility of  serial CSF sampling for up to 2 hours.
3.2 Nasal delivery of  HC: upright-90° angle position
HC was administered intranasal in two dosages (140 and 280 µg/animal)
to rats using the cisternal puncture method in the upright-90° angle posi-
tion. The plasma concentration-time curve (Figure 3a) shows that the
absorption of  HC from the nasal cavity in plasma is dose-dependent.
The C
max 
in plasma after administration of  the higher HC dose (t = 30
min) was almost twice as high as after administration of  the lower dose (t
= 20 min): 257 ± 89 and 157 ± 34 ng/ml, respectively.
In CSF the HC levels after nasal administration of  a dose of  140 µg were
around the detection limit of  the radioimmunoassay (2 ng/ml), as evi-
dent from Figure 3b. This explains the strange shape of  the curve and
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Figure 3 Mean HC concentrations in plasma (a) and CSF (b) after intranasal adminis-
tration of 140 µg HC /rat (n = 6) and 280 µg HC/rat (n = 7), using the upright-90°
































































the remarkably high variability. On the other hand, the CSF levels after
nasal dosing of  280 µg were above the limit of  detection. In this case the
CSF concentration-time curve (Figure 3b) showed an uptake profile with
an absorption phase (0 – 45 min), an elimination phase (45 – 120 min)
and a C
max
 of 5.3 ± 2.4 ng/ml at 45 min. Compared to the plasma con-
centration-time curve, the C
max
 was reached about 15 min later.
3.3 Nasal delivery of  HC: supine-90° angle position
In order to avoid the scratching wounds around the rat’s shoulders, the
position of  the rat in the stereotaxic frame needed for cisternal puncture
was changed from upright-90° angle to supine-90° angle. In this position
HC was delivered to rats intranasal. Only the 280 µg dose was tested,
because in the former experiment the CSF levels after nasal delivery of
140 µg were difficult to determine, in contrast to those obtained with the
280 µg dose (see Figure 3b). In this position CSF sampling was driven by
gravitation only, which made collection of  CSF very easy. Within 4 min
samples of 3 drops (40 – 50 µl) could be obtained.
In Figure 4a the plasma levels after HC administration in rats using the
supine-90° angle position are shown. A striking difference with the plasma
curve for the 280 µg dose delivered in the upright-90° angle position was
the difference in C
max
; 257 ± 89 ng/ml (upright-90° angle, t = 30 min)
compared to 454 ± 90 ng/ml (supine-90° angle, t = 15 min). This in-
crease in HC absorption by changing the position of  the rat and thereby
changing the position of  the rat’s head was also observed in the CSF
levels (Figure 4b). In CSF the C
max
 in upright-90° angle position was 5.3
± 2.4 ng/ml (t = 45 min) and in supine-90° angle position 10.3 ± 2.3 ng/
ml (t = 20 min). Thus both blood and CSF levels of  HC were almost
increased 2-fold by changing the position of  the rat from upright to su-
pine. The C
max
 in CSF was only 5 min later compared to the C
max
 in plasma
using the supine-90° angle position.
3.4 Nasal delivery of  HC: supine-45° and 70° angle positions
To further investigate the influence of  the position of  the rats head on
the uptake of  HC from the nasal cavity into the CSF the supine-90° angle
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Figure 4 Mean HC concentrations in plasma (a) and CSF (b) after intranasal admin-
istration of 280 µg HC/rat, using the supine-90° (n = 5), supine-45° (n = 5) and
































































position was varied. The head was pushed backwards while the rat was
fixed in the stereotaxic frame until an angle of  45° or 70° was achieved
(Figure 1c, d), referred as supine-45° and supine-70° angle position, re-
spectively. Using these positions of  the head, intranasal administration
of  HC (280 µg/rat) was carried out. In Figure 4a and 4b the obtained
plasma and CSF levels are shown. Moving the rat’s head backward to an
angle of  70° did not change the absorption of  HC in plasma and the
uptake into the CSF compared to the supine-90° angle position. On the
contrary, the supine-45° angle position resulted in an increased uptake
into the CSF (Figure 4b). However, the collection of  CSF in the supine-
70° angle position (about 2 min/sample) occurred much faster compared
to the supine-45° (> 5 min/sample) and the supine-90° (about 4 min/
sample) angle positions, thus resulting in more accurate CSF sampling.
4. Discussion
The cisternal puncture method described in the present study has proven
to be a suitable method for serial sampling of  CSF from the cisterna
magna in rats over a time period of  at least two hours. This method is
easy to perform and offers several advantages over previously reported
CSF sampling methods (2, 5, 16, 17, 25, 27, 30). Multiple CSF and blood
samples can be taken simultaneously, which makes it possible to obtain
complete drug concentration-time profiles in both CSF and plasma in
the same rat. The method is not terminal for the animal, which means
that, provided the rat is in a healthy condition, it could be used in a sec-
ond experiment. This opens-up the possibility to re-use the animal, so it
can serve as its own control and thereby decreasing the variability in data
and decreasing the number of  animals needed. This will lead to a further
refinement of this model (23), and is in contrast to the commonly used
cisternal puncturing (5, 29) which allows only one CSF sample per ani-
mal. Nevertheless, the applicability of  re-using the animal needs to be
further evaluated.
Using the present method, CSF samples of about 40 µl can be with-
drawn which are virtually blood-free. Especially after having gained ex-
perience, the contamination of  CSF samples is negligible (< 0.01 % of
56
2 Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity
normal blood contents). The collection of  blood-free CSF is important
to give an unambiguous interpretation of  the CSF concentration-time
profiles: after drug administration blood cells contaminating the CSF could
contribute to the drug concentration measured in the CSF samples, which
would result in erroneous high drug concentrations in CSF. Taking small
CSF samples is necessary, because the total CSF volume in adult rats is
ranging from 300 to 400 µl (7, 20). The amount of  CSF collected during
the 2-hours experiment (about 320 µl) should be balanced by the CSF
turnover rate of  the rats, being 2.2 µl/min (7). Thus after two hours
about 264 µl of  CSF has been replaced, which means that at the end of
the experiments already 80 % of  the collected CSF has been replaced.
However, the total amount of  sampled CSF is quite a large volume (about
75 % of  the original total volume) and, despite the observed clear CSF
concentration-time profiles after nasal HC administration, it should be
realised that the physiological CSF flow and drug distribution in the CSF
may be altered by this sampling procedure. Another disadvantage of  the
puncture method is the need of  anaesthetising the animal. The effect
that the anaesthetics may have on the drug absorption should be taken
into account.
Besides the cisternal puncture method, in this study also the cannulation
of  the a-o membrane has been investigated as a CSF sampling method.
According to Huang et al. (13) this method would be almost atraumatic,
non-inflammatory, and multiple sampling of  CSF over a time period of
at least one week would be possible in unanaesthetised rats. These issues
are serious problems observed in the earlier published cisternal cannula-
tion methods (2, 16, 17, 25, 27, 30). However, our experience was that the
surgery needed to attach the cannula to the a-o membrane is very diffi-
cult and that, if  it succeeded, the rat could not be used in nasal drug
delivery studies because of  blockage of  the cannulas during the recovery
period. Therefore, this cannulation method was considered as unsuitable
for multiple CSF sampling in rats.
The present cisternal puncture method described in this study was fur-
ther studied by testing different positions of  the rat as depicted in Figure
1b-d. A remarkable difference was found in the absorption of  HC in
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plasma and CSF between the upright-90° and supine-90° angle positions
(Figure 3 and 4).  When administering the nasal drug formulation in the
upright-90° angle position, the drops were delivered into the nasal cavity
by pushing the plunger of  a Hamilton syringe. In the supine-90° angle
position this formulation was also driven by gravitation, which probably
delivered the formulation deeper into the nasal cavity as compared with
the upright-90° angle position. Pushing the head of  the rat backwards, as
done in the supine-70° angle position, did not change the absorption of
HC into plasma compared to the absorption observed after nasal admin-
istration in the supine-90° angle position, whereas for the supine-45°
angle position the plasma levels were increased. The uptake of  HC into
CSF using the supine-45° angle position was quite similar to that found
in the supine-90° angle position until 40 min after administration. There-
after, it increased rather than diminished. This might be due to a decrease
in CSF volume during the experiment, but such increases were not ob-
served for the other positions tested. Moreover, the CSF volume is con-
tinuously replaced by the rapid CSF turnover.
Applying this CSF sampling method to the commonly used supine (-0°
angle) position in nasal drug absorption studies would minimise the space
between the upper cervical vertebral and the skull in such a way that
puncturing of  the cisterna magna will become impossible. Therefore,
this position was not tested in for CSF sampling. However, the supine-0°
angle position was studied on nasal HC absorption in plasma and gave
similar results to those found for the supine-90° angle position (data not
shown).
The supine-70° angle position facilitated the collection of  a CSF sample:
2 min/sample instead of 4 or more than 5 min/sample as found for the
supine-90° angle position and the supine-45° angle position, respectively.
Therefore, the cisternal puncture method using the supine-70° angle
position will be chosen as CSF sampling method in future nose-to-CSF
drug delivery studies.
The present results show the importance of  putting the animal on its
back in nasal delivery experiments, which is already the most frequently
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used position in reported nasal drug delivery studies in rats (3, 6, 12, 14,
21, 28). In some earlier studies the head of  the rat was also positioned as
shown in Figure 1a (upright-90° angle position) for CSF sampling pur-
poses (4). In addition, the present study demonstrates that the position
of  the rat’s head as depicted in Figure 1d (supine-70° angle position) is
preferable for studying nasal drug uptake into the CSF. Thus the position
of  the head may also have important implications for studying nose-to-
CSF drug transport in humans. Different head positions for nasal drug
delivery in men have already been investigated. These studies show that
the upright position for humans is not always the most effective one.
Raghavan and Logan (22) observed that, when using the Mygind’s posi-
tion (supine with the head extended off  the end of  the bed) or the Ragan
position (on side, head down), the nasal formulation reaches the middle
meatus of  the nasal cavity. For reaching the nasal and paranasal sinus
mucosa, Wilson et al. (31) found that the head down and forwards posi-
tion (comparable to the ‘praying to mecca’ position (22)) is most suitable.
These studies indicate that the most effective position for nasal delivery
in man can differ from that used in animals. Thus, for reaching the olfac-
tory epithelium in humans it may be possible that the most effective po-
sition will be different from the ones used in the present study. The ‘pray-
ing to mecca’ position shows disposition of  the nasal formulation to-
wards the olfactory cleft, but this position is experienced as uncomfort-
able (22).
In summary, the CSF sampling method using the supine-70° and 90°
angle positions as described in this report are suitable methods to study
drug uptake into the CSF after nasal delivery in rats. The supine-70° an-
gle position is preferred because of  the faster sampling speed, which will
result in more accurate CSF sampling. A complete absorption profile in
blood and CSF can be obtained simultaneously in the same animal. In
future studies this model will be used to compare intranasal and intrave-
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Uptake of  hydrocortisone into the cerebrospinal
fluid of  rats:
Comparison of  intranasal and intravenous
administration in the same animal
M.P. van den Berg, J.C. Verhoef, S.G. Romeijn, and F.W.H.M. Merkus.
S.T.P. Pharma Sciences (2002) 12 251-255.
Abstract
In this study, the contribution of  the nose-CSF pathway in the uptake of
hydrocortisone into the cerebrospinal fluid (CSF) was determined by
comparing the intranasal and intravenous routes of  administration. A
vascular access port was used as intravenous delivery device. Besides, the
influence of  different nasal delivery volumes on the uptake of
hydrocortisone into plasma and CSF was investigated. Male Wistar rats
were given hydrocortisone (280 µg/rat) intranasally in volumes of  20, 40
and 60 µl, by intravenous bolus injection (280 µg/rat) to determine the
infusion rate to achieve the same C
max
 as obtained after nasal delivery, and
by intravenous infusion (0.14 mg/ml, 68 µl/min for 15 min). Increasing
the nasal delivery volume from 20 to 60 µl did not further influence the
absorption of  hydrocortisone in plasma or the uptake in CSF. The C
max
observed after intravenous infusion was higher than the one obtained
after intranasal delivery, but they did not differ significantly. The amount
of  hydrocortisone in CSF was in the order of  3 – 4 % of  that found in
plasma after both routes of  administration. Therefore, there is no
indication for nose-CSF transport of  the lipophilic steroid hormone HC
after nasal administration.
Keywords
nasal delivery, vascular access port, hydrocortisone, nose-CSF pathway
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1. Introduction
During the past decade the connection between the nasal cavity and the
brain has been under extensive investigation in nasal drug delivery research
(11, 12). This connection possibly implies direct drug targeting to the
brain tissue and the surrounding cerebrospinal fluid (CSF). Such a shortcut
could offer more specific and efficient delivery of  drugs to the brain
without the need to pass the blood-brain barrier, which is still the main
problem in brain targeting of  drugs.
When investigating the nose-CSF transport route, the results after nasal
drug delivery have to be compared with intravenous (i.v.) delivery to
determine the contribution of  the olfactory pathway to the uptake of
compounds into the CSF. A commonly used technique for i.v. delivery in
nose-brain/CSF transport research is cannulation of  a vein with a catheter
in direct contact with the open air (4-6, 16). A disadvantage of  this
technique is the susceptibility to infections via this catheter.  To overcome
this problem a vascular access port (VAP) was used as i.v. delivery device
in the present study. The VAP consists of  a depot attached to a catheter
and is implanted subcutaneously (1, 13). Implanting the VAP requires no
specialised surgery techniques. The catheter makes the connection with
the systemic circulation and can be implanted in any vein that is suitable
for cannulation. In this report the jugular vein of  rats was cannulated and
the depot was attached to subcutaneous tissue at the level of  the lower
ribs on the abdominal side. This is different from the commonly used
place (the neck (1, 13)), because the rats were lying in supine position
during the experiment. The VAP can be entered by penetration of  a
Huber point needle through the skin of  the animal and the rubber, elastic
septum in the roof  of  the depot. This needle contains a deflected point,
which prevents damaging the septum while it is penetrated by the needle.
The elasticity of  the septum ensures closure of  it after removal of  the
needle from the septum, which prevents extravasation of  fluid out of  the
VAP.
In the present study the VAP was used for delivering the steroid hormone
hydrocortisone (HC) as an i.v. bolus injection and an i.v. infusion. The
bolus injection was performed to determine the i.v. infusion rate needed
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to reach a pharmacokinetic profile and maximal plasma concentration
(C
max
) of  HC as found after intranasal administration in rats. Simulating
the C
max
 after nasal delivery with the i.v. infusion ensures that the plasma
concentrations of  HC following both routes of  administration are as
similar as possible.
In our previous report (15) the position of  the rat’s head in relation to
the uptake of  HC in CSF after nasal administration was investigated.
Moving the rat from the upright-90° angle to the supine-70° angle position
appeared to increase the uptake of  HC into CSF and nasal plasma
absorption about 2-fold. In the supine-70° angle position the formulation
is probably delivered deeper into the nasal cavity compared to the upright
position. Therefore, the contact surface between the drug formulation
and the nasal epithelium is larger, which resulted in enhanced uptake of
HC in plasma and CSF. In the present study it was also investigated if
increasing the delivery volume from 20 to 40 and 60 µl will further increase
this contact surface and thereby the uptake of  HC into plasma and CSF.
2. Materials and methods
2.1. Materials
Hydrocortisone (at least 98 % purity) and povidone iodine were from
Sigma Chemical (St. Louis, MO, USA) and randomly methylated beta-
cyclodextrin (RAMEB; degree of  substitution 1.8) was from Wacker-
Chemie (Krommenie, The Netherlands). Ethanol (96 %) of  analytical
grade was from Merck (Darmstadt, Germany) and sterile saline (0.9 %
NaCl) and sterile heparin (400 IU/ml) were from the Hospital Pharmacy
of  Leiden University Medical Centre (Leiden, The Netherlands). Janssen
Pharmaceutica (Beerse, Belgium) supplied Hypnorm® (fentanyl citrate
0.315 mg/ml, fluanisone 10 mg/ml). Midazolam (5 mg/ml) was from
Genthon B.V. (Nijmegen, the Netherlands). Nembutal® (pentobarbital
sodium, 60 mg/ml) was purchased from Sanofi Sante Nutrition Animale
(Libourne, France) and Temgesic® (buprenorphine, 0.3 mg/ml) from
Schering-Plough (Maarssen, The Netherlands). All other reagents were
of  analytical grade.
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2.2. Hydrocortisone formulations
HC and RAMEB were dissolved in ethanol in a molar ratio of  1:1.2 to
generate inclusion complexes. RAMEB was used to improve the solubility
of  HC by inclusion complex formation. After evaporation of  ethanol at
35°C under a mild nitrogen stream, the residues were dissolved in sterile
saline to obtain formulations with the following concentrations HC (mg/
ml) and RAMEB (%, w/v), respectively: 0.14 mg/ml and 0.06 % (i.v.
infusion); 1.4 mg/ml and 0.6 % (i.v. bolus injection); 4.6 mg/ml and 2.0
% (i.n.-60 µl); 7.0 mg/ml and 3.0 % (i.n.-40 µl) and 14.0 mg/ml and 6.0 %
(i.n.-20 µl).
2.3. Animals
Male Wistar rats (Charles River, Someren, The Netherlands) were used,
weighing 290 – 340 g at the start of  the experiments. The animals were
housed separately with free access to food and water with a 12-h light/
dark cycle. At the end of  the experiments the animals were euthanised
with an overdose of  Nembutal® (1 – 2 ml, intraperitoneally).
2.4. Implantation of  vascular access port (VAP)
Rats were anaesthetised with Hypnorm® (0.5 ml/kg) and Midazolam (2.5
mg/kg) intramuscularly. Body temperature was maintained at 37°C by
putting the rats on a heating blanket. The skin inferior to the right front-
paw at the abdominal side and skin overlying the right jugular vein were
shaven. The shaven areas were disinfected with povidone iodine solution
(5 % in 70 % ethanol, home made). An incision (2 cm) was made at the
level of  the lower ribs and the skin was loosened from the underlying
tissue to create a pocket for inserting the VAP (Access Technologies,
Skokie, IL, USA). The pocket was made large enough to place the VAP
without putting tension on the skin after suturing the incision. A second
incision was made in the neck to cannulate the jugular vein. The VAP
with a silicone catheter (ID 0.5 mm, OD 1.0 mm) attached was filled with
heparin solution (200 IU/ml) using a Huberpoint needle (Access
Technologies, Skokie, IL, USA) and fitted into the pocket. Using a pair
of  forceps the catheter was tunnelled underneath the skin from the pocket
to the second incision in the neck. The VAP was attached to the underlying
tissue using a non-degradable suture, followed by suturing the skin with
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clamps. Hereafter the jugular vein was exposed and the catheter was
inserted into the vein. The cannulation of  the jugular vein was checked
by flushing the VAP again with heparin solution. The catheter was attached
to underlying tissue with non-degradable sutures and the skin was sutured
with clamps. As post-operative care Temgesic® was given (0.1 mg/kg,
intramuscularly) for pain relief. The rats were allowed to recover 1 week
before starting the experiments. To avoid blockage of  the catheter, the
VAP was flushed weekly with heparin solution (400 µl, 200 IU/ml).
2.5. Cisternal puncture using a stereotaxic frame
A cisternal puncture for taking CSF samples was performed as described
before (15). Briefly, rats were anaesthetised as mentioned above and fixed
in a stereotaxic frame (model 51600, Stoelting, Wood Dale, IL, USA) in
the supine-70° angle position. The cisternal punction was performed 5.2
– 6.5 mm ventrally from the occipital crest, dependent the rat weight.
After the punction, 10 µl of  CSF was microscopically examined on
erythrocyte contents, and the experiment was continued when the
erythrocyte contamination was less then 500 cells/µl (< 0.01 % of  normal
blood content). Hereafter a blank sample (40 µl) was taken and then the
rat was given 25 min to restore its CSF volume.
2.6. Intranasal and intravenous drug delivery
For intranasal administration of  the HC formulations, a polyvinylchloride
(PVC) tube (ID 0.5 mm, OD 1.0 mm) attached to a Hamilton syringe was
inserted into the left nostril of  the rat for about 2 cm, while the animal
was fixed in a stereotaxic frame. The HC dose (280 µg/rat) was delivered
in volumes of  20, 40 and 60 µl by gently pushing the plunger of  the
syringe. After delivery of  the formulation the PVC tube was removed.
The i.v. bolus injection (280 µg HC/rat) was given after shaving the skin
overlying the VAP and disinfecting this area with povidone iodine. The
formulation (280 µg HC/200 µl) was administered using a 1 ml syringe
attached to a Huberpoint needle. The VAP was subsequently rinsed with
500 µl saline to make sure that the entire formulation had entered the
blood stream.
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For i.v. infusion the formulation (0.14 mg/ml formulation, 142 µg HC/
rat) was delivered using a peristaltic pump (ISMATEC SA, IPS-8,
Glattbrugg – Zürich, Germany). Before starting the infusion, the pump
tubing (ISMAPRENE, ID 0.25 mm, OD 0.90 mm, ISMATEC SA,
Glattbrugg – Zürich, Germany) was cleaned with ethanol (70 %) and
rinsed with the formulation. The skin overlying the VAP was prepared as
described above. The pump was stopped and the Huberpoint needle
attached to the pump tubing was inserted into the VAP. Then the infusion
was started at a rate of  68 µl/min for 15 min.
Before and after HC delivery, blood (t = 0, 2.5, 5, 10, 15, 20, 30, 45, 60, 90
and 120 min) and CSF (t = 0, 5, 15, 25, 40, 60, 90 and 120 min) samples
were taken until 120 min after administration. Each rat received all nasal
(n = 8) treatments and the i.v. infusion, and some rats received also the i.v.
bolus injection (n = 3). In between two experiments the animals were
allowed to recover for one week.
2.7. Calculation of HC infusion rate
The plasma concentration-time profiles after the i.v. bolus injection of
HC were plotted on a semi-logarithmic scale, and the elimination constant
(k) was determined from the slope of  the curve. The half-life (t
1/2
) of  HC





A being the dose and C
0
 the extrapolated HC concentration at the start
of  the i.v. bolus injection. The clearance (CL) was calculated as k * V
d
.
Finally, the applied infusion rate (R
0
) for intravenous HC administration
was determined from Equation 1 and 2. In which C
max
 is the maximal HC
plasma concentration after nasal delivery, t
max





 the theoretical steady state concentration that will be reached
when the infusion is given continuously.
R
0







 / (1 – e -k*tmax) Equation 2
71
2. Materials and methods
2.8. Blood and CSF sampling
Blood samples (200 µl) were taken from the tail vein according to Fluttert
et al. (9) using heparinised tubes (Microvette® CB 100/200, Sarstedt,
Nümbrecht, Germany). Samples were centrifuged (15 min at 14.000 rpm;
ambient temperature) and plasma (25 µl) was pipetted into
radioimmunoassay tubes and stored at 4°C until analysis.
CSF samples (about 40 µl) were taken according to the cisternal puncture
method using a stereotaxic frame with the rats in the supine-70° angle
position as described earlier (15). CSF samples were directly collected in
pre-weighed radioimmunoassay tubes and stored at 4°C until further
analysis.
2.9. Hydrocortisone and data analysis
Plasma and CSF samples were analysed on HC by radioimmunoassay
(Coat-A-Count® Cortisol RIA kit, DPC, Los Angeles, CA, USA) with a
detection limit of  2 ng/ml. The analysis was performed according to the
manufacturer’s protocol. When calculating the HC concentration for the
CSF samples, the different sample volumes were taken into account.
The AUC
0-120 min
 values were calculated using the trapezoidal rule. Data
were analysed according to the paired Student’s t-test using the computer
program SPSS version 8.0 for windows.
3 Results
3.1. Intranasal HC delivery
In the first series of  experiments, rats were given HC (280 µg/animal)
intranasally in three different volumes (20, 40 and 60 µl) and during a
period of  2 hours blood and CSF samples were taken. The results are
shown in Figure 1a and 1b respectively. Increasing the nasal delivery
volume did not influence the absorption of  HC in plasma nor the uptake
into CSF. All three delivery volumes gave similar plasma concentration-
time profiles with a C
max
 ranging from 550 to 700 ng/ml at 10 – 20 min.
In CSF a C
max
 of about 12 ng/ml (20 and 40 µl) and 16 ng/ml (60 µl) with
a delayed t
max
 (t = 60, 25 and 40 min, respectively) was observed.
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a
b
Figure 1 Mean (± sd) plasma (a) and CSF (b) levels after intranasal delivery of  HC
(280 µg/rat) in 20 µl (i.n.-20 µl; n = 8), 40 µl (i.n.-40 µl; n = 7) and 60 µl (i.n.-60 µl; n


































































3.2. Intravenous HC administration
In order to determine the contribution of  the nose-CSF pathway to the
uptake of  HC in CSF after nasal administration, the nasal route was
compared with intravenous delivery. To that purpose the rats were
provided with a subcutaneously implanted VAP, making it possible to
give the i.v. bolus injection and the i.v. infusion of  HC in the same set of
rats as used for the nasal studies. First, an i.v. bolus injection (280 µg HC/
rat) was performed to determine the pharmacokinetic parameters. Figure
2 shows that using the VAP a common plasma-time profile for i.v. bolus
administration was obtained. From the calculated parameters (Table I)
the infusion rate of  HC needed to reach the C
max
 levels found after nasal




The plasma concentration-time curve following i.v. infusion of  HC
according to the calculated infusion rate (HC formulation, 0.14 mg/ml;
68 µl/min for 15 min) is depicted in Figure 3a together with the plasma
profile after intranasal administration. The CSF profiles are shown in
Figure 3b. For i.v. infusion higher plasma levels were achieved until 20
min after HC delivery, although not significantly different from those
after nasal administration. The elimination phase (20 –120 min) for both
delivery routes was comparable. Nevertheless, the uptake of  HC into
CSF after nasal administration appeared to be prolonged compared to
i.v. infusion.
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Table I Pharmacokinetic parameters of HC in rats 
Parameter Mean ± sd (n = 3) 
k (min-1) 0.017 ± 0.004 
t1/2  (min) 44.1 ± 12.6 
C0 (ng/ml) 1294 ± 70 
Vd (ml/rat) 217 ± 12 
CL (ml/min/rat) 3.6 ± 1.1 
R0 (µg/min) 9.48 ± 0.82 
k: elimination constant, t1/2: elimination half-life, C0: HC concentration at t = 0 
after i.v. bolus injection, Vd: distribution volume, CL: clearance, R0: infusion 
rate needed to reach a Cmax of 580 ng/ml at t = 15. 
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Figure 2 Mean (± sd) plasma levels after intravenous bolus injection of  HC (280 µg/
rat; n = 3).
3 Results
Table II AUCCSF/AUCplasma ratios of HC  































Data are presented as mean ± sd (n = 6 – 7). AUCCSF, AUCplasma and 
AUCCSF/AUCplasma ratios are given per treatment; the values for the various 

































Figure 3 Mean (± sd) plasma (a) and CSF (b) levels after i.v. infusion (0.14 mg/ml;
68 µl/min for 15 min; n = 7) and intranasal delivery of  HC (i.n.-20 µl; 280 µg/rat; n
= 8) in rats.



































































The contribution of  the nose-CSF pathway to the uptake of  HC into the





infusion and intranasal delivery (Table II). The amount of  HC found in
CSF was in the order of  3 – 4 %, and no significant differences were
observed between both routes of  administration.
4 Discussion
This paper evaluates the animal model that has been set-up previously to
study the nose-CSF pathway in rats (15). Also the influence of  the delivery
volume on nasal absorption of  HC was investigated. In addition, the
uptake of  HC into the CSF was determined after the nasal and intravenous
routes of administration.
For nasal administration and CSF sampling the rat was fixed in a stereotaxic
frame in the supine-70° angle position. Increasing the delivery volume
from 20 to 40 and 60 µl did not further influence the absorption of  HC
into plasma or the uptake of  HC into CSF (Figure 1). An increase in
delivery volume is expected to increase the contact surface and deposition
area between the formulation and the nasal epithelium (respiratory and
olfactory epithelium), thereby enhancing drug absorption and/or uptake
into the CSF via the nasal epithelium. However, this was not observed in
the present study. It might be that the formulations of  40 and 60 µl were
partly swallowed and taken up via the gastro-intestinal tract, although
this was not evident from the HC plasma concentration-time curves. For
the rat it is known that, when using a nasal delivery volume of  20 µl to
one nostril, there is no risk on oral absorption (2).
By providing the rats with a subcutaneous VAP, the animal model was
extended with the possibility to give the test compound both nasally and
intravenously in the same animal. The VAP allows a direct and easy
entrance to the blood circulation and it is easily implanted. It can be used
multiple times for i.v. administration as well as for blood sampling (13,
18) although sampling via the VAP was not used in the present studies.
When using the VAP for i.v. bolus administration, the dead volume (100
µl) has to be taken into account. Rinsing the VAP with 500 µl saline
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immediately after delivering the bolus ensures that the whole formulation
will enter the systemic circulation. Our experience was that, when giving
an i.v. infusion, there is no need to adapt the infusion for the dead volume
of  the VAP.
Using the present rat model, the contribution of  the nose-CSF pathway
to the uptake of  HC from the nasal cavity into the CSF could be





intranasal delivery and intravenous infusion of  HC (Table II) showed no
difference in HC distribution over plasma and CSF following both routes
of  administration. This suggests that after nasal delivery HC was rapidly
taken up in the systemic circulation and subsequently transported to the
CSF via the blood-brain barrier, without a significant contribution via
the direct nose-CSF pathway. The lipophilicity of  HC is probably the
cause for its rapid absorption from the nasal cavity into the blood stream.
This has also been reported for the lipophilic compounds (S)-UH-301
(5HT-antagonist) (6) and compound 1 (cognition enhancer) (10). In the
latter study brain tissue was sampled instead of  CSF. Hussain et al. (10)
already hypothesised that drugs that are rapidly absorbed after nasal
administration will not have enough time to be taken up via the olfactory
epithelium, and this was also supported by other studies (3, 7, 17).
Hydrophilic drugs will probably be taken up via the nose-brain pathway
more efficiently, because their diffusion from the nasal cavity into the
systemic circulation is rather slow and their residence time in the nasal
cavity long enough for uptake by the olfactory epithelium. However, other
studies showed the opposite, that lipophilic compounds are transported
to the brain or CSF more efficiently than hydrophilic substances following
nasal administration (4, 14). These studies report that within a certain
group of  compounds the lipophilicity of  a compound, expressed as the
LogP or partition coefficient, influences the transport along the nose-
brain/CSF route. However, the contradictory trends between the groups
indicate that more factors determine the uptake of  drugs into the brain
or CSF after nasal delivery. For example, it is well known that lipophilicity
plays an important role in drug transport across the blood-brain barrier.
Moreover, Feher et al. (8) found that, besides the lipophilicity of  a drug,
the polar surface area and the number of  hydrogen-bond acceptors in an
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aqueous medium are needed to predict drug partitioning across the blood-
brain barrier.
In summary, the present rat model including the VAP as intravenous
delivery device is suitable for studying nose-CSF transport of  drugs by
comparing intranasal and intravenous administration in the same animal.
Increasing the nasal delivery volume from 20 to 60 µl did not influence




ratios after nasal and intravenous administration showed no differences
in HC uptake into the CSF. These results indicate that there is no direct
nose-CSF transport of  HC after nasal administration. CSF uptake after
nasal delivery is presently investigated for a number of  central nervous
system active drugs with differences in hydrophilicity/lipophilicity balance,
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Uptake of  estradiol or progesterone into the
CSF following intranasal and intravenous
delivery in rats
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Abstract
The uptake of  estradiol and progesterone into the CSF after intranasal
and intravenous administration in rats was investigated. Each animal re-
ceived estradiol intranasally (40 µg/rat) and by intravenous infusion (10
µg/rat) into the jugular vein using a vascular access port. Hereafter, the
same set of  rats was treated with progesterone intranasally (200 µg/rat)
and by intravenous infusion (104 µg/rat). Following nasal delivery, both
steroid hormones reach C
max
 values in plasma and CSF at 15 min after
administration. Intravenous infusion of  estradiol and progesterone shows
comparable plasma and CSF concentration-time profiles compared to





± sd) after intranasal delivery (estradiol: 2.3 ± 1.1 %; progesterone: 1.9 ±
0.7 %) do not differ significantly from the ratios shown after intravenous
infusion (estradiol: 2.0 ± 0.6 %; progesterone: 2.2 ± 0.8 %). These results
indicate that after nasal delivery estradiol and progesterone are rapidly
absorbed into the systemic circulation, from where probably the non-
protein bound hormones enter the CSF by crossing the blood-brain bar-
rier. No extra direct nose-CSF transport could be demonstrated.
Keywords
estradiol; progesterone; intranasal delivery; intravenous delivery; nose-
CSF drug transport
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1. Introduction
Targeting of  drugs to the central nervous system is still a difficult task to
full-fill. This is due to the tight blood-brain barrier, which prevents the
influx of  xenobiotic compounds from the systemic circulation into the
brain. In order to overcome this barrier, nasal delivery has been explored
as alternative administration route to target drugs directly to the brain via
the olfactory neurons (16, 19). However, whether this direct delivery route
is effective or not, is still under debate.
For direct nose-cerebrospinal fluid (CSF) drug delivery the reported stud-
ies by Anand Kumar and co-workers with the female steroid hormones
estradiol and progesterone are often referred to as evidence of  a direct
transport route from the nasal cavity into the CSF for such compounds
(1-3, 11, 23). These hormones are involved in the physiological regula-
tion of  reproduction and used in contraceptives and as drugs for the
treatment of  menopausal symptoms. Due to a high first-pass effect in
the gastrointestinal tract and liver, both hormones have a low bioavailability
after oral administration. Therefore, alternative administration routes have
been investigated such as transdermal (4, 30) and intranasal delivery (25,
29). The physiological production of  estradiol and progesterone is sub-
ject to neuro-endocrine regulation in the brain (5), and from this per-
spective Anand Kumar et al. investigated the uptake of  both steroids into
the CSF after intranasal and intravenous administration in monkeys (1-3,
11, 23). From these studies the authors concluded that a direct uptake of
both steroid hormones occurred from the nasal cavity into the CSF. The
fact that these studies are often cited in literature, show their importance
in this research area. However, to the authors’ opinion their experimental
conditions used for nasal drug delivery were rather aggressive. The ster-
oid hormones were dissolved in either pure propylene glycol (PG) (3) or
several mixtures of  ethanol, PG and water (1:1:3 and 3:3:4) (1, 2, 11, 23).
Moreover, the estradiol and progesterone formulations were adminis-
tered to monkeys using an atomiser, which device sprayed the formula-
tion into the nasal cavity with a very high pressure (0.25 kg/cm2) and a





 ratios after both intranasal and intrave-
nous delivery of  the steroids were not measured, although this is a well
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accepted approach to determine an additional contribution of  the nose-
CSF pathway to the uptake of  drugs into the CSF after nasal delivery in
comparison with intravenous administration (7-10, 15, 28).
In the present study the possibility of  direct nose-CSF transport for
estradiol and progesterone was investigated by comparing the relative
distribution of  these drugs over CSF and plasma after both intranasal
and intravenous administration in rats. In order to dissolve the lipophilic
steroids in saline, randomly methylated ß-cyclodextrin (RAMEB) was used
as solubiliser. RAMEB is able to form an inclusion complex with lipophilic
drugs, thereby enhancing their solubility in aqueous solutions (18). Nasal
delivery in rats was subsequently performed by drop application of  the
steroid formulations. In order to monitor the distribution of  the admin-
istered drug a recently developed rat model was used, which enables se-
rial and simultaneous sampling of  CSF and plasma (27). The CSF sam-
pling technique is not terminal for the animals and therefore the same set
of  rats can be used for both the intranasal and the intravenous routes of
drug administration (28).
2. Materials and methods
2.1. Materials
Estradiol (17ß-estradiol) and progesterone were from Sigma Chemical
(St. Louis, MO, USA) and randomly methylated ß-cyclodextrin (RAMEB;
degree of  substitution 1.8) from Wacker-Chemie (Krommenie, The Neth-
erlands). All other reagents were of  analytical grade or highest grade com-
mercially available.
2.2. Drug formulations
Estradiol and progesterone were dissolved in ethanol with RAMEB (molar
ratio 1:2) to form inclusion complexes (14). Ethanol was evaporated un-
der a mild nitrogen stream (35°C) and the inclusion complexes were dis-
solved in sterile saline to obtain the final estradiol and progesterone for-
mulations. The estradiol formulations contained the following estradiol
(mg/ml) and RAMEB (%, w/v) concentrations: 2 mg/ml and 2 % (w/v)
for nasal delivery and 0.01 mg/ml and 0.01 % (w/v) for intravenous infu-
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sion. For the progesterone (mg/ml) formulations these concentrations
were 10 mg/ml and 9 % (w/v) for nasal delivery and 0.1 mg/ml and 0.09
% (w/v) for intravenous infusion.
2.3. Animals
Male Wistar rats (Charles River, Someren, The Netherlands) were used,
weighing 250 – 340 g at the start of  the experiments. The animals (n = 7)
were housed separately with free access to food and water with a 12-h
light/dark cycle. All animal experiments were approved by the Ethical
Committee for Animal Experiments (Leiden University).
2.4. Implantation of  Vascular Access Port (VAP)
The animals were provided with a VAP as described before (28). Briefly,
the rats were anaesthetised with Hypnorm® (0.5 ml/kg) and Dormicum®
(0.5 ml/kg) intramuscularly. Two incisions were made, one at the level of
the lower ribs to create a pocket for inserting the VAP (Access Technolo-
gies, Skokie, IL, USA) and one in the neck to cannulate the jugular vein.
The VAP, attached to a silicone catheter (ID 0.5 mm, OD 1.0 mm), was
filled with heparin solution (400 IU/ml) using a Huberpoint needle (Ac-
cess Technologies, Skokie, IL, USA) and fitted into the pocket. The cath-
eter was tunnelled underneath the skin from the pocket to the second
incision in the neck and inserted into the jugular vein. As post-operative
care Temgesic® (0.3 ml/kg, intramuscularly) was given for pain relief.
The rats were allowed to recover 1 week before starting the experiments.
To avoid blockage of  the catheter, the VAP was flushed weekly with
heparin solution (400 µl; 400 IU/ml).
2.5. Nasal and intravenous delivery
Estradiol was delivered intranasally (40 µg /20 µl/rat) into the left nostril
using a polyvinylchloride (PVC) tube attached to a Hamilton syringe,
while the animal was fixed in a stereotaxic frame in the supine-70° angle
position (27). Intravenous infusion of  estradiol (67 µl/min for 15 min
(10 µg /rat)) was performed into the jugular vein using the VAP as previ-
ously described (28). In between experiments the rats were allowed to
recover for one week. Hereafter the same set of  rats was treated with
progesterone intranasally (200 µg/20 µl/rat) and by intravenous infusion
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(69 µl/min for 15 min (104 µg/rat)) following the same methods and
time schedule.
The intravenous infusion rates for estradiol and progesterone were cho-
sen in such a way to simulate the observed maximal steroid plasma levels
after intranasal delivery. This infusion rate was determined by giving the
rats (n = 3) an intravenous bolus injection of  the steroid hormone as
described previously (28).
Prior to and following drug delivery, blood and CSF samples were taken
until 120 min after each administration. Each rat received the nasal and
intravenous treatment for both estradiol and progesterone.
2.6. Blood and CSF sampling
Blood samples (200 µl) were taken from the tail vein using heparinised
tubes (Microvette® CB 100/200, Sarstedt, Nümbrecht, Germany). Sam-
ples were centrifuged (15 min at 14000 rpm; ambient temperature) and
plasma obtained was stored at 4°C until analysis.
For CSF sampling a cisternal puncture was performed as described be-
fore (27). Briefly, rats were anaesthetised as mentioned above and fixed in
a stereotaxic frame using the supine-70° angle position. The cisternal
puncture was performed 5.2 – 6.5 mm ventrally from the occipital crest,
dependent on the rat’s weight. After the puncture, one drop of  CSF was
microscopically examined on erythrocyte contents; the experiment was
continued when the erythrocyte contamination was less than 500 cells/µl
(< 0.01 % of  normal blood content). Following intranasal or intravenous
drug administration, CSF samples (30 – 40 µl) were taken and directly
collected in pre-weighed antibody-coated radioimmunoassay tubes and
stored at 4°C until analysis.
2.7. Estradiol and progesterone analysis
Plasma and CSF samples were analysed on estradiol or progesterone by
radioimmunoassay (Coat-A-Count® Estradiol and Progesterone RIA kits,
DPC, Los Angeles, CA, USA) with detection limits of  8 pg/ml and 20
pg/ml, respectively. The analyses were performed according to the manu-
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facturer’s protocol. When calculating the estradiol and progesterone con-
centrations for the CSF samples, the different sample volumes were taken
into account.
2.8. Data analysis
The area under the plasma or CSF concentration – time curve (AUC)





 ratios were calculated for each individual
animal before determining mean values. Data were analysed according to
the paired Student’s t-test, using the computer program SPSS version 8.0
for Windows.
3. Results
To determine whether or not estradiol and progesterone are transported
from the nasal cavity into the CSF via the olfactory neurones, these ster-
oid hormones were administered intranasally and intravenously in the
same set of  rats. Both estradiol and progesterone reached a C
max
 (mean ±
sd) in plasma at 15 min after intranasal administration (17.3 ± 2.2 ng/ml
and 63.0 ± 12 ng/ml, respectively; Figure 1a and 2a). In CSF the C
max
values for estradiol and progesterone were about 50 - fold lower (0.32 ±
0.15 ng/ml and 1.16 ± 0.39 ng/ml at t = 15 min, respectively) compared
to the observed plasma levels (Figure 1b and 2b). Intravenous infusion
of  estradiol and progesterone showed comparable plasma and CSF con-
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Table I AUCCSF/AUCplasma ratios of estradiol and progesterone after intranasal 
delivery (i.n.) and intravenous infusion (i.v.) in ratsa 
 Estradiol  Progesterone 
  
 
i.n. i.v.  i.n. i.v. 
AUCCSF 
(ng*min/ml) 
22.1 ± 10.6 
 
12.0 ± 5.5  94.8 ± 44.9 74.3 ± 27.4 
AUCplasma 
(ng*min/ml) 
975 ± 91 
 
583 ± 113  4739 ± 790 3333 ± 544 
AUCCSF / 
AUCplasma (%) 
2.3 ± 1.1 
 
2.0 ± 0.6  1.9 ± 0.7 2.2 ± 0.8 
aData are presented as mean ± sd (n = 7). 
 
b
Figure 1 Estradiol plasma (a) and CSF (b) concentrations after intranasal (i.n.; 40 µg/
rat) and intravenous (i.v. ; 10 µg/rat) administration in rats. Data are presented as mean
± sd of  7 animals.
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Figure 2 Progesterone plasma (a) and CSF (b) concentrations after intranasal (i.n.; 200
µg/rat) and intravenous (i.v. ; 104 µg/rat) administration in rats. Data are presented as










































































centration-time profiles compared to the nasal route of administration
for these steroid hormones.




 ratios after intranasal delivery
(estradiol: 2.3 ± 1.1 %; progesterone: 1.9 ± 0.7 %) did not differ signifi-
cantly from the ratios observed after intravenous infusion (estradiol: 2.0
± 0.6 %; progesterone: 2.2 ± 0.8 %; Table I).
4. Discussion




ratios are observed for
estradiol and progesterone after nasal and intravenous administration to
rats, which demonstrates that there is no additional uptake of  these hor-
mones from the nasal cavity into the CSF. This finding is supported by a
study investigating nasal estradiol in monkeys measuring plasma and CSF
profiles (21). However, this is in contrast to the observations in monkeys
by the research group of  Anand Kumar (1-3, 11, 23). A remarkable fea-
ture in their studies is the composition of  the nasal formulations and the
used delivery method. The formulations contained mixtures of  ethanol,
PG and water (1:1:3 and 3:3:4) (1, 2, 11, 23) or even pure PG (3) to dis-
solve the steroid hormones. PG and ethanol are widely used as solvents
and drug excipients (13). However, PG may also cause local irritation of
the mucous membranes. The atomiser, used as delivery device, blows the
formulation into the nose with a great force (0.25 kg/cm2) which is con-
tinued for a time period of  10 – 60 sec (1, 3). Furthermore, experimental
groups of  only 2 – 3 animals were used (1, 3, 11, 23), which is too few to
prove significant differences between groups. The transport of  proges-





 values, following intranasal delivery compared to
intravenous administration (1, 2, 11). In our view simultaneously elevated
AUC values in blood and in CSF after nasal delivery is an indication that
the uptake of  progesterone into CSF occurs via the blood-brain barrier,
rather than via direct transport between the nasal cavity and the CSF.




 was reported for only a
few time points (3, 23), not offering a representative drug distribution
profile after nasal or intravenous delivery. Taken together, the aggressive
delivery method and the experimental design of  these studies are re-
sponsible for the so-called nose-CSF transport of  estradiol and proges-
terone in monkeys.
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In the present study the distribution of  estradiol and progesterone over
plasma and CSF was determined using a previously described rat model
(28), which has the advantage of  simultaneous and serial sampling of
blood and CSF. In order to diminish the inter-animal variability, the ster-
oid hormones were delivered both intranasally and intravenously in the





(Table I) show that the distribution of  these drugs over CSF and plasma
are similar after both routes of  administration. This indicates that after
nasal delivery estradiol and progesterone are rapidly absorbed into the
systemic circulation, from where probably the non-protein bound hor-
mones subsequently enter the CSF by crossing the blood-brain barrier.
Moreover, nasal estradiol and progesterone formulations containing
RAMEB in similar concentrations as described here, are not toxic for
ciliary movement (20). Also in humans during a treatment period of  one
year (n > 1400) the safety of  a RAMEB-estradiol formulation has been
demonstrated (12). This indicates that the nasal estradiol and progester-
one formulations used in the present study are not aggressive.
A transport to the CSF via the blood-brain barrier has also been reported
for low molecular weight and lipophilic compounds such as a cognition
enhancing drug (15), a serotonin antagonist (10) and the steroid hor-
mone hydrocortisone (28), and for the high molecular weight and hy-
drophilic vitamin B
12
 analogue hydroxocobalamin (26). Nevertheless, other
reports claim a direct nose-CSF pathway for lipophilic (lidocaine (7) and
the antihistamine hydroxyzine (6)) and hydrophilic (zidovudine (24), L-
dopa prodrugs (17), cephalexin (22)) low molecular weight drugs. This
demonstrates that there is still no unambiguous answer to the question
whether or not a direct nose-to-CSF/brain transport route exists.
In conclusion, the present study examined the uptake of  estradiol and
progesterone into the CSF after nasal and intravenous delivery in rats.




 ratios were found after
both routes of  administration. This proves there is no direct nose-to-





1. Anand Kumar, T.C., David, G.F.X., and Puri, V. (1979) Nasal spray
 and contraceptives. In: Recent Advances in Reproduction and Regu-lation
of  Fertility,  Editor: Talwar, G.P.; Elsevier/North-Holland Bio-medi-
cal Press, Amsterdam, 49-56.
2. Anand Kumar, T.C., David, G.F.X., Sankaranarayanan, A., Puri, V.,
and Sundram, K.R. (1982) Pharmacokinetics of  progesterone after
its administration to ovariectomized rhesus monkeys by injection,
infusion, or nasal spraying. Proceedings of  the National Academy of  Sci-
ences of the United States of America 79 4185-4189.
3. Anand Kumar, T.C., David, G.F.X., Umberkoman, B., and Saini, K.D.
(1974) Uptake of  radioactivity by body fluids and tissues in rhesus
monkeys after intravenous injection or intranasal spray of  tritium-
labelled oestradiol and progesterone. Current Science 43 435-439.
4. Balfour, J.A. and Heel, R.C. (1990) Transdermal estradiol. A review
of  its pharmacodynamic and pharmacokinetic properties and thera-
peutic efficacy in the treatment of  menopausal complaints. Drugs
40 561-582.
5. Berne, R.M. and Levy, M.D. (1990) Principles of  physiology, Edi-
tors: Bircher Manning, S., Steiner, T.J., Gunter, A., and Salway, J.;
Wolfe Publishing Ltd.,
6. Chou, K.J. and Donovan, M.D. (1997) Distribution of  antihistamines
into the CSF following intranasal delivery. Biopharmaceutics and Drug
Disposition 18 335-346.
7. Chou, K.J. and Donovan, M.D. (1998) Lidocaine distribution into
the CNS following nasal and arterial delivery: a comparison of  local
sampling and microdialysis techniques. International Journal of  Phar-
maceutics 171 53-61.
8. Chow, H.H.S., Anavy, N., and Villalobos, A. (2001) Direct nose-brain
transport of  benzoylecgonine following intranasal administration in
rats. Journal of  Pharmaceutical Sciences 90 1729-1735.
9. Chow, H.H.S., Chen, Z., and Matsuura, G.T. (1999) Direct transport
of  cocaine from the nasal cavity to the brain following intranasal
cocaine administration in rats. Journal of  Pharmaceutical Sciences 88 754-
758.
10. Dahlin, M. and Björk, E. (2000) Nasal absorption of  (S)-UH-301
94
4 Uptake of  estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats
and its transport into the cerebrospinal fluid of  rats. International Journal
of  Pharmaceutics 195 197-205.
11. David, G.F.X., Puri, C.P., and Anand Kumar, T.C. (1981) Bioavailability
of  progesterone enhanced by intranasal spraying. Experientia 37 533-
534.
12. Dooley, M., Spencer, C.M., and Ormrod, D. (2001) Estradiol-intra-
nasal - A review of  its use in the management of  menopause. Drugs
61 2243-2262.
13. Golightly, L.K., Smolinske, S.S., Bennet, M.L., Sutherland, E.W., and
Rumack, B.H. (1988) Pharmaceutical excipients. Adverse effects as-
sociated with inactive ingredients in drug products (part I). Medical
Toxicology 3 128-165.
14. Hermens, W.A.J.J., Deurloo, M.J.M., Romeijn, S.G., Verhoef, J.C., and
Merkus, F.W.H.M. (1990) Nasal absorption enhancement of  17-b-
oestradiol by dimethyl-b-cyclodextrin in rabbits and rats. Pharma-
ceutical Research 7 500-503.
15. Hussain, M.A., Rakestraw, D., Rowe, S., and Aungst, B.J. (1990) Na-
sal administration of  a cognition enhancer provides improved
bioavailability but not enhanced brain delivery. Journal of  Pharma-
ceutical Sciences 79 771-772.
16. Illum, L. (2000) Transport of  drugs from the nasal cavity to the cen-
tral nervous system. European Journal of  Pharmaceutical Sciences 11 1-18.
17. Kao, H.D., Traboulsi, A., Itoh, S., Dittert, L., and Hussain, A. (2000)
Enhancement of  the systemic and CNS specific delivery of  L-dopa
by the nasal administration of  its water soluble prodrugs. Pharma-
ceutical Research 17 978-984.
18. Marttin, E., Verhoef, J.C., and Merkus, F.W.H.M. (1998) Efficacy, safety
and mechanism of  cyclodextrins as absorption enhancers in nasal
delivery of  peptide and protein drugs. Journal of  Drug Targeting 6 17-
36.
19. Mathison, S., Nagilla, R., and Kompella, U.B. (1998) Nasal route for
direct delivery of  solutes to the central nervous system: Fact or fic-
tion? Journal of  Drug Targeting 5 415-441.
20. Merkus, P., Romeijn, S.G., Verhoef, J., Merkus, F.W.H.M., and
Schouwenburg, P.F. (2001) Classification of  cilio-inhibiting effects
of  nasal drugs. Laryngoscope 111 595-602.
95
5. References
21. Öhman, L., Hahnenberger, R., and Johansson, E.D.B. (1980) 17b-
Estradiol levels in blood and cerebrospinal fluid after ocular and
nasal administration in women and female rhesus monkeys (Macaca
mulatta). Contraception 22 349-358.
22. Sakane, T., Akizuki, M., Yoshida, M., Yamashita, S., Nadai, T., Hashida,
M., and Sezaki, H. (1991) Transport of  cephalexin to the cerebros-
pinal fluid directly from the nasal cavity. Journal of  Pharmacy and Phar-
macology 43 449-451.
23. Sehgal, A. and David, G.F.X. (1980) Patterns of  transfer of  tritiated
progesterone into blood & cerebrospinal fluid of  rhesus monkeys
following diverse methods of  administration. Indian Journal of  Ex-
perimental Biology 18 707-708.
24. Seki, T., Sato, N., Hasegawa, T., Kawaguchi, T., and Juni, K. (1994)
Nasal absorption of  zidovudine and its transport to cerebrospinal
fluid in rats. Biological and Pharmaceutical Bulletin 17 1135-1137.
25. Studd, J., Pronel, B., Marton, I., Bringer, J., Varin, C., Tsouderos, Y.,
and Christiansen, C. (1999) Efficacy and acceptability of  intranasal
17 ß-oestradiol for menopausal symptoms: randomised dose-response
study. Lancet 353 1574-1578.
26. Van den Berg, M.P., Merkus, P., Romeijn, S.G., Verhoef, J.C., and
Merkus, F.W.H.M. (2003) Hydroxocobalamin uptake into the cer-
ebrospinal fluid after nasal and intravenous delivery in rats and hu-
mans. Journal of  Drug Targeting 11 325-331.
27. Van den Berg, M.P., Romeijn, S.G., Verhoef, J.C., and Merkus,
F.W.H.M. (2002) Serial cerebrospinal fluid sampling in a rat model to
study drug uptake from the nasal cavity. Journal of  Neuroscience Methods
116 99-107.
28. Van den Berg, M.P., Verhoef, J.C., Romeijn, S.G., and Merkus,
F.W.H.M. (2002) Uptake of  hydrocortisone into the cerebrospinal
fluid of  rats: comparison of  intranasal and intravenous administr-
tion in the same animal. STP Pharma Sciences 12 251-255.
29. Wattanakumtornkul, S., Pinto, A.B., and Williams, D.B. (2003) Intra-
nasal hormone replacement therapy. Menopause The Journal of  the
North American Menopause Society 10 88-98.
96
4 Uptake of  estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats
30. Whitehead, M.I., Fraser, D., Schenkel, L., Crook, D., and Stevenson,
J.C. (1990) Transdermal administration of  oestrogen/progestagen




Uptake of  melatonin into the cerebrospinal
fluid after nasal and intravenous delivery:
Studies in rats and comparison with a human
study
M.P. van den Berg, P. Merkus1, S.G. Romeijn, J.C. Verhoef  and F.W.H.M. Merkus
Pharmaceutical Research (2004) 21 799-802.
1 Department of  Oto-Rhino-Laryngology, Head & Neck surgery, Vrije Universiteit Medical Centre,
P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
Abatract
Purpose. To investigate the possibility of  direct transport of  melatonin
from the nasal cavity into the cerebrospinal fluid (CSF) after nasal ad-
ministration in rats, and to compare the animal results with a human
study.
Methods. Rats (n = 8) were given melatonin both intranasally in one nostril
(40 µg/rat) and intravenously by bolus injection (40 µg/rat) into the jugu-
lar vein using a Vascular Access Port. Just before and after drug adminis-
tration blood and CSF samples were taken and analysed by HPLC.
Results. Melatonin is quickly absorbed in plasma (T
max
 = 2.5 min) and
shows a delayed uptake into CSF (T
max
 = 15 min) after nasal administra-
tion. The melatonin concentration-time profiles in plasma and CSF are




ratio after nasal delivery (32.7 ± 6.3 %) does not differ from the one after
intravenous injection (46.0 ± 10.4 %), which indicates that melatonin
enters the CSF via the blood circulation across the blood-brain barrier.
This demonstrates that there is no additional transport via the nose-CSF-
pathway. These results resemble the outcome of  a human study.
Conclusions. The present results in rats show that there is no additional
uptake of  melatonin in the CSF after nasal delivery compared to intrave-
nous administration. This is in accordance with the results found in hu-
mans, indicating that animal experiments could be predictive for the hu-
man situation when studying nose-CSF transport.
Keywords
melatonin, intranasal, intravenous, cerebrospinal fluid, rat, human
100
5 Uptake of  melatonin into the cerebrospinal fluid after nasal and intravenous delivery
1. Introduction
The main problem in the development of  neuro-active compounds is
the passage of  these drugs across the blood-brain barrier (BBB). This
tight barrier protects the brain from exogenous compounds including
drugs (18). Several methods have been investigated to open or manipu-
late the BBB (28) to enable drugs passing from the blood circulation into
the brain. Nevertheless, these methods did not give a satisfying solution
to the problem of  brain targeting. Circumventing the BBB by targeting
via the nose to brain pathway has been suggested as a possible alternative
way to reach the brain and the surrounding cerebrospinal fluid (CSF) (9,
15).
The neuronal connection between the nasal cavity and the CSF and brain
has been extensively investigated on the possibility for brain targeting of
drugs. Animal and human studies have been performed providing
pharmacokinetic (PK) (2, 3, 24) and pharmacodynamic (PD) data (5, 11,
19-21, 27), respectively. In human studies hormones and peptide drugs
were tested, mainly monitoring PD effects. Arginine-vasopressin (20),
cholecystokinin-8 (21), adrenocorticotropin (ACTH) 4-10 (27) and insu-
lin (11) increased brain potentials after nasal delivery compared to intra-
venous administration. Nasal delivery of  angiotensin II increased both
norepinephrine and vasopressin release, which was opposite to the ef-
fects after intravenous administration (5). These effects after nasal angi-
otensin II administration show similarities with the results after
intracerebroventricular delivery in rats (22, 33), suggesting that nasal ad-
ministration of angiotensin II induces a direct central effect.
Animal studies give a PK support for drug targeting via the nose-brain/
CSF pathway. The influence of  physicochemical factors like molecular
weight, ionisation degree and lipophilicity on nose-brain transport has
been investigated in animals (24). A large number of  animal studies with
low molecular weight drugs as hydroxyzine (2), dopamine (4), cephalexin
(23), anti-HIV agents as D4T (34) and zidovudine (26), metals (29), vi-
ruses (10, 14), steroid hormones (1) and polypeptides (7, 13) claim that
the nasal route of  drug administration offers direct access to the brain
and CSF in animals.
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The key-question is still whether this direct transport route is really effec-
tive or not. To verify the actual feasibility of  this novel approach, it is
necessary to compare animal studies with human data. In order to ex-
trapolate the results from animals to humans, the studies mentioned above
need to be complemented with human PK and animal PD data. This
difference in available data between animals and men is due to practical
reasons. It is more difficult to sample human CSF than to monitor PD
effects in human subjects, while the contrary holds for animal studies. A
recent Neurology paper describes for the first time the uptake of  two model
compounds in blood and CSF after nasal and intravenous delivery in the
same human being. In neurosurgery patients with a CSF drain it was
possible to investigate the nose-CSF pathway of  the low molecular weight
and lipophilic substance melatonin and the high molecular weight and
hydrophilic molecule hydroxocobalamin, both serving as model com-
pounds (17). Due to the strict inclusion and exclusion criteria only three
subjects could be investigated. In order to substantiate the results of  this
human study, in the present paper the same melatonin formulation was
investigated in rats (n = 8) using a comparable experimental set-up. Fur-
thermore, such a comparison can provide a basis for extrapolating the
results of nose-CSF studies from animals to men.
2. Materials and methods
2.1. Materials
Melatonin (LogP = 1.2 (12)) was from Biosynth AG (Staad, Switserland),
povidone iodine from Sigma Chemical (St. Louis, MO, USA) and ß-
cyclodextrin from Wacker-Chemie (Krommenie, The Netherlands). Etha-
nol (96 %) of  analytical grade was from Merck (Darmstadt, Germany).
Sterile saline (0.9 % NaCl) and heparin (400 IU/ml) were obtained from
the Hospital Pharmacy of  Leiden University Medical Centre (Leiden,
The Netherlands). Janssen Pharmaceutica (Beerse, Belgium) supplied
Hypnorm® (fentanyl citrate 0.315 mg/ml, fluanisone 10 mg/ml).
Dormicum® (midazolam, 5 mg/ml) was from Genthon B.V. (Nijmegen,
The Netherlands). Nembutal® (pentobarbital sodium, 60 mg/ml) was
purchased from Sanofi Sante Nutrition Animale (Libourne, France) and
Temgesic® (buprenorphine, 0.3 mg/ml) from Schering-Plough (Maarssen,




 were from J. Baker
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(Deventer, The Netherlands), and acetonitrile was from Biosolve LTD
(Valkenswaard, The Netherlands). All other reagents were of  analytical
grade.
2.2. Melatonin formulations
The melatonin formulation for nasal delivery consisted of  melatonin (2.0
mg/ml) and ß-cyclodextrin (7.5 mg/ml) dissolved in saline (16). This
formulation also contained benzalkonium chloride (0.01 % w/v) and
EDTA (0.1 % w/v) as preservatives. A 10-fold lower concentration was
used for intravenous bolus injection.
2.3. Animals
Male Wistar rats (Charles River, Someren, The Netherlands) were used,
weighing 330 – 465 g at the start of  the experiments. The animals (n = 8)
were housed (2 per cage) with free access to food and water with a 12-h
light/dark cycle. At the end of  the experiments the animals were
euthanised with an overdose of  Nembutal® (1 – 2 ml, intraperitoneally).
All animal experiments were approved by the Ethical Committee for
Animal Experiments (Leiden University).
2.4. Nasal and intravenous delivery of  melatonin
Prior to drug administration rats were anaesthetised with Hypnorm® (0.5
ml/kg) and Dormicum® (0.5 ml/kg) intramuscularly and fixed in a stere-
otaxic frame (model 51600, Stoelting, Wood Dale, IL, USA) using the
supine-70° angle position (31). For intranasal administration of  the me-
latonin formulation, a polyvinylchloride (PVC) tube (ID 0.5 mm, OD 1.0
mm) attached to a Hamilton syringe was inserted into the left nostril of
the rat for about 2 cm. The nasal melatonin dose (40 µg/20 µl/rat) was
delivered by gently pushing the plunger of  the syringe. After delivery of
the formulation the PVC tube was removed.
For the intravenous bolus injection the rats were provided with a Vascu-
lar Access Port (VAP) as described before (32). The intravenous mela-
tonin formulation (40 µg melatonin/200 µl/rat) was administered using a
1 ml syringe attached to a Huberpoint needle. Subsequently, the VAP was
rinsed with 500 µl saline to make sure that the entire formulation had
entered the blood stream.
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Prior to and following melatonin delivery, blood and CSF samples were
taken until 120 min after administration. Each rat received both the nasal
and intravenous treatment. Between experiments the animals were al-
lowed to recover for one week.
2.5. Blood and CSF sampling
Blood samples (200 µl) were taken from the tail vein using heparinised
tubes (Microvette® CB 100/200, Sarstedt, Nümbrecht, Germany) and the
samples were stored at 4°C until analysis.
For CSF sampling a cisternal puncture was performed as described be-
fore (31). Briefly, rats were anaesthetised and fixed in a stereotaxic frame
as mentioned above. The cisternal puncture was performed 5.2 – 6.5 mm
ventrally from the occipital crest, dependent on the rat’s weight. After the
puncture, one drop of  CSF was microscopically examined on erythro-
cyte contents; the experiment was continued when the erythrocyte con-
tamination was less than 500 cells/µl (< 0.01 % of  normal blood con-
tent). Following intranasal or intravenous drug administration, CSF sam-
ples (about 30 µl) were taken and directly collected in pre-weighed HPLC
vials and the volume was added up to 180 µl with Millipore® water. All
samples were analysed the same day.
2.6. Melatonin analysis
Blood samples were pretreated as follows. Blood samples were centri-
fuged (15 min at 14.000 rpm; ambient temperature) and the obtained
plasma (100 µl) was extracted with dichloromethane (2 ml) by shaking at
1000 rpm (Vibrax, type VXR; Fisher Scientific, ‘s Hertogenbosch, The
Netherlands) for 10 min. The two-phase system was centrifuged (5 min
at 3000 rpm; ambient temperature) and the organic phase was pipetted
into other tubes. Then dichloromethane was evaporated under a mild
nitrogen stream at 35°C, and the residue was dissolved in 250 µl mobile




 (pH 3.0) : acetonitrile = 73 : 27). Plasma and CSF
samples were analysed on melatonin as described previously (25). Briefly,
samples were analysed by isocratic HPLC consisting of  a Jasco PU-980
pump (Jasco, B&L systems, Zoetermeer, The Netherlands), a chromspher
C
18
 column (100 x 3.0 mm) with 5 µm sized particles (Varian BV, Houten,
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The Netherlands) using a flow of  1.0 ml/min and fluorescence detection
(excitation wavelength = 224 nm, emission wavelength = 348 nm; Jasco
821, B&L systems, Zoetermeer, The Netherlands) with a detection limit
of 8 pg/ml.
2.7. Data analysis
The area under the concentration-time curve (AUC) values (0-120 min)
were calculated using the trapezoidal rule. The CSF ratio was determined
according to Equation 1. This ratio is a measure for CSF uptake after
nasal delivery related to the uptake after intravenous administration (17).
All AUC values and CSF ratios were calculated per individual animal be-
fore determining the mean value. Data were analysed according to the
















2. Materials and methods
Table I AUCCSF/AUCplasma ratios and the CSF ratio of melatonin 
 Intranasal Intravenous 
   
Ratsa   
   AUCCSF (ng*min/ml) 774 ± 133 1069 ± 313 
   AUCplasma(ng*min/ml) 2429 ± 576 2310 ± 400 
   AUCCSF/AUCplasma (%) 32.7 ± 6.3 46.0 ± 10.4 
   CSF ratio (Equation 1) 0.76 ± 0.31 
  
Humansb  
   CSF ratio (Equation 1) 0.71 ± 0.30 
Data are presented as mean ± sd, a (n = 8), b (n = 3) (17). 
 
3. Results
In eight rats melatonin (40 µg/rat) was administered intranasally and sub-
sequently intravenously. Following intranasal administration, the plasma
C
max
 for melatonin was observed in the first sample taken after delivery (t
= 2.5 min) which was similar after intravenous bolus injection. Both routes
showed comparable plasma concentration-time profiles of  melatonin
(Figure 1). The uptake of  melatonin into the CSF was delayed for about
10 – 15 min compared to the absorption in plasma after intranasal and
intravenous delivery (for both routes: T
max
 = 15 min; Figure 1). In CSF
the uptake phase was similar for the intranasal and the intravenous route
of  administration, reaching mean C
max
 values of  18 ng/ml. This value
was 3.5 – 5 fold lower than the C
max
 found in plasma (64 ± 37 and 87 ± 30
ng/ml after intravenous and intranasal administration, respectively; Fig-
ure 1).
Table I gives an overview of  the AUC values in plasma and CSF after





tios and the CSF ratio. The calculated CSF ratio (0.76 ± 0.31) shows that
the relative uptake of  melatonin into the CSF after nasal delivery is not
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Figure 1 Plasma and CSF concentrations after intranasal (i.n.) and intravenous (i.v.)
delivery of  melatonin (40 µg/rat) in rats. Results are expressed as mean ± sd (n = 8).



































significantly different from the uptake after intravenous injection. This
ratio is smaller than 1, which indicates that there is no additional trans-
port from the nasal cavity into the CSF. The CSF ratio found in rats is
similar to that obtained in humans, as is also shown in Table I.
4. Discussion
The present study demonstrates that nasal delivery of  melatonin in rats
does not result in additional uptake of  this lipophilic/low molecular weight
drug (M
w
 = 232 Da) into the CSF via the nose-CSF pathway compared to
intravenous administration. This is in contrast to some earlier reported
rat studies with low molecular weight lipophilic and hydrophilic com-
pounds (1, 4, 23). In these studies the drug concentrations in CSF after
intranasal and intravenous delivery were determined at 1 – 2 time points
only, which gives limited information about the CSF uptake of  a drug
and may therefore be misleading. Possible discarding of  CSF samples
contaminated with blood was also not reported. Blood contamination in
CSF may lead to false positive conclusions. Nevertheless, in a previous
study from our laboratory another lipophilic and low molecular weight
drug, hydrocortisone, was evaluated for nose-CSF transport in rats (32).




 ratios after intranasal and intra-
venous delivery for this steroid hormone, no direct nose-CSF transport
was observed. These findings are supported by studies with other lipophilic
drugs such as the serotonin antagonist (S)-UH-301 (3), a cognition en-
hancer (8) and the antihistamine triprolidine (2). A lack of  direct nose-
CSF transport was also reported for the hydrophilic vitamin B
12
 analogue
hydroxocobalamin, which was studied in the same rat model as described
here (30).
The present rat studies show results similar to a human study (Table I;
(17)), in which, the same melatonin formulation is tested. The adminis-
tered melatonin dose in rats is relatively high in comparison with the
human study on a mg/kg basis: about 20- and 40-fold higher for intrana-
sal and intravenous administration, respectively. If  the same dose (mg/
kg) for humans would be used for rats, the melatonin concentrations in
plasma and particularly in CSF would have been below the limit of  de-
tection of  the used HPLC assay. Therefore, in the present rat study the
same melatonin formulation but at a higher dose (40 µg/rat) was used.
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Similar to this rat study, all human subjects received two melatonin treat-
ments (intranasally and intravenously (17)) and in both species melatonin
is rapidly absorbed in the blood circulation after nasal delivery (T
max
 = 2.5
and 5 min for rats and humans, respectively). The relative uptake of  me-
latonin into the CSF after nasal delivery compared to intravenous admin-
istration is comparable in rats and humans, which is evident from the
calculated CSF ratios (Table I).
It should be noted that large interspecies differences exist in the anatomy,
especially with respect to the shape of  the nasal cavity and the relative
sizes of  the olfactory and respiratory epithelia. In rats about 50 % of  the
nasal cavity is covered with olfactory epithelium, whereas in humans this
is only 8 % (6). Therefore, for compounds that are taken up via the olfac-
tory epithelium, a difference in CSF ratio between rats and humans can
be expected. Our study shows however no direct or extra transport of
melatonin from the nose to the CSF. Obviously, there is no transport via
the olfactory area and in both species the observed fast nasal absorption
takes place via the respiratory epithelium that is highly vascularised and
easily permeable for the low molecular weight lipophilic compound me-
latonin.
In conclusion, no additional transport from the nasal cavity to the CSF is
found after intranasal and intravenous administration of  melatonin in
rats. Furthermore, the results of  the present rat studies and the reported
human study (17) offer an opportunity to compare animal and human
PK data, obtained by using the same drug formulation and a resemblance
in experimental methods. Comparison of  these two studies demonstrates
that for nose-CSF transport of  melatonin rat experiments can be predic-
tive for human studies. To strengthen the basis for extrapolation from
animal data to the human situation, more nasal drug formulations need
to be investigated in both animals and men.
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Abstract
The possibility of  direct transport of  hydroxocobalamin from the nasal
cavity into the cerebrospinal fluid (CSF) after nasal administration in rats
was investigated and the results were compared with a human study.
Hydroxocobalamin was given to rats (n = 8) both intranasally (214 µg/
rat) and intravenously (49.5 µg/rat) into the jugular vein using a Vascular
Access Port (VAP). Prior to and after drug administration, blood and
CSF samples were taken and analysed by radioimmunoassay.
The AUCCSF/AUCplasma ratio after nasal delivery does not differ from
the ratio after intravenous infusion, indicating that hydroxocobalamin
enters the CSF via the blood circulation across the blood–brain barrier
(BBB). This same transport route is confirmed by the cumulative AUC-
time profiles in CSF and plasma, demonstrating a 30 min delay between
plasma absorption and CSF uptake of  hydroxocobalamin in rats and in a
comparative human study.
The present results in rats show that there is no additional uptake of
hydroxocobalamin in the CSF after nasal delivery compared to intrave-
nous administration, which is in accordance with the results found in
humans. This indicates a predictive value of  the used rat model for the
human situation when studying the nose to CSF transport of  drugs.
Keywords
hydroxocobalamin; intranasal delivery; intravenous infusion; cerebrospi-
nal fluid; rat; human
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1. Introduction
With the growing number of  patients suffering from central nervous
system (CNS) diseases a suitable approach for drug targeting to the brain
becomes more and more important. The blood–brain barrier (BBB) ham-
pers drugs to access the CNS and therefore unables a direct therapy for
such diseases. In the last decades the nasal administration route has gained
much interest in this respect, because the olfactory neurons connect the
nasal cavity directly with the brain and the surrounding cerebrospinal
fluid (CSF). Dyes, viruses, metals, proteins and small molecular weight
drugs have been investigated on nose–brain/CSF transport in animals
and men (10, 13). However, the feasibility of  the nose–brain pathway for
drug targeting to the brain and CSF is still controversial. In rats most of
the investigated lipophilic drugs like the steroid hormone hydrocorti-
sone (25), a serotonin antagonist (4) and a cognition enhancing drug (9)
are taken up into the CSF following absorption into blood and subse-
quent crossing the BBB. This is in contrast to a number of  hydrophilic
drugs like cephalexin (21), the anti-HIV agents zidovudine (22) and D4T
(28), dopamine (5) and L-dopa butylester (11), which have been found to
be directly transported into the CSF after nasal administration in rats.
Moreover, direct transport of  the lipophilic drugs hydroxyzine and lido-
caine (2, 3) has also been reported in animals.
Human pharmacodynamic studies mainly suggested direct uptake of  hy-
drophilic, high molecular weight peptide drugs into the brain after nasal
delivery (7). These observations were based on differences in event re-
lated brain potentials following an auditory odd ball task, whereas
pharmacokinetic evidence was not provided.
In a recently published human study in neurosurgery patients with a CSF
drain the hydrophilic and high molecular weight drug hydroxocobalamin
(vitamin B12 analogue, M
w
 = 1346 Da; aqueous solubility 10 % w/v (15))
was tested on nose-CSF transport (16). This compound was chosen, be-
cause as a hydrophilic compound it is relatively well absorbed after nasal
delivery (bioavailability is 5.4 %; 27) and safe to be used in humans (12,
23). However, increases of  CSF levels of  hydroxocobalamin were some-
times very low and near the detection limit of  the radioimmunoassay
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(16), although it was tried to increase the hydroxocobalamin concentra-
tion by evaporation of  the CSF samples according to Nijst et al. (18).
Therefore, it was decided in the present study to increase the dose of
hydroxocobalamin by using in rats the same formulation as in the human
study. This resulted in a relatively higher dose (30-fold high per kg
bodyweight than in humans) to ensure that the hydroxocobalamin levels
in the CSF were well above the detection limit of  the radioimmunoassay.
The rat experiments were performed using a rat model (24, 25), which
allows simultaneous and serial CSF and blood sampling and also the com-
parison of  intranasal and intravenous drug delivery in the same animal.
The aim of  the present paper was to study the CSF uptake of  hydroxo-
cobalamin after intranasal and intravenous administration in rats and to
compare the results with that of the human study (16).
2. Materials and methods
2.1. Materials
Hydroxocobalamin chloride was from BUFA B.V. (Uitgeest, The Neth-
erlands) and povidone iodine from Sigma Chemical (St. Louis, MO, USA).
Janssen Pharmaceutica (Beerse, Belgium) supplied Hypnorm®(fentanyl
citrate 0.315 mg/ml, fluanisone 10 mg/ml). Dormicum® (midazolam, 5
mg/ml) was from Genthon B.V. (Nijmegen, The Netherlands) and
Temgesic® (buprenorphine, 0.3 mg/ml) from Schering-Plough (Maarssen,
The Netherlands). All other reagents were of  analytical grade.
2.2. Hydroxocobalamin formulations
The hydroxocobalamin formulation for nasal delivery consisted of  hy-
droxocobalamin chloride (11 mg/ml), sodium acetate (2.7 mg/ml) and
sodium chloride (7.0 mg/ml) dissolved in Millipore® water, and the pH
was adjusted at 4.5 with hydrochloride (15). For intravenous infusion
hydroxocobalamin was dissolved in sterile saline (11 µg/ml).
2.3. Animals
Male Wistar rats (Charles River, Someren, The Netherlands) were used,
weighing 330 – 470 g at the start of  the experiments. The animals (n = 8)
were housed 2 per cage, with free access to food and water and a 12 h
light/dark cycle. The animal experiments were approved by the Ethical
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Committee for Animal Experiments (Leiden University, Leiden, The
Netherlands). All rats were used for intranasal and intravenous treatment
in a cross-over design.
2.4. Implantation of  Vascular Access Port
The animals were provided with a Vascular Access Port (VAP) as de-
scribed before (25). Briefly, the rats were anaesthetised with Hypnorm®
(0.5 ml/kg) and Dormicum® (0.5 ml/kg) intramuscularly. Two incisions
were made, one at the level of  the lower ribs to create a pocket for insert-
ing the VAP (Access Technologies, Skokie, IL, USA) and one in the neck
to cannulate the jugular vein. The VAP, attached to a silicone catheter (ID
0.5 mm, OD 1.0 mm), was fitted into the pocket, and the catheter was
tunnelled underneath the skin from the pocket to the second incision in
the neck and inserted into the jugular vein. As post-operative care
Temgesic® (0.3 ml/kg, intramuscularly) was given for pain relief. The rats
were allowed to recover 1 week before starting the experiments. To avoid
blockage of  the catheter, the VAP was flushed weekly with heparin solu-
tion (400 µl; 400 IU/ml).
2.5. Nasal and intravenous delivery of  hydroxocobalamin
Prior to drug administration the rats were anaesthetised as described above
and fixed in a stereotaxic frame (model 51600, Stoelting, Wood Dale, IL,
USA) using the supine-70° angle position (24). The animals were kept
anaesthetised throughout the experiment, if  necessary top op anaesthe-
sia was given. For intranasal administration of  the hydroxocobalamin
formulation, a polyvinylchloride (PVC) tube (ID 0.5 mm, OD 1.0 mm)
attached to a Hamilton syringe was inserted into the left nostril of  the rat
for about 2 cm. The nasal hydroxocobalamin dose (214 µg/20 µl/rat)
was delivered by gently pushing the plunger of  the syringe and after de-
livery the PVC tube was removed.
Subsequently, hydroxocobalamin was administered to the rats by intrave-
nous infusion (49.5 µg/rat). The infusion rate (30 µl/min for 150 min)
was chosen in such a way to simulate the observed maximal hydroxoco-
balamin plasma levels after intranasal delivery. This infusion rate was de-
termined by giving the rats (n = 3) an intravenous bolus injection of  the
vitamin as described previously (25).
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Prior to and following hydroxocobalamin delivery, blood and CSF sam-
ples were taken until 240 min after administration. Fifteen blood samples
were taken at t = 0; 2.5, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 210 and
240 min and 11 CSF samples were taken at t = 0; 15, 30, 45, 60, 90, 120,
150, 180, 210, and 240 min. Each rat received both the nasal and the
intravenous treatment. Between experiments the animals were allowed to
recover for one week.
2.6. Blood and CSF sampling
Blood samples (200 µl) were taken from the tail vein using heparinised
tubes (Microvette® CB 100/200, Sarstedt, Nümbrecht, Germany). Sam-
ples were centrifuged (15 min at 14,000 rpm; ambient temperature) and
the obtained plasma was stored at 4°C until analysis.
For CSF sampling a cisternal puncture was performed as described be-
fore (24). Briefly, rats were anaesthetised and fixed in a stereotaxic frame
as mentioned above. The cisternal puncture was performed 5.2 – 6.5 mm
ventrally from the occipital crest, dependent on the rat’s weight. After the
puncture, one drop of  CSF was microscopically examined on erythro-
cyte contents; the experiment was continued when the erythrocyte con-
tamination was less than 500 cells/µl (< 0.01 % of  normal blood con-
tent). Following intranasal or intravenous drug administration, CSF sam-
ples (about 30 µl) were taken and directly collected in pre-weighed radio-
immunoassay tubes and stored at 4°C until analysis.
2.7. Hydroxocobalamin analysis
Plasma and CSF samples were analysed on hydroxocobalamin by radio-
immunoassay (Dualcount Solid Phase No Boil Assay, DPC, Los Angeles,
CA, USA) with a detection limit of  25 pmol/l. The analysis was per-
formed according to the manufacturer’s protocol. When calculating the
hydroxocobalamin concentrations for the CSF samples, the sample vol-
umes were taken into account.
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2.8. Data analysis
To determine the contribution of  the nose-CSF pathway to the hydroxo-




 ratios were calculated
for each route of  administration. The area under the concentration-time
curve (AUC) values (0 – 240 min) were calculated using the trapezoidal




 ratios were calculated per
individual animal before determining the mean value. Data were analysed
according to the paired Student’s t-test, using the computer program SPSS
version 8.0 for Windows.
3. Results
Hydroxocobalamin was administered intranasally (214 µg/rat) and by in-
travenous infusion (49.5 µg/rat) to the same set of  rats to determine the
relative uptake of  this vitamin analogue into CSF after nasal delivery com-
pared to intravenous administration. The plasma concentrationtime pro-
files (Figure 1a) show a slow and prolonged absorption of  hydroxoco-
balamin after nasal delivery, reaching maximal plasma levels of  192 ± 53
nmol/l (mean ± sd) at 150 min after administration. This was simulated
by intravenous infusion of  hydroxocobalamin, resulting in similar plasma
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Table I AUCCSF/AUCplasma ratios of hydroxocobalamin 
 Intranasal Intravenous 
Ratsa   
AUCCSF (nmol min/l) 166 ± 105 202 ± 148 
AUCplasma(nmol min/l) 31272 ± 8000 32086 ± 5284 
AUCCSF/AUCplasma (%) 0.5 ± 0.2 0.6 ± 0.4 
Humansb   
AUCCSF/AUCplasma (%)c 0.5 0.5 
Data are presented as mean ± sd, a n = 8, b n = 5 (Merkus et al., 2003), c Ratio of 
mean AUC values. 
 
b
Figure 1 Hydroxocobalamin concentrations in plasma (a) and CSF (b) after intranasal
delivery (i.n.; 214 µg/rat) and intravenous infusion (i.v.; 49.5 µg/rat) in rats. Results are
expressed as mean ± sd of  eight animals.
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profiles (Figure 1a). The observed hydroxocobalamin concentrations in
CSF following both intranasal and intravenous delivery increased slowly,
but did not reach a maximum within the sampling period of  240 min
(Figure 1b).
As stated in Table I, the distribution of  the drug over CSF and plasma
after intranasal delivery (0.5 ± 0.2 %) was not significantly different (p =
0.57) from that following intravenous infusion (0.6 ± 0.4 %) in rats, which
is similar to the results found in humans (Table I). Besides, the hydroxo-
cobalamin uptake into CSF followed the same pattern as the absorption
in plasma after intranasal and intravenous delivery, which is demonstrated
by the cumulative AUC values plotted against time (Figure 2). This is also
in accordance with the results observed in the human study (Figure 3). In
both species the uptake of  hydroxocobalamin in CSF showed a lag time
of  about 30 min after absorption in plasma.
4. Discussion
In the present study the distribution of  hydroxocobalamin over CSF and
plasma after intranasal administration is compared to that following in-
travenous infusion in rats. The observed similarity in distribution pro-
files after both delivery routes demonstrates no direct hydroxocobalamin
transport to the CSF from the nasal cavity. These results are consistent
with a human study, in which the same hydroxocobalamin formulation





 ratios after intranasal and intravenous adminis-
tration are similar in both species (Table I), just like the cumulative AUC-
time profiles of  hydroxocobalamin in plasma and CSF (Figure 2 and 3).
Also, the lag time of  about 30 min between the plasma absorption and
CSF uptake of  hydroxocobalamin indicates that this hydrophilic drug is
taken up into the CSF subsequent to passage of  the BBB, and not by
direct transport from the nasal cavity into the CSF.
It should be noted that the rat and human study show remarkable differ-
ences in the time to reach plasma C
max
 values of  nasal hydroxocobalamin,
being about 150 min in rats (Figure 1a) and about 30 min in men (16). In




Figure 2 Hydroxocobalamin cumulative AUC values in plasma (a) and CSF (b) after
intranasal delivery (i.n.; 214 µg/rat) and intravenous infusion (i.v.; 49.5 µg/rat) in rats.
Results are expressed as mean ± sd of  eight animals.
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Figure 3 Hydroxocobalamin cumulative AUC values in plasma (a) and CSF (b) after
intranasal delivery (i.n.; 1500 µg/subject) and intravenous infusion (i.v.; 75 µg/subject)













































































rats, whereas in the human study this vitamin is administered in con-
scious patients. It is well known that anaesthetics, due to their inhibitory
effect on the nasal mucociliary clearance, prolong the residence time of
the formulation in the nasal cavity and therefore, the absorption phase
of  the administered drug (9, 14). Obviously, the very high nasal dose
used in rats compared to the human study and/or the slow mucociliary
clearance in the experimental conditions of the rat study causes a nasal
absorption in rats that is slower than in humans. In order to exclude
possible oral absorption, the nasally administered dose was also instilled
at the back of  the throat in rats to simulate possible swallowing of  the
formulation after intranasal delivery, and in these studies no hydroxoco-
balamin absorption in plasma was found (data not shown). This is sup-
ported by a study in human volunteers, in which the reported oral hy-
droxocobalamin bioavailability is negligible (26).
The safety of  the used hydroxocobalamin formulation was tested previ-
ously in vitro and classified as ciliofriendly (17). This formulation was
also investigated in vivo during 4 weeks in geriatric patients (n = 21); and
no adverse effects were reported (12).
The present results are in contrast to the reported human studies using
nasal vasopressin (1, 19), angiotensin II (6), cholecystokinin-8 (CCK-8)
(20) and MSH/ACTH4–10 (1, 8). These are all hydrophilic peptide drugs
with a molecular weight in the range of  1000 – 1600 Da, which is compa-
rable to that of  hydroxocobalamin (M
w
 = 1346 Da): In the pharmacody-
namic study by Fehm et al. (8) and the pharmacokinetic study by Born et
al. (1) intranasal delivery of  MSH/ACTH4–10 and vasopressin in hu-
mans was compared with placebo treatment only, and therefore no proof
for a direct nose–brain/CSF route was given. Born et al. (1) claimed some
nose to CSF transport after nasal administration of  MSH/ACTH4–10,
because they could not find any absorption of  this peptide in the sys-
temic circulation. However, uptake of  this peptide into CSF was only
observed after delivery of  the 10 mg and not after the 5 mg dose. The
vasopressin uptake in CSF determined after nasal administration was at-
tributed to a combination of  direct nose to CSF and BBB transport (1).
Nevertheless, this needs to be confirmed by delivery of  vasopressin via
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the intravenous route. The pharmacodynamic studies on vasopressin (19),
angiotensin II (6) and CCK-8 (20) investigated intranasal and intrave-
nous administration of  these peptides. The observed differences in event
related brain potentials suggest a direct entry of  the delivered drugs from
the nasal cavity into the CNS. Such a direct transport route was not evi-
dent from the present study examining the distribution of  hydroxoco-
balamin over plasma and CSF after intranasal and intravenous delivery in
rats. This could be explained by the fact that this vitamin analogue is
better absorbed into the systemic circulation than the above mentioned
neuropeptides. Therefore, more of  the neuropeptides is left in the nasal
cavity compared to hydroxocobalamin to be transported via the olfac-
tory neurones into the CSF. Secondly, in some of  the studies the nasal
formulation was administered by giving repeated puffs (1, 6), instead of  a
single administration as used in the present and in the patient study (16).




 ratios after intranasal and intrave-
nous administration of  hydroxocobalamin in rats and humans demon-
strate no direct nose- CSF transport of  this hydrophilic and high mo-
lecular weight drug. The results indicate also the predictive value of  the
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Uptake of  fluorescein isothiocyanate-labelled
dextran into the CSF after intranasal and
intravenous administration to rats
J.P.M. in ‘t Veen, M.P. van den Berg, S.G. Romeijn, J.C. Verhoef, and F.W.H.M.
Merkus European Journal of  Pharmaceutics and Biopharmaceuics submitted
Abstract
With the growing number of patients suffering from central nervous
system (CNS) diseases a suitable approach for drug targeting to the
brain becomes more and more important. In the present study the con-
tribution of the nose-CSF pathway to the uptake of the model drug
fluorescein isothiocyanate-labelled dextran with a molecular weight
of 3.0 kDa (FD3) into the CSF was determined in rats. FD3 was ad-
ministered intranasally (489 mg/rat) and by intravenous infusion (24.4
mg/ml; 119 mg/rat) in the same set of animals (n = 6). Blood samples
were taken from the tail vein and CSF was sampled by cisternal punc-
ture using a stereotaxic frame. The contribution of the olfactory path-





 ratios after intranasal and after intravenous ap-
plication of  FD3 mimicking the blood levels after intranasal delivery. No





tios of FD3 after intranasal administration (1.33 ± 0.40 %) and intra-
venous infusion (1.03 ± 0.56 %). This indicates that in rats about 1%
of  the amount of  FD3 in plasma reaches the CSF both after nasal and
intravenous administration, and that no direct transport of  FD3 from
the nose to the CSF could be found.
Keywords
fluorescein isothiocyanate-labelled dextran (FD); rats; nose-CSF drug
transport; nasal delivery; intranasal administration; intravenous infusion
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1. Introduction
The olfactory neurons connect the brain and surrounding cerebrospinal
fluid (CSF) with the open air that is inhaled via the nasal cavity (11, 28).
This anatomical observation raised the hypothesis that drugs may have a
direct access to the central nervous system following intranasal adminis-
tration, thereby circumventing the blood-brain barrier (BBB). In the past
decades this possible transport route has been investigated extensively
(10, 14).
The small molecular weight (M
w
 < 1 kDa) and lipophilic drugs triprolidine
(4), a cognition enhancer (9) and a serotonin antagonist (6) are quickly
absorbed from the nasal cavity into the systemic circulation and taken-up
via the BBB into the CSF, which indicates no direct nose-CSF transport
of  these substances. For several hydrophilic and low M
w
 compounds like
cephalexin (19), zidovudine (20), D4T (27), dopamine (5), dopamine butyl
ester (13), and methotrexate (26) direct nose-CSF/brain transport via the
olfactory nerve pathway has been claimed. However, in a recent publica-
tion of  Bagger and Bechgaard (1) no direct nose-ISF (interstitial fluid)
transport for sodium fluorescein (M
w
 330 Da) has been found. For peptides
like melanocortin(4-10) and insulin
 
(2) and cholecystokinin-8 (17), which
are all hydrophilic compounds with a M
w
 ranging from about 1 to 6 kDa,
direct transport from the nasal cavity into the CSF has been reported.
These findings are in contrast to our own observation after nasal delivery
of  the hydrophilic compound hydroxocobalamin (M
w
 1.3 kDa) in rats.
No direct nose-CSF transport was found (21), which is also in agreement
with a human study using the same hydroxocobalamin formulation (16).
The hydrophilic model compound fluorescein isothiocyanate-labelled
dextran (FD) has been tested in a broad M
w
 range in rats (4.0 – 40 kDa)
(18), claiming an increase in the uptake of  FD into CSF with decreasing
M
w
. Furthermore, in a histological study by Jansson and Björk (12) the
uptake of  FD3 (M
w
 = 3.0 kDa) in the olfactory bulb in the brain via the
olfactory neurons after nasal delivery in rats was demonstrated.
A rat model has been developed to study the nose-CSF transport of
drugs, comparing the intranasal and intravenous routes of  administra-
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tion (23). With this model the lipophilic and low molecular weight sub-
stances hydrocortisone, estradiol, progesterone and melatonin were in-
vestigated (24). No direct nose-CSF transport was found (25),(22) con-
firming earlier studies by Hussain et al. (9) and Dahlin et al. (6).
The aim of  the present study was to investigate the uptake of  a hydrophilic
and high M
w
 compound in CSF after intranasal and intravenous delivery
in the same set of  rats by taking serial CSF and blood samples from one
animal (23). The dextran FD3 (M
w
 = 3.0 kDa) was used as model com-
pound.
2. Materials and methods
2.1. Materials
Fluorescein isothiocynate-labelled dextran (FD3, M
w
 = 3.0 kDa) was from
Molecular Probes (Leiden, The Netherlands) and stored as prescribed at
– 20°C and protected from light. Sterile saline (0.9 % NaCl) and heparin
(400 IU/ml) were obtained from the Hospital Pharmacy of  Leiden Uni-
versity Medical Centre (Leiden, The Netherlands). Hypnorm® (fentanyl
citrate 0.315 mg/ml, fluanisone 10 mg/ml) was from Janssen
Pharmaceutica (Beerse, Belgium), Dormicum® (midazolam, 5 mg/ml)
from Genthon B.V. (Nijmegen, The Netherlands) and Temgesic®
(buprenorphine, 0.3 mg/ml) from Schering-Plough (Maarssen, The Neth-
erlands). All other chemicals were of  analytical grade or highest grade
commercially available.
2.2. Drug formulations
FD3 was dissolved in saline in concentrations of  24.5 mg/ml and 24.4
µg/ml for nasal delivery and intravenous infusion, respectively.
2.3. Animals
Male Wistar rats (Charles River, Someren, The Netherlands) were used,
weighing 260 – 310 g at the start of  the experiments. The animals were
housed 2 per cage with free access to food and water with a 12-h light/
dark cycle. The experiments were approved by the Ethical Committee
for Animal Experiments (Leiden University, Leiden, The Netherlands).
All rats were used for intranasal and intravenous treatment. Besides the
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recovery period, the rats were monitored daily on well-being and weight.
In case of  weight loss, the rat was given more time to recover.
2.4. Implantation of  Vascular Access Port (VAP)
The animals (n = 6) were provided with a VAP as described before (24).
Briefly, the rats were anaesthetised with Hypnorm® (0.5 ml/kg) and
Dormicum® (0.5 ml/kg) intramuscularly. Two incisions were made, one
at the level of  the lower ribs to create a pocket for inserting the VAP
(Access Technologies, Skokie, IL, USA) and one in the neck to cannulate
the jugular vein. The VAP, attached to a silicone catheter (ID 0.5 mm,
OD 1.0 mm), was filled with heparin solution (400 IU/ml) using a
Huberpoint needle (Access Technologies, Skokie, IL, USA) and fitted
into the pocket. The catheter was tunnelled underneath the skin from the
pocket to the second incision in the neck and inserted into the jugular
vein. As post-operative care Temgesic® (0.3 ml/kg, intramuscularly) was
given for pain relief. The rats were allowed to recover 1 week before
starting the experiments. To avoid blockage of  the catheter, the VAP was
flushed weekly with heparin solution (400 µl; 400 IU/ml).
2.5. Intranasal and intravenous delivery of  FD3
Prior to drug administration the rats (n = 6) were anaesthetised with
Hypnorm® (0.5 ml/kg) and Dormicum® (0.5 ml/kg) intramuscularly and
fixed in a stereotaxic frame (model 51600, Stoelting, Wood Dale, IL, USA)
using the supine-70° angle position (23). The animals were kept anaes-
thetised throughout the experiment and if  necessary top op anaesthesia
was given. FD3 was administered in the left nostril (489 µg/20 µl/rat)
using a Hamilton syringe attached to PVC tubing and by intravenous
infusion (54 µl/min for 90 min; 119 µg/rat). In between these experi-
ments the rats were allowed to recover for at least 17 days. The intrave-
nous infusion rate for FD3 was chosen in such a way to simulate the
observed maximal plasma levels after intranasal delivery. Therefore all
rats were treated intranasally with FD 3 before the intravenous experi-
ments. The infusion rate was determined separately by giving three rats
an intravenous bolus injection of  the model compound as described pre-
viously (24).
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Prior to and following drug delivery, blood samples were taken at 0, 2.5,
5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 210 and 240 minutes after
administration and CSF samples were taken at 0, 15, 30, 45, 60, 90, 120,
150, 180, 210 and 240 minutes after administration. Each rat received the
nasal and intravenous treatment of  FD3.
2.6. Blood and CSF sampling
Blood samples (200 µl) were taken from the tail vein using heparinised
tubes (Microvette® CB 100/200, Sarstedt, Nümbrecht, Germany). Sam-
ples were centrifuged (15 min at 14000 rpm; ambient temperature) and
plasma obtained was protected from light and stored at 4°C until analy-
sis.
For CSF sampling a cisternal puncture was performed as described be-
fore (23). Briefly, rats were anaesthetised and fixed in a stereotaxic frame
using the supine-70° angle position as mentioned above. The cisternal
puncture was performed 4.8 – 6.5 mm ventrally from the occipital crest,
dependent on the weight of  the rat. After the puncture, one drop of  CSF
was microscopically examined on erythrocyte contents to exclude con-
tamination with blood. The experiment was continued when the eryth-
rocyte contamination was less than 500 cells/µl (< 0.01 % of  normal
blood content). Following intranasal or intravenous drug administration,
CSF samples (30 – 40 µl) were taken and directly collected in pre-weighed
tubes, protected from light and stored at 4°C until analysis.
2.7. FD3 analysis
Each plasma sample (80 µl) was mixed with trichloroacetic acid (10 %,
100 µl) and centrifuged (5 min at 14000 rpm; ambient temperature). Sub-
sequently, 0.25 M Borax buffer (pH 12.0; 70 µl) was added to the
supernatant (130 µl). The CSF samples were weighed and added up with
MilliPore® water to a total volume of  180 µl.
Blood and CSF samples were analysed by HPLC using a size-exclusion
column (Suprema 30 size exclusion, 10 µ, 8 x 300 mm, Polymer Stand-
ards Service, Mainz, Germany) and a fluorescence detector (Jasco 821
fluorescence detector, B & L systems, Zoetermeer, The Netherlands;
excitation wavelength = 478 nm, emission wavelength = 521 nm). The
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injection volume was 150 µl, the flow was 2.0 ml/min and the mobile
phase contained acetonitrile : 0.05 M ammonium acetate buffer (pH 8) =
1 : 4 (v/v). The chromatograms were integrated using Ezchrom 6.4 soft-
ware (Scientific Software, San Ramon, CA, USA) and the detection limit
was 0.15 ng/ml.
When calculating the FD3 concentrations for the CSF samples, the dif-
ferent sample volumes were taken into account.
2.8. Data analysis
The area under the plasma or CSF concentration – time curve (AUC
0-240
)
values were calculated using the trapezoidal rule. To determine the con-
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Table I Mean AUCCSF/AUCplasma ratios of FD3 in rats after intranasal 
administration (i.n.) and intravenous infusion (i.v.)a 
 i.n. i.v. 
AUCCSF (ng*min/ml) 1022 ± 386 1209 ± 779 
AUCplasma (ng*min/ml) 82343 ± 45192 112352 ± 27134 
AUCCSF/AUCplasma (%) 1.33 ± 0.40b 1.03 ± 0.56b 
a Data are presented as mean ± sd (n = 6), the AUC was calculated from 0 to 240 





Table II Individual AUCCSF/AUCplasma ratios of FD3 in six rats (1–6) after 
intranasal administration (i.n.) and after intravenous infusion (i.v.) 
Rat 1 2 3 4 5 6 
i.n. 2.31 1.47 1.20 0.96 0.87 1.60 
i.v. 0.52 0.55 1.39 1.99 0.79 0.96 
 
were calculated for each individual animal before determining mean val-
ues. Data were analysed according to the paired Student’s t-test, using the
computer program SPSS version 8.0 for Windows, p values < 0.05 were
considered as significantly different.
3. Results
The concentration-time profiles in plasma and CSF after intranasal and
intravenous administration of  the hydrophilic model compound FD3 in
rats are shown in Figure 1. Taken into account the dose given intranasally
and intravenously and the corresponding AUC values of  the plasma
curves, the uptake of  FD3 into the CSF is comparable after both routes
of  administration (Figure 1b). The AUCs of  the CSF curves after both
routes of  administration are approximately only 1 % of  the AUCs of  the





ter nasal delivery and intravenous infusion of  each individual rat. In four




 ratio after nasal delivery was larger
than after intravenous infusion, which could be an indication for direct









 ratios after intranasal (1.33 ± 0.40
%) and intravenous (1.03 ± 0.56 %) delivery were not significantly differ-
ent from each other (p = 0.40).
4. Discussion
In the present study the absorption and uptake of  FD3 in plasma and
CSF was determined after nasal and intravenous delivery in rats. By using
the described animal model, concentration-time profiles in plasma and
CSF could be obtained in the same animal. With these profiles the distri-
bution of  FD3 over plasma and CSF following both delivery routes was




 ratios per in-




 ratios after nasal and intra-
venous delivery of  FD3 were not significantly different from each other.
This indicates no direct transport of  FD3 from the nasal cavity into the
CSF after intranasal administration in rats.
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b
Figure 1 Plasma (a) and CSF (b) concentrations after intranasal administration (i.n.;
489 µg/rat) and intravenous infusion (i.v.; 119 µg/rat) of  FD3 in rats. Results are





































































In contrast to the studies of Sakane et al. (18), who found FDs in CSF
only after nasal delivery, in the present study FD3 could be determined in
CSF following both intranasal and also after intravenous delivery in rats.
Because FDs are hydrophilic and high molecular weight compounds, they
can hardly cross the BBB. However, the blood-CSF barrier contains fe-
nestrated endothelial capillaries, which are permeable. These provide ex-
tracellular distribution of  blood-borne macromolecules within the CSF
from sites deficient in a BBB such as the subarachnoid space/pial surface
and the circumventricular organs (3). These capillaries in the choroid
plexus allow macromolecular molecules like FD3 to diffuse from the sys-
temic circulation into the CSF. Therefore, it is possible that FD3 can be
determined in CSF after intravenous infusion in rats. In the study of
Sakane et al. (18) the FD intravenous formulation was administered not
by slow infusion but by intravenous bolus injection, which resulted in
very fast plasma peak concentrations and subsequent fast clearance of
the compound. By giving an intravenous infusion during 90 minutes in
the present study, slowly increasing FD3 plasma levels were obtained,
comparable with the plasma profile after nasal delivery. A plausible ex-
planation for the difference in study results could be that a threshold
concentration of  FDs has to be reached in order to facilitate passive
diffusion from blood into CSF via the fenestrated capillaries. After intra-
venous bolus injection the FD concentration will exceed this threshold
only for a limited time period, whereas following intravenous infusion
during 90 minutes this time span will be prolonged. Sakane et al. (18)
studied the uptake of  FDs in CSF only at one time point, 60 minutes
after administration, when a large part of  FDs had already been cleared
from the systemic circulation. This could explain why these authors were
not able to detect the FD compounds in CSF after intravenous bolus
injection. Furthermore, it is not clear why these authors measured FDs
in the second CSF fraction sampled as in the present study FD3 could be
determined without a problem in the first 30 – 40 µl CSF. Nevertheless,
Jansson and Björk (12) demonstrated that FD3 was directly taken up into
the olfactory bulb in the brain after nasal delivery in rats, using confocal
laser scanning microscopic examination of  the nasal and olfactory tis-
sues. This difference in FD3 uptake between CSF and the olfactory bulb
may therefore be a topic for further investigation.
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After nasal delivery of  FD3 in our study a long absorption phase was
observed (T
max
 = 90 min), which is remarkable because the nasal clear-
ance half-life in rats is about 5 min (7). The slow nasal absorption may be
due to the use of  anaesthetics, which inhibit the nasal mucociliary clear-
ance and thereby prolong the residence time of  the administered formu-
lation in the nasal cavity (8, 15). Such a prolonged absorption phase after
intranasal delivery to anaesthetised rats was also found for other FDs (4 –
40 kDa) (18).
In conclusion, in rats about 1% of  the amount of  FD3 in plasma reaches
the CSF, both after intranasal and intravenous administration. No addi-
tional direct transport of  FD3 from the nose-CSF could be found.
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General discussion and conclusions
The relevance of  the published results on nose-brain/CSF drug trans-
port is dependent on the method of  investigation. As outlined in the
General introduction and study objectives, several models have been used to
examine the transport of  a nasally administered drug and each one has
its own limitations and advantages. In order to study nose-CSF drug trans-
port in rats according to the theoretical study design described in the
General introduction and study objectives, a model was developed starting with
the method for CSF sampling. A prerequisite was to be able to take serial
CSF samples from one animal following nasal delivery, not being con-
taminated with blood. The CSF puncture method using a stereotaxic frame
and putting the rat in the supine-70° angle position appeared to meet
these requirements (Chapter 2; 103). The supine position of  the rat allows
CSF sampling by spontaneous CSF flow via the tubing attached to the
puncture needle at determined time points. In this way small volumes (30
– 40 µl) can be collected, which makes it possible to take multiple sam-
ples from one animal. The sampled CSF is virtually free from erythro-
cytes (< 0.01 % blood content) as determined by microscopic examina-
tion. Subsequent to an experiment the rats are allowed to recover and can
even be used for a second study. This makes it possible to compare intra-
nasal and intravenous drug delivery in one animal. The intravenous deliv-
ery is performed by an infusion into the jugular vein using a vascular
access port, aiming to simulate the plasma levels obtained after intranasal
drug administration (Chapter 3; 104). In this way the possible blood-brain
transport of  the administered drug will be subject to a similar diffusion-
drive following both routes of  administration.
Taken together, the developed rat model allows for studying the nose-
CSF transport of  a drug by determining the CSF/plasma ratio following
intranasal and intravenous administration. With the recently published
methods of  Bagger and Bechgaard (4), Chou and Donovan (18), Wang et
al. (109) and Van den Berg et al. (Chapter 2; 103, Chapter 3; 104) as pre-
sented in this Thesis, conclusive pharmacokinetic results can be provided
on drug transport from the nasal cavity into the extracellular brain fluid
or CSF in rats.
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The results obtained with our animal model will be discussed below in
the context of  the literature on this subject. The literature reviewed in
the discussion below is the same selection of  papers as used in the Gen-
eral introduction and study objectives of  this Thesis. Because the results in
nose-brain/CSF transport seem to be related to the physicochemical prop-
erties of  the tested compound, the following substance classes are dis-
cussed: dyes, micro-organisms, metals, small and high molecular weight
drugs.
1. Dyes
The publications describing dye administration with respect to the neu-
ronal connection between the olfactory bulb and the nasal cavity mainly
concern the brain/CSF-nose transport route instead of  the opposite (13,
15, 23, 38, 42, 58, 65, 95, 113, 116). Faber (42) published one of  the first
results on the nose-brain transport of  dyes, demonstrating that in rabbits
aqueous dye solutions like Prusian Blue (an iron ferrocyanide suspen-
sion) and thorotrast are readily absorbed from the nasal mucosa into the
cranial cavity and cervical lymph nodes, whereas oil-based dye formula-
tions such as olive oil coloured with Sudan III, Victorian Blue or Scharlach
R, give less uniform results after intranasal administration. In dogs the
innervation of  the nasal mucosa was investigated by nasal administration
of  the fluorescent neuronal tracer (E)-2,2’vinylendi-benzofuran-5-
carboxamidin-diaceturate (true blue dye (110)). Nine days following na-
sal administration, dye labelling of  the spheropalatine ganglion and the
superior cervical ganglion, which are connected to the nasal mucosa by
the parasympathetic and sympathetic fibers, was demonstrated.
These dye-investigations show that the olfactory neurons, connecting
the nasal cavity with the olfactory bulb, suggest a pathway for compounds
to travel from the nose into the CSF and brain. Whether this direct route
is suitable to transfer sufficient drug molecules into the right brain area in
order to elicit a pharmacological effect, needs to be determined by quan-




Viruses and bacteria are the most frequently investigated micro-organ-
isms in the literature concerning nose-brain transport. This pathway to
the CNS is mainly explored in mice, only a few publications were found
in other species like monkeys (11, 40, 41, 43, 83), pigs (61, 71), rabbits
(22, 64) and rats (35). An exceptional feature of  this category is the ability
of  the “active compound” to multiply itself, even after delivery (73). This
makes it difficult to control the administered amount of  micro-organ-
isms.
In the first half  of  the previous century the poliomyelitis virus was ex-
tensively investigated using histological tissue examination (11, 40, 41,
43, 83), which was also used in more recent papers sometimes extended
with virus titration of  tissue extracts (9, 60, 61, 67, 71, 75). The research
group of  Shinya et al. (92) was the only one reporting a direct nose-brain
transport route for micro-organisms by comparing nasal and intravenous
delivery. In a few publications infection of  the olfactory bulb and/or
mitral cells was observed after nasal inoculation (35, 100, 114). However,
comparing these results with intravenous administration would have been
more convincing, because the histology results show the presence of
micro-organisms inside the brain and not in the olfactory nerve bundles
that connect the nasal cavity with the olfactory bulb.
In the rabbit study by Chowdhury et al. (22) a decrease in brain infection
was observed for brain areas with increasing distance from the olfactory
neurons, which is an indication for direct transport. Two publications
investigating the Streptococcus pneumonia bacteria (66) and an influenza vi-
rus strain (93) in mice did not give convincing evidence for a clear-cut
conclusion on the transport route as the comparison with intravenous
delivery was lacking. Mori et al. (70) observed no direct transport for the
neurovirulent influenza A virus in mice, whereas Park et al. (73) reported
on invasion of  the CNS by influenza viruses via the respiratory tract and
sympathetic nerves in the same species.
Overall, most publications mentioned present histological evidence for
direct nose-brain transport of  viruses and bacteria.
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3. Metals
The direct nose-brain transport of  metals has been investigated mainly
in rats, determining the presence of  manganese, gold, cadmium, nickel,
aluminium, zinc or cobalt in the brain quantitatively and/or qualitatively.
Henriksson et al. (51) and Tallkvist et al. (97) reported the direct transport
of  nickel and cadmium by showing uptake of  these metals into the olfac-
tory nerve layer following nasal delivery in rats. The nose-brain transport
for cadmium (39) and manganese (49, 52) was demonstrated by increased
brain concentrations in the ipsilateral brain compared to the contralateral
brain side. In recent publications Persson et al. (77) demonstrated the
direct uptake of  cobalt and zinc, showing clear radioactivity uptake in the
right but not in the left olfactory bulb after unilateral nasal delivery in
rats, and Rao et al. (82) observed no olfactory transport for iron in rats
after inhalation, which is contrary to the results on manganese inhalation
(115).
Other studies appear to lack sufficient evidence, such as microscopic stud-
ies not showing metal uptake into the olfactory neurons after nasal ad-
ministration (14, 74, 99) or no comparison with intravenous delivery (34,
44, 53). These investigations can only be considered as possible indica-
tions for a direct pathway between the nasal cavity and the brain and not
as proof.
The quantitative studies in the categories of  micro-organisms (61, 66, 71,
92, 114) and metals (14, 24, 34, 39, 44, 49-51, 53, 97, 99), do not give any
information about the percentage of  the dose found in the brain after
nasal administration, except for Henriksson et al. (52). These authors
observed a wide range of  the dose recovery of  manganese in rat brain of
0.05 to 5.9 % for a nasal dose in the range of  1120 to 0.1 µg. The very low
recovery for the highest dose was explained by the fact that the transport
of  manganese from the nasal cavity into the brain is regulated via a satu-
rated transport mechanism (52).
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4. Small molecular weight drugs
The criterion for small molecular weight compounds was set at a M
w
 <
600 Da, because lipophilic substances smaller than this can pass the blood-
brain barrier (BBB; see General introduction and study objectives). The litera-
ture concerning this group of  molecules describes the nose-brain/CSF
transport of  various substances such as hormones, anaesthetics, chemi-
cals, CNS- and HIV-drugs and antibacterial compounds. In most of  these
studies intranasal administration was compared with the intravenous route.





55, 69), because in the majority of  the literature CSF or brain tissue was
not sampled in a serial manner as discussed in the General introduction and
study objectives of  this Thesis. For the lipophilic compounds cocaine (108),
melatonin (69), lidocaine (4), a cognition enhancer (55), a physostigmine
analogue (27), a serotonin antagonist (26), the steroid hormone estradiol
(72) and the antihistamine triprolidine (17), no direct transport from the
nasal cavity into the CSF or brain could be demonstrated. These obser-
vations were based on similar CSF/plasma ratios after nasal and intrave-
nous administration (17, 26, 55, 69) or higher CSF drug uptake after in-
travenous delivery compared to nasal administration, achieving similar
plasma levels for both delivery routes (27). In rats Bagger and Bechgaard
(4) found comparable drug uptake into brain extracellular fluid (ECF) in
the striatum for lidocaine. This is different from the observation by Chou
and Donovan (19), measuring enhanced uptake of  lidocaine in the olfac-
tory bulb ECF. However, because the striatum is located about 6 mm
posterior to the olfactory bulb, these results are not considered as contra-
dictory to those of  Bagger and Bechgaard (4). For cocaine similar effects
on dopamine transport blockage and ‘high’ feeling were observed after
nasal and intravenous administration in healthy volunteers, achieving com-
parable cocaine plasma levels following both delivery routes (108). Öhman
et al. (72) reported that the observed estradiol concentrations in human
CSF represent the non-protein bound estradiol fraction in plasma, sug-
gesting that this steroid hormone is transported from the nasal cavity
into the CSF via the systemic circulation and not via the olfactory neu-
rons. This is confirmed by our own studies with the steroid hormones
estradiol and progesterone in rats (Chapter 4; 105). For both steroids a
similar CSF/plasma ratio was found after nasal and intravenous delivery.
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Similar results were observed for the lipophilic steroid hormone hydro-
cortisone, also presented in this Thesis (Chapter 3; 104). Studies investi-
gating the nose-CSF transport of  progesterone in monkeys (2, 29) claimed
a direct pathway, as the CSF levels of  progesterone were increasing in
time. However, the progesterone plasma levels appeared to increase si-
multaneously with the CSF levels. When calculating the CSF/plasma ra-
tios for these monkey studies, no significant difference could be found
between nasal and intravenous delivery of  progesterone; this has also
been demonstrated in the estradiol/progesterone studies in rats described
in this Thesis (Chapter 4; 105).
The recent study in neurosurgery patients investigating another lipophilic
drug, melatonin, also demonstrates no direct nose-CSF transport of  this
compound (69). This is the first human study describing the distribution
of  a drug over plasma and CSF following both intranasal and intrave-
nous administration. Due to the strict inclusion and exclusion criteria,
only three patients were able to finish this clinical trial. Therefore, in
order to substantiate these observations, the same melatonin formula-
tion was tested in rats using a similar experimental set-up as described in
this Thesis (Chapter 5; 102). The administered melatonin dose in rats is
relatively high in comparison with the human study on a mg/kg basis:
about 20- and 40-fold higher for intranasal and intravenous administra-
tion, respectively. If  the same dose (mg/kg) for humans would be used
for rats, the melatonin concentrations in plasma and particularly in CSF
would have been below the limit of  detection of  the used HPLC assay.
Therefore, in the rat study the same melatonin formulation but at a higher
dose (40 µg/rat) was used. In the human as well as in the rat study, all
subjects received two melatonin treatments (intranasally and intravenously)
and in both species melatonin is rapidly absorbed in the blood circula-
tion after nasal delivery (T
max
 = 2.5 and 5 min for rats and humans, re-
spectively). The relative uptake of  melatonin into the CSF after nasal
delivery compared to intravenous administration is comparable in rats
and humans, which is evident from the calculated mean CSF ratios (rats:
0.76; humans: 0.71; see Chapter 5). Thus, also in this animal study no
direct nose-CSF transport of  melatonin could be shown.
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Several publications claim a direct transport route from the nasal cavity
into the CSF or brain for low molecular weight compounds, although
scientifically sound evidence is not presented. Sehgal et al. (89) did not
relate the measured progesterone uptake into CSF after nasal administra-
tion to that after intravenous or intramuscular delivery in monkeys, but
only compared the different concentration-time profiles without giving
any pharmacokinetic data. Blood levels were not measured in studies in-
vestigating lidocaine (18) and dopamine agonists (30) in rats, and the
hydrophilic neurotransmitter dopamine (25) and the neurotoxin MPTP
(33) in mice. If  CSF or brain drug concentrations are not related to the
accessory blood levels, the pathway of  drug transport can not be deter-
mined as the relative distribution over the systemic circulation and the
CSF or brain tissue is not known.
Sakane et al. (85-88) investigated several hydrophilic and low molecular
weight substances in rats for possible nose-CSF transport by monitoring
drug levels in CSF at only one time point after nasal delivery. This also
holds for rat studies with the anti-HIV drugs zidovudine (90) and D4T
(112). These results are only indicative of  direct nose-CSF transport and
not at all conclusive.
Dahlin et al. (28) measured total radioactivity levels after nasal and intra-
venous administration of  tritiated dopamine in rats in CSF and brain
tissue also at one time point (t = 30 min), showing similar plasma levels
for both routes of  administration. The significantly increased total radio-
activity in brain tissue after the nasal route compared to intravenous in-
jection might point to a direct nose-brain transport. Nevertheless, meas-
uring total radioactivity (i.e. dopamine and its metabolites) may lead to
erroneous conclusions. Furthermore, in a study by Anand Kumar et al.
(1) hardly any dopamine uptake into CSF was observed following intra-
venous injection in monkeys. However, the first CSF sample was taken at
30 min, while plasma peak levels of  dopamine were found at 15 min after
injection. The T
max
 in plasma is generally indicative for the timing of  the
peak concentrations in CSF. Thus in this monkey study valuable infor-
mation was probably not monitored.
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several time intervals after intranasal and intravenous administration of
cocaine in rats. The ratio covering the first 4 min after nasal administra-
tion was higher than that after intravenous injection. Although the over-
all ratio (0 - 120 min) after nasal delivery was significantly lower than the
one after intravenous delivery, the authors have the opinion that cocaine
is transported directly from the nasal cavity into the brain. However, the
observed difference in the first 4 minutes is probably due to different
pharmacokinetic drug profiles after the nasal and intravenous routes.
Within this category of  small molecular weight drugs only a few research-
ers used the histological approach to investigate the nose-brain transport
route. Using this technique a direct nose-brain transport was demon-
strated for the relatively hydrophilic compounds picolinic acid (10), the
carboxylic acids benzoic acid and salicylic acid (37) in mice, and aflatoxin
B
1
 (63) and the lipophilic molecule benzo(a)pyrene (78) in rats. In the
carboxylic acids and benzo(a)pyrene studies the histological findings con-
firmed the pharmacokinetic results, showing drug uptake from the nasal
cavity into brain tissue.





 ratios as pharmacokinetic evidence. For the lipophilic
drugs hydroxizine (17), lidocaine and bupivacaine (19), and the hydrophilic
compounds procaine (19), benzoylecgonine (20) and methotrexate (109)
higher CSF/plasma ratios were shown after nasal delivery compared to
intravenous administration. However, in all of  these rat studies the
oesophagus was tied off  which hampers the natural clearance of  excess
of  the nasal formulation. Moreover, the last two studies lack important
information about the composition of  the drug formulations.
Bagger and Bechgaard (5) are the only one who report no additional
nose-brain transport of  a small hydrophilic compound. The transport
route of  fluorescein was investigated after nasal and intravenous delivery
in rats, using microdialysis as ECF sampling device in the left and right




 ratios after both adminis-
tration routes were not significantly different from each other.
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5. High molecular weight drugs
Hydrophilic compounds like peptides and the tracermolecules horserad-
ish peroxidase (HRP) and wheat germ agglutinin – horse radish peroxi-
dase (WGA-HRP) are the most investigated high molecular weight sub-
stances (M
w
 > 600 Da). Furthermore, studies were performed on the
nose-brain/CSF transport of  fluorescein-isothiocyanate (FITC) labelled
dextrans (59, 84) and the vitamin B
12
 analogue hydroxocobalamin (69).
HRP and WGA-HRP were mainly used for histological examination of
the transport route following intranasal delivery in rats and mice. These
compounds are transported from the nasal cavity into the brain via the
axonal route (6, 68, 96, 98), which is a long lasting process taking more
than one day (see General introduction and study objectives of  this Thesis).
This is not relevant for drug targeting purposes to the brain, where a fast
onset of  action is required. Therefore, these studies will not be discussed
in detail.
One publication describes the intranasal pathway into the CNS, showing
both histological and kinetical evidence (91). In transgenic mice
overexpressing the amyloid ß protein precursor, the cerebral amyloid ß
deposits were labelled with intranasally delivered basic fibroblast growth
factor (bFGF; M
w
 = 16.4 kDa) or serum amyloid P component (SAP; M
w
= 235 kDa), but not when injected intravenously. However, for the intra-
venous route no kinetic data were provided. Another recent mice study
reports on the direct transport of  the glucagon-like peptide-1 antagonist
exendin (9-39) (M
w
 = 3.4 kDa) following nasal administration (7). This
finding is only based on a significant difference in brain/serum ratios per
sampling point, but not on full AUC ratios.
About half  of  the publications reviewed in this General discussion report
on pharmacodynamic effects of  neuropeptides, mostly only after intra-
nasal delivery and placebo treatment. Nevertheless, the angiotensin II
(M
w
 = 1.0 kDa) study by Derad et al. (32) compared intranasal and intra-
venous delivery. A difference in neurotransmitter release and cardiovas-
cular function was claimed for the nasal administration of  angiotensin II;
however, this could only be determined at particular time points. Overall
there was no difference between nasal and intravenous delivery. The in-
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vestigations by Pietrowsky et al. (80, 81) on vasopressin (M
w
 = 1.1 kDa)
and cholecystokinin-8 (CCK-8; M
w
 = 1.1 kDa), affecting event-related
brain potentials, are the only pharmacodynamic studies, showing that
intravenous delivery resulted in similar or higher peptide plasma levels
than after intranasal administration. These human studies claim a direct
nose-brain transport route for vasopressin and CCK-8. However, the
direct transport of  vasopressin is not supported by the following studies.
In dogs similar uptake of  radioactivity was found in CSF following nasal
and intravenous administration of  vaspressin, but no intact vasopressin
could be demonstrated in the CSF after nasal delivery (3). Gais et al. (48)
did not found any effect on memory consolidation for intranasal vaso-
pressin compared to placebo treatment, and in another placebo-control-
led study the effect of  this neuropeptide on sleep quality was not im-
proved according to the patients’ diary reports (76). Furthermore, an ac-
tive saturable carrier-mediated transport mechanism exists across the BBB
for vasopressin (8), which makes a nose-blood-brain pathway more plau-
sible than a direct one. This also holds for the neuropeptide delta sleep-
inducing peptide (M
w
 = 8.7 kDa) (8); even after intravenous injection
central effects of  this peptide drug were reported (54). This also under-
lines the importance of  comparing intranasal administration with intra-
venous injection in order to determine unambiguously the drug trans-
port route from the nasal cavity into the CNS.
Besides active BBB transport mechanisms, the circumventricular organs
also serve as a portal of  entry to the brain for peptides such as adreno-




 = 1.0 kDa) and CCK-8 as
they lack a BBB (106, 111). Therefore, intravenous administration should
have been compared with nasal delivery in the studies of  CCK-8 and
ACTH analogues by Denecke et al. (31), Fehm et al. (45), Pietrowsky et al.
(79, 81) and Smolnik et al. (94). In the majority of the literature describing
pharmacodynamic effects of  nasally administered peptide drugs, the in-
travenous route was not investigated.
Most publications presenting pharmacokinetic results on nose-brain/CSF
transport of  high molecular weight compounds compared intranasal de-
livery with intravenous administration. However, brain or CSF samples
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were mainly taken at one particular time point or time interval after drug
delivery (16, 36, 47, 84). This gives only limited information on the
pharmacokinetic fate of  the administered drug, especially when CSF sam-
ples are taken at 60 min after intravenous bolus injection as done for
nerve growth factor (NGF; M
w
 = 26.5 kDa) (47) and several FITC-dextrans
(84) in rats. At the sampling time of  60 min the drug plasma concentra-
tions had already decreased to minimum levels, which coincides with clear-
ance of  the drug from the CSF compartment as well. Therefore, these
low drug concentrations found in CSF are not representative for drug
uptake following intravenous administration. Furthermore, in the vasoac-
tive intestinal peptide (M
w
 = 3.5 kDa) (36) and NGF (47) studies in rats
the nasal formulations were administered by nasal perfusion or instilla-
tion of  drops to both nares for a period of  at least 30 minutes, which is
rather aggressive and not representative for nasal drug delivery to hu-
mans. The FITC-dextran FD3 (M
w
 = 3.0 kDa) was also tested in our rat
model (Chapter 7; 57). FD3 distribution over CSF and plasma after intra-
venous infusion was not different from that following intranasal delivery.
However, Jansson et al. (59) demonstrated that FD3 was directly taken up
into brain tissue after nasal delivery in rats, using microscopic visualisa-
tion of  the olfactory tissues. In the olfactory epithelium a transcellular
transport route was observed, subsequently followed by an extracellular
route through the connective tissue. This shows that the drug uptake into
CSF is not always representative for the uptake in brain tissue and vice
versa. This difference in observed drug transport should be kept in mind
when the actual pharmacological target-site does not cohere with the site
of  sampling.




 = 1.0 kDa), insulin (M
w
 = 5.8 kDa) and vasopressin (M
w
 = 1.1 kDa)
in healthy volunteers. For MSH/ACTH
4–10
 and insulin some nose-to-
CSF transport was claimed after nasal administration, mainly because no
systemic absorption of  these peptides was found. However, uptake of
MSH/ACTH
4–10
 into CSF was only observed after nasal delivery of  the
10 mg and not of  the 5 mg dose. Moreover, in a case study in obese
children no effect on body weight was observed after a 3 month period
of  intranasal ACTH
4-10
 treatment (62). The measured insulin concentra-
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tions in CSF were extremely low, making the clinical relevance of  these
levels questionable1. The reported vasopressin uptake in CSF after nasal
administration was attributed to a combination of  direct nose-to-CSF
and BBB transport (12). Nevertheless, this needs to be confirmed by
delivery of  vasopressin via the intravenous route. Furthermore, the
peptides were administered every 30 – 45 seconds by nasal spray until the
required nasal dose was achieved. This procedure is not reproducible
because the human nasal cavity can cope with a delivery volume of  about
100 µl, which will be exceeded after a few sprays. Excess volumes of
formulation will drop out of  the nose or be swallowed and not taken up
via the nasal mucosa, which unables to control the delivered dose. It is
also remarkable that sterile water is used as placebo, because sterile water
being extreme hypotonic is severely irritant to the nose.





 = 1.3 kDa) in the CSF of  neurosurgery patients following
intranasal and intravenous administration. The observed CSF/plasma ratio
for nasal delivery was not different from that after intravenous adminis-
tration, demonstrating no direct nose-CSF transport of  hydroxocobala-
min in these patients. However, the low hydroxocobalamin levels in CSF
after both delivery routes were difficult to determine and therefore the
same formulation was examined in our rat model in order to confirm the





after intranasal and intravenous administration were observed in both
species. Together with the earlier discussed melatonin study in rats and
patients, this indicates that our developed rat model can be predictive for
nose-CSF transport of  drugs in humans. In a recent review article by
Illum (56) the patient study by Merkus et al. (69) is criticised, but two
serious mistakes are made in this review. Firstly, the bioavailability of
hydroxocobalamin in these patients is 1.95 % (and not 19.5 %) and sec-
ondly, it is claimed that these results do proof  direct nose-CSF transport
in humans. The main criticism is that the CSF ratio (see Chapter 5) was
calculated by using the mean AUC values and not by determining the
CSF ratio per individual subject, before calculating the mean CSF ratio.
In order to determine the CSF ratio per patient, Illum substituted the
quoted 0-values with the detection limit of  the used hydroxocobalamin
1 see Appendix I
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assay (25 pmol/L) for calculation purposes and found a CSF ratio of
1.61 and not 1.00 (69). However, the mean CSF/plasma ratios that result
in this CSF ratio of  1.61 are not significantly different from each other2.
This means that the conclusion remains unchanged: there is no direct
nose-CSF transport of  hydroxocobalamin in humans.
6. Conclusions
The concept of  drug targeting to the brain using the nasal route of  ad-
ministration is not new. Some papers on Alzheimer’s disease (46, 47) and
obesity (45, 94) therapies started a ‘hype’ in the scientific literature, with-
out offering a critical discussion and evaluation of  the used methods of
investigation. Therefore, in this Thesis firstly an animal model was devel-
oped meeting the criteria as mentioned in the General introduction and study
objectives: 1) comparing intranasal administration with intravenous injec-
tion and also aiming to achieve similar drug plasma levels after both routes,
2 see Appendix II
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Table I Pharmacokinetic parameters (mean ± sd) in ratsa for substances investigated 




















3.7 ± 1.2 
 
2.8 ± 1.9 
 
54 ± 11 
Estradiol 
 
272 40 7 2.3 ± 1.1 2.0 ± 0.6 43 ± 8 
Progesterone 
 
314 200 7 1.9 ± 0.7 2.2 ± 0.8 76 ± 18 
Melatonin 
    Rat 









32.7 ± 6.3 
80 
 
46.0 ± 10.4 
130 
 
107 ± 26 
80 
Hydroxocobalamin 
    Rat 









0.5 ± 0.2 
0.8 ± 1.1 
 
0.6 ± 0.4 
0.5 ± 0.4 
 
23 ± 8 
2.0 ± 0.9 
FD3 
 
3000 489 6 1.33 ± 0.40 1.03 ± 0.56 18 ± 8 
a Except where noted otherwise. Mw: molecular weight; n: number of subjects; 
CSF/plasma: relative distribution of the compound over CSF and plasma after 
intranasal (i.n.) or intravenous (i.v.) delivery; F: nasal bioavailability.  
 
and 2) serial plasma and CSF sampling in order to obtain accurate drug




 values after both delivery routes.
The developed CSF puncture method in rats, using a stereotaxic frame
and putting the rat in the supine-70° angle position, is a suitable method
to sample CSF in a serial manner in one animal for up to 4 hours after
nasal or intravenous administration (Chapter 2; 103). Using the vascular
access port as intravenous delivery device enables infusion of  the formu-
lation into the jugular vein for 15 – 150 min to reach plasma levels similar
to those after intranasal drug administration (Chapter 3; 104). In the de-
veloped animal model the drug transport route into the CSF after nasal
delivery can be determined by calculating the CSF/plasma ratios follow-
ing nasal and intravenous administration in rats.
From the compounds investigated in this Thesis (see Table I) the lipophilic
drugs hydrocortisone, estradiol, progesterone and melatonin did not show
a direct transport route from the nasal cavity into the CSF in rats. This
observation for lipophilic compounds is supported by several studies
performed in rats and men (4, 17, 26, 27, 55, 69, 72, 108), demonstrating
that drug uptake into the CSF or brain occurs via the systemic circula-
tion.
For the hydrophilic compounds hydroxocobalamin and FD3 no direct
nose-to-CSF transport was shown in rats either. These observations are
supported by Bagger and Bechgaard (5) studying fluorescein uptake in
rats and Merkus et al. (69) studying hydroxocobalamin uptake in men.
The melatonin and hydroxocobalamin studies performed in rats and hu-
mans show that the presented rat model can be predictive for the human
situation, which makes this animal model a valuable screening tool.
In this Thesis it has been demonstrated that for all lipophilic and hy-
drophilic drugs investigated, the amount of  the drug that enters the CSF
is completely dependent on the amount of  drug in the blood, after intra-
nasal and after intravenous administration.
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In the literature a number of  studies claim a direct transport route via the
olfactory area in the nose, but most of  these studies are animal studies
using extreme experimental conditions, not comparable with the human
situation when taking a nasal drop or nasal spray.
Those investigators who believe in direct nose-to-brain/CSF transport
are encouraged to prove this direct transport route in human studies,
because based on the results presented in this Thesis the observed drug
uptake into the CSF is mainly a result of  drug transport over the blood-
brain and blood-CSF barriers and not via a direct nasal route.
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Appendix I: Explanation of note 1.
The clinical relevance of  the measured insulin levels by Born et al. (2002)
is uncertain. Therefore, the amount of  insulin that is transported into the
CSF after nasal delivery of  40 IU of  insulin in humans is expressed as a
percentage of  the nasally administered dose. In order to calculate this
percentage the following parameters published by Born et al. (2002) are
taken into account:
- The amount of  insulin determined in the CSF after nasal delivery of
a 40 IU insulin dose in humans: 1091.1 pmol/l*min (AUC
CSF, in
).
- The endogenous level of  insulin determined in the CSF after pla-
cebo administration in humans: 603.2 pmol/l*min (AUC
CSF, placebo
).
- The nasally administered insulin dose: 40 IU equals 264.8 nmol (D).
- The total CSF volume in humans: estimated at 150 ml (V
CSF
).
The amount of  insulin transported into the CSF after nasal delivery as
percentage of  the administered dose (R
CSF
) is calculated from the AUC
CSF,
in
 by correcting this value for the endogenous insulin level in CSF (AUC
CSF,
placebo
), the total sampling time (T) and the total CSF volume in humans
(V
CSF










This results in an R
CSF
 of:
((1091.1 – 603.2) * 10-12 * 0.15)/(80 * 264.8 * 10-9) * 100 = 0.0003 %,
which is a negligible portion of  the nasally administered dose.
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Appendix II: Explanation of note 2.
In the human study by Merkus et al. (2003) the AUC-values in plasma and
CSF were determined for each patient after intranasal and intravenous
delivery. Due to the measured 0-values in CSF for patient P and S the
CSF ratio was calculated by determining first mean AUC values and
subsequently CSF/plasma ratios for nasal and intravenous delivery. The
CSF/plasma
in
-ratio divided by the CSF/plasma
iv
-ratio gives the CSF ratio
of  1.0, which means that the relative amount of  hydroxocobalamin that
is transported into the CSF after intranasal administration is similar to
that after intravenous delivery (Table IIa).
According to Illum (2004) the CSF ratio should be determined firstly per
patient before calculating a mean value. In order to do this the 0-values in
Table IIa were substituted with the value of  the detection limit (25 pmol/
l) of  the used hydroxocobalamin assay. The corresponding CSF/plasma
and CSF ratios are shown in Table IIb. Following this calculation method
the mean CSF ratio, intranasal versus intravenous administration, is 1.61.
This does not mean that there is a direct transport to the CSF after
intranasal delivery, because the mean CSF/plasma ratios for intranasal
and intravenous administration are not significantly different, as indicated
by the p-value of  0.46 (Table IIb). Therefore, the conclusion is correct
that the uptake of  hydroxocobalamin into the CSF in patients after
intranasal delivery is similar to that after intravenous administration.
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With the growing number of  patients suffering from central nervous
system (CNS) diseases a suitable approach for drug targeting to the brain
becomes more and more important. This is a major problem in drug
delivery research, which is due to the tight blood-brain barrier (BBB) that
prevents the influx of  xenobiotic compounds including drugs from the
systemic circulation into the brain. Only small lipophilic compounds (M
w
< 600 Da), nutrients and a few peptides, which have a carrier-mediated
transport system in the BBB, can be transported from the systemic circu-
lation into the brain. To enhance the uptake into the CNS of  drugs that
do not meet these criteria, several strategies have been investigated to
manipulate this barrier. However, there is still no satisfactory method to
target drugs into the brain.
The olfactory neurons, that allow humans and other species to smell,
connect the brain and surrounding cerebrospinal fluid (CSF) with the
open air that is inhaled via the nasal cavity. This anatomical observation
raised the hypothesis that drugs may access the CNS directly following
intranasal administration, thereby circumventing the BBB. Dyes, viruses,
metals, small and high molecular weight drugs have been investigated on
nose–brain/CSF transport in animals and men. However, the feasibility
of  this direct pathway for drug targeting to the brain and CSF is still
under debate. One of  the reasons is the used method of  investigation
reported in the literature on drug transport via the nose-brain/CSF route
as outlined in Chapter 1.
Many investigators who claim a direct nose to brain transport after nasal
drug delivery are using unrealistic experimental methods. Therefore, a
new experimental method has been developed, which allowed monitor-
ing the drug distribution in plasma and CSF after nasal and intravenous
delivery in rats. Subsequently, the actual route of  drug transport can be
determined by calculating the relative distribution of  a drug over CSF
and plasma after both ways of  administration according to Equation 1.
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ratioplasmaCSF = Equation 1
In case of  direct drug transport from the nasal cavity it is expected that
the CSF/plasma ratio following intranasal delivery will be significantly
higher than that after intravenous administration. When the nasal distri-
bution parameter is equal to or lower than the intravenous one, the ob-
served drug transport can be considered as systemically and not via the
olfactory receptor neurons (Chapter 1).
1. Development of  a suitable rat model
First a method to sample CSF from the rat was developed (Chapter 2).
Sampling CSF from the cisterna magna by cisternal puncture was com-
pared with cannulation of  the atlanto-occipital membrane, which is lo-
cated in between the skull and the upper cervical vetrebral. In the cisternal
puncture method a needle is advanced through the skin and muscles over-
lying the atlanto-occipital membrane into the cisterna magna, while the
rat is fixed in a stereotaxic frame in upright position. After attaching a
micro-syringe via a piece of  tubing to the needle the CSF can be sampled
in amounts as small as 30 µl. For the cannulation method the atlanto-
occipital membrane was exposed and cannulated by attaching a piece of
tubing to the membrane, which was perforated by putting a double nee-
dle through the cannula in order to get access to the CSF in the underly-
ing cisterna magna. The cisternal puncture method appeared to be supe-
rior over cannulation of  the atlanto-occipital membrane for CSF sam-
pling. The major advantages of  the puncture method are the ability of
serial and simultaneous CSF and blood sampling for over 2 – 4 hours in
the same rat. Furthermore, the sampled CSF is virtually free from eryth-
rocytes (< 0.01 % of  normal blood content) and the rats are allowed to
recover and can be used for a second study. This makes it possible to
compare intranasal and intravenous drug delivery in one animal.
To obtain maximal drug absorption from the nasal cavity and uptake into
the CSF, different positions of  the rat’s head (upright-90° angle, supine-
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90° angle, supine-45° angle and supine-70° angle; Figure 1 of  Chapter 2)
were tested in nasal delivery studies using hydrocortisone (molecular
weight (M
w
) = 362 Da) as a model drug. Putting the rat in the supine-90°
angle position increased the absorption of  hydrocortisone into plasma
and CSF two-fold compared to the upright-90° angle position. The su-
pine-70° angle position did not change the hydrocortisone plasma and
CSF levels compared to the supine-90° angle position. However, the su-
pine-70° angle position showed the fastest CSF sampling rate, enabling
more accurate CSF sampling and therefore preferred over the other po-
sitions.
The contribution of  the nose-CSF pathway in the uptake of  hydrocorti-
sone into the CSF was determined by comparing the intranasal and intra-
venous routes of  administration. A vascular access port was used as in-
travenous delivery device (Chapter 3). The vascular access port consists
of  a depot attached to a catheter and is implanted subcutaneously. An
intravenous bolus injection was given to determine the intravenous infu-
sion rate needed to reach a similar drug plasma concentration (C
max
) as
found after intranasal administration in rats. Simulating the C
max
 after na-
sal delivery with the intravenous infusion ensures that the plasma con-
centrations of  the drug following both routes of  administration are as
similar as possible. Besides, the influence of  different nasal delivery vol-
umes (20, 40 and 60 µl) on the uptake of  hydrocortisone into plasma and
CSF was investigated. Increasing the nasal delivery volume from 20 to 60
µl did not further influence the absorption of  hydrocortisone in plasma
or the uptake in CSF. The CSF/plasma ratio of  hydrocortisone was in
the order of  3 – 4 % for both routes of  administration. Therefore, there
is no indication for nose-CSF transport of  the lipophilic steroid hor-
mone hydrocortisone after nasal administration (Chapter 3).
The developed rat model comprising serial CSF sampling using the
cisternal puncture method in rats in the supine-70° angle position and
simulation of  the nasal plasma profile by intravenous infusion using a
vascular access port (Chapter 2 and 3) was used throughout this Thesis to
investigate the nose-CSF transport route of  a variety of  compounds with
different physicochemical properties (Chapters 4 - 7).
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2. Estradiol and progesterone:
     Two lipophilic and small molecular weight compounds
In the research area of  direct nose-CSF drug delivery the reported stud-
ies by Anand Kumar and co-workers with the female steroid hormones
estradiol (M
w
 = 272 Da) and progesterone (M
w
 = 314 Da) are often re-
ferred to as evidence of  a direct transport route from the nasal cavity into
the CSF for such compounds. The fact that these studies are often cited
in literature, show their importance in this research area. However, the
experimental conditions used for these nasal drug delivery studies were
rather aggressive. Therefore, in this Thesis the possibility of  direct nose-
CSF transport for estradiol and progesterone was re-examined by com-
paring the relative distribution of  these drugs over CSF and plasma after
both intranasal and intravenous administration in rats. In order to dis-
solve the lipophilic steroids in saline, randomly methylated ß-cyclodextrin
(RAMEB) was used as solubiliser. RAMEB is able to form an inclusion
complex with lipophilic drugs, thereby enhancing their solubility in aque-
ous solutions. Nasal delivery in rats was subsequently performed by drop
application of  the steroid formulations (Chapter 4). Following nasal deliv-
ery, both steroid hormones reach C
max
 values in plasma and CSF at 15
min after administration. Intravenous infusion of  estradiol and proges-
terone shows comparable plasma and CSF concentration-time profiles
as observed for the nasal route. For both hormones the CSF/plasma
ratios (mean ± sd) after intranasal delivery (estradiol: 2.3 ± 1.1 %; pro-
gesterone: 1.9 ± 0.7 %) do not differ significantly from the values shown
after intravenous infusion (estradiol: 2.0 ± 0.6 %; progesterone: 2.2 ± 0.8
%). These results indicate that after nasal delivery estradiol and proges-
terone are rapidly absorbed into the systemic circulation, from where
most likely the non-protein bound hormones enter the CSF by crossing
the BBB. No extra direct nose-CSF transport could be demonstrated
(Chapter 4).
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3. Melatonin and hydroxocobalamin:
   A comparison of rat and human studies
The key-question is still whether this direct transport route is effective in
humans or not. To verify the actual feasibility of  this novel approach, it is
necessary to compare animal studies with human data. A recent Neurology
paper describes for the first time the uptake of  two model compounds in
blood and CSF after nasal and intravenous delivery in the same subject.
In neurosurgery patients with a CSF drain it was possible to investigate
the nose-CSF pathway of  the low molecular weight and lipophilic sub-
stance melatonin (M
w
 = 232 Da) and the high molecular weight and hy-
drophilic molecule hydroxocobalamin (M
w
 = 1346 Da), both serving as
model compounds (Merkus et al., 2003). In the last study an extra compli-
cation was met as the achieved hydroxocobalamin levels in CSF were
near the limit of detection. In order to substantiate the results of these
human studies, in this Thesis the same melatonin and hydroxocobalamin
formulations were investigated in rats (n = 8) using a comparable experi-
mental set-up.
In rats, melatonin (Chapter 5) is quickly absorbed in plasma (T
max
 = 2.5
min) and shows a delayed uptake into CSF (T
max
 = 15 min) after nasal
administration. The melatonin concentration-time profiles in plasma and
CSF are comparable to those after intravenous delivery. The CSF/plasma
ratio after nasal delivery (32.7 ± 6.3 %) does not differ significantly from
the one after intravenous injection (46.0 ± 10.4 %), which is also indi-
cated by the CSF ratio (Equation 2): 0.76 ± 0.31. This demonstrates that
melatonin enters the CSF via the blood circulation across the BBB and
not via the nose-CSF-pathway. These results resemble the outcome of
the human study, showing also a fast nasal absorption (T
max
 = 5 min) and
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For hydroxocobalamin (Chapter 6) the CSF/plasma ratio after nasal deliv-
ery (0.5 ± 0.2 %) does not differ from that after intravenous infusion (0.6
± 0.4 %) in rats, indicating that hydroxocobalamin enters the CSF via the
blood circulation across the BBB, which is in accordance with the results
found in humans (CSF/plasma ratio = 0.5 % for both administration
routes). This same transport route is confirmed by the cumulative area
under the concentration-time profiles in CSF and plasma, demonstrating
a 30 min delay between plasma absorption and CSF uptake of  hydroxo-
cobalamin in rats and in the comparative human study. These results dem-
onstrate that in both humans and rats there is no additional uptake of
hydroxocobalamin in the CSF after nasal delivery compared to intrave-
nous administration.
Thus the melatonin as well as the hydroxocobalamin studies indicate that
the used rat model can be predictive for the human situation when study-
ing nose-to-CSF transport of  drugs (Chapter 5 and 6).
4. FITC-labelled dextran (M
w
 = 3000 Da):
    A hydrophilic and high molecular weight compound
The hydrophilic and high molecular weight substance, fluorescein
isothiocyanate-labelled dextran with a molecular weight of  3000 Da (FD3),
was examined on nose-CSF transport in rats (Chapter 7). Following both
routes of administration, comparable concentration-time profiles of FD3
are obtained in CSF. However, no significant differences are observed
between the CSF/plasma ratios of  FD3 after intranasal administration
(1.33 ± 0.40 %) and intravenous infusion (1.03 ± 0.56 %). This indicates
that in rats there is no direct transport of  FD3 from the nasal cavity into
the CSF (Chapter 7).
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5. Concluding remarks
In this Thesis it has been demonstrated that for all lipophilic and hy-
drophilic drugs investigated, the amount of  the drug that enters the CSF
is completely dependent on the amount of  drug in the blood, after intra-
nasal and after intravenous administration.
In the literature a number of  studies claim a direct transport route via the
olfactory area in the nose, but most of  these studies are animal studies
using extreme experimental conditions, not comparable with the human
situation when taking a nasal drop or nasal spray.
Those investigators who believe in direct nose-to-brain/CSF transport
are encouraged to prove this direct transport route in human studies,
because based on the results presented in this Thesis the observed drug
uptake into the CSF is mainly a result of  drug transport over the blood-
brain and blood-CSF barriers and not via a direct nasal route.
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SAMENVATTING
Door een toenemende groei van het aantal patiënten met een
hersenaandoening, neemt het belang van de ontwikkeling van een
geschikte methode om geneesmiddelen naar de hersenen te brengen toe.
Dit is een groot probleem binnen het geneesmiddelenonderzoek, wat te
wijten is aan de sterke barrière tussen bloed en hersenweefsel, de
zogenaamde bloed-hersen barrière (BHB), die voorkomt dat
lichaamsvreemde stoffen, inclusief  geneesmiddelen, vanuit de bloedbaan
de hersenen binnendringen. Alleen bepaalde stoffen, zoals lipofiele
(vetoplosbare) stoffen met een molecuulgewicht (M
w
) < 600 Dalton (Da),
voedingsstoffen en peptiden (kleine eiwitten), die een speciaal
transportsysteem hebben in deze barrière, kunnen de BHB passeren en
hebben daarmee toegang tot de hersenen vanuit de bloedcirculatie. Om
de opname van geneesmiddelen in de hersenen te verhogen of  mogelijk
te maken, zijn verschillende methodes onderzocht om deze barrière te
omzeilen of  te manipuleren. Het is echter tot nu toe nog niet mogelijk
om geneesmiddelen op een effectieve manier naar de hersenen te sturen.
De reukzenuwen, die het mogelijk maken om geuren waar te nemen,
ontspringen in de hersenen en eindigen in de neusholte. Op deze manier
verbinden deze zenuwen de hersenen en de omringende cerebrospinaal
vloeistof  (CSV; vloeistof  die de hersenen en het ruggenmerg omringt)
direct met de buitenlucht die wordt ingeademd door de neus. Deze
anatomische waarneming leidde tot de hypothese dat geneesmiddelen na
nasale toediening direct toegang zouden hebben tot het centrale
zenuwstelsel en daarmee de sterke BHB zouden kunnen omzeilen. Dit
zogenaamde neus-hersen/CSV transport is onderzocht in proefdieren
en mensen voor verschillende kleurstoffen, virussen, metalen en laag- en
hoogmoleculaire stoffen (kleine en grote moleculen). Of  deze directe
route daadwerkelijk bruikbaar is om geneesmiddelen in de hersenen en
de CSV te krijgen, staat nog steeds ter discussie. Eén van de redenen is de
in de literatuur gebruikte methodes in het onderzoek naar
geneesmiddeltransport via de neus-hersen/CSV route, zoals besproken
in Hoofdstuk 1. Veel onderzoekers die claimen direct neus-hersentransport
te hebben aangetoond van een geneesmiddel na nasale toediening,
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gebruiken onrealistische experimentele methodes. Een ander belangrijk
punt dat over het hoofd wordt gezien is het feit dat stoffen vanuit de neus
gemakkelijk kunnen worden opgenomen in het bloed en van daaruit in
de hersenen en de CSV terecht kunnen komen. Het eerste doel van dit
proefschrift was daarom het ontwikkelen van een nieuwe experimentele
methode, waarmee de verdeling van het geneesmiddel over plasma
(onderdeel van bloed) en CSV na nasale en intraveneuze (in de ader)
toediening in ratten kan worden bepaald. Door de relatieve verdeling van
een geneesmiddel over CSV en plasma na beide toedieningswegen (nasaal
en intraveneus) te berekenen volgens Vergelijking 1 kan de transportroute






ratioplasmaCSV = Vergelijking 1
De opname van het geneesmiddel in de CSV dan wel in plasma wordt
uitgedrukt in de oppervlakte onder de concentratie/tijd curve ofwel AUC
(Area Under the Curve). Als een geneesmiddel direct vanuit de neus in de
CSV wordt opgenomen, dan is de verwachting dat de CSV/plasma ratio
na nasale toediening groter zal zijn dan die na intraveneuze toediening.
Wanneer deze parameter na nasale toediening gelijk is aan of  kleiner is
dan na intraveneuze injectie, dan kan het geneesmiddeltransport worden
beschouwd als systemisch (via de bloedbaan) en verloopt het blijkbaar
niet via de reukzenuw (Hoofdstuk 1).
1. Ontwikkeling van een geschikt rattenmodel
In de eerste plaats is een methode ontwikkeld om CSV monsters te kunnen
nemen bij ratten (Hoofdstuk 2). Hiertoe zijn twee methodes met elkaar
vergeleken: de punctiemethode en de canuleringsmethode. Bij de
punctiemethode wordt een naald ingebracht door de huid en het
spierweefsel dat het atlanto-occipitale membraan (bevindt zich tussen de
schedel en de bovenste ruggenwervel) bedekt totdat deze uitkomt in de
cisterna magna (holte achter het atlanto-occipitale membraan, die CSV
bevat). Hiervoor wordt de rat vastgezet in een stereotact (een frame) in
de zogenaamde rechtop-90° positie: rechtop zittend met de neus recht
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vooruit, in een hoek van 90° met de ruggenwervel (zie ook Hoofdstuk 2,
Figuur 1). Met behulp van een micro-spuit, die via een slangetje aan de
naald wordt gekoppeld kunnen kleine hoeveelheden CSV van circa 30 µl
worden afgetapt. Bij de canuleringsmethode wordt operatief  het atlanto-
occipitale membraan blootgelegd, zodat er een canule op bevestigd kan
worden. Vervolgens wordt het membraan geperforeerd door met een
dubbele naald via de canule door het membraan te prikken. Via de
perforatie in het membraan kan er nu CSV vanuit de cisterna magna in de
canule lopen. De uitgevoerde experimenten wijzen uit dat voor het nemen
van CSV monsters bij ratten de punctiemethode beter werkt dan de
canuleringsmethode. Het belangrijkste voordeel van de punctiemethode
is de mogelijkheid om tegelijkertijd bij één rat een reeks CSV monsters
en een reeks bloed monsters te nemen gedurende een tijdspanne van 2 –
4 uur. Bovendien zijn de genomen CSV monsters nauwelijks besmet met
rode bloedcellen (< 0.01 % van de hoeveelheid in bloed) en na het ex-
periment ontwaken de ratten uit de verdoving en kunnen na een
herstelperiode worden gebruikt in een volgend experiment. Hierdoor is
het mogelijk om nasale toediening en intraveneuze toediening van een
geneesmiddel in één proefdier te onderzoeken.
De absorptie van stoffen vanuit de neusholte in het bloed en de opname
hiervan in de CSV zijn geoptimaliseerd, door verschillende houdingen
van het hoofd van de rat te testen (rechtop-90°, liggend-90°, liggend-45°
en liggend-70°; zie Hoofdstuk 2, Figuur 1). Hiervoor is het hormoon
hydrocortison (M
w
 = 362 Da) als modelstof  gebruikt en de rechtop-90°
houding is het uitgangspunt. Na nasale toediening van hydrocortison in
de rat in de liggend-90° positie werd dit tweemaal zo goed geabsorbeerd
in plasma en opgenomen in CSV dan in vergelijking met de rechtop-90°
houding. De liggend-70° houding veranderde de concentratie van
hydrocortison in plasma en CSV niet ten opzichte van die na nasale
toediening in de liggend-90° houding net als de liggend-45° houding.
Het nemen van CSV monsters verliep echter het snelst en daarmee het
meest nauwkeurig, bij gebruik van de liggend-70° houding. Hierdoor heeft
deze positie de voorkeur boven de andere posities en is gebruikt in de
verdere experimenten beschreven in dit proefschrift.
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In welke mate de neus-CSV weg heeft bijgedragen aan de opname van
hydrocortison in de CSV werd bepaald door nasale toediening te
vergelijken met intraveneuze toediening. Een zogenaamde ‘vascular ac-
cess port’ werd gebruikt voor de intraveneuze toediening van stoffen
(Hoofdstuk 3). De vascular access port bestaat uit een plastic kamertje
waaraan een stuk slang is bevestigd, die uitmondt in een ader. Dit geheel
wordt onderhuids bevestigd. Het streven hierbij is om met de intraveneuze
toediening de maximale geneesmiddelconcentratie in plasma (C
max
) na te
bootsen die bereikt is na nasale toediening in de rat. Op deze manier
wordt de variatie in de AUC
plasma
 na beide toedieningswegen beperkt.
Hiertoe wordt eerst een intraveneuze injectie gegeven, om de snelheid
van het infuus te bepalen, die nodig is om deze C
max
 na nasale toediening
te benaderen. Daarnaast werd de invloed van het nasale toedieningsvolume
(20, 40 en 60 µl) op de opname van hydrocortison in plasma en CSV
onderzocht.
Het vergroten van het nasale toedieningsvolume van 20 naar 60 µl had
geen invloed op de absorptie van hydrocortison in plasma of  de opname
hiervan in CSV. De CSV/plasma ratio (Vergelijking 1) van hydrocortison
was in de orde van 3 – 4 % voor beide toedieningswegen. Dit duidt er op,
dat het lipofiele steroïdhormoon hydrocortison niet via direct neus-CSV
transport in de CSV is opgenomen na nasale toediening bij ratten
(Hoofdstuk 3).
Het ontwikkelde rattenmodel, dat bestaat uit het afnemen van CSV mon-
sters in serie door gebruik te maken van de punctiemethode in ratten die
gepositioneerd zijn in de liggend-70° houding en het benaderen van het
nasale plasma profiel met een intraveneus infuus door gebruik te maken
van een vascular access port (Hoofdstuk 2 en 3), is in dit gehele proefschrift
gebruikt om de neus-CSV transportroute te onderzoeken van stoffen
met verschillende fysisch-chemische eigenschappen (Hoofdstukken 4 – 7).
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2. Estradiol en progesteron:
    Twee lipofiele, laagmoleculaire stoffen
In het onderzoeksveld van direct neus-hersen/CSV
geneesmiddeltransport worden de studies van Anand Kumar en
medewerkers met betrekking tot de vrouwelijke steroïdhormonen estradiol
(M
w
 = 272 Da) en progesteron (M
w
 = 314 Da) vaak aangehaald als een
bewijs voor een direct transport vanuit de neusholte naar de CSV van
dergelijke stoffen. Het feit dat aan deze studies zo vaak wordt gerefereerd
in de literatuur, geeft aan hoe belangrijk ze zijn in dit onderzoeksgebied.
De experimentele condities die gebruikt zijn in deze nasale
toedieningsstudies zijn echter nogal agressief. Er is onder meer gebruik
gemaakt van organische oplosmiddelen om estradiol en progesteron te
kunnen oplossen en deze oplossingen werden langdurig en met kracht
bij apen in de neusholte geblazen. Daarom is in dit proefschrift de
mogelijkheid van direct neus-CSV transport van estradiol en progesteron
opnieuw onderzocht door de relatieve verdeling van deze stoffen over
plasma en CSV na zowel nasale als intraveneuze toediening in ratten te
onderzoeken. De oplosbaarheidsbevorderende stof  RAMEB (randomly
methylated ß-cyclodextrin) is gebruikt om de lipofiele steroïden in
fysiologisch zout te kunnen oplossen. RAMEB vormt met lipofiele stoffen
een inclusiecomplex, dat de oplosbaarheid van deze stoffen in waterige
oplossingen verhoogt. De steroïdformuleringen zijn in de vorm van
neusdruppels aan ratten toegediend (Hoofdstuk 4). Vijftien minuten na
nasale toediening bereikten beide hormonen maximale concentraties in
plasma en CSV. De intraveneuze infusie-experimenten met estradiol en
progesteron laten plasma en CSV spiegels zien die vergelijkbaar zijn met
die na nasale toediening. Voor beide hormonen verschilt de CSV/plasma
ratio (gemiddelde ± standaard deviatie) na nasale toediening (estradiol:
2,3 ± 1,1 %; progesteron: 1,9 ± 0,7 %) niet significant van die na
intraveneus infuus (estradiol: 2,0 ± 0,6 %; progesteron: 2,2 ± 0,8 %).
Deze resultaten duiden op een snelle absorptie van estradiol en
progesteron in de bloedbaan na nasale toediening. Vanuit de bloedbaan
worden zeer waarschijnlijk de hormonen die niet aan eiwitten zijn
gebonden opgenomen in de CSV na passage van de BHB. De resultaten
tonen aan dat er geen extra of  direct neus-CSV transport van estradiol en
progesteron plaatsvindt (Hoofdstuk 4).
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3. Melatonine en hydroxocobalamine:
    Een vergelijking van ratten- en humane studies
De vraag waar het uiteindelijk om draait is natuurlijk of  deze directe
transportroute van de neus naar de CSV bij de mens al of  niet kan worden
aangetoond. Om het bestaan van deze transportroute te verifiëren, is het
nodig om dierproeven te vergelijken met humane studies. Een recent
artikel in Neurology beschrijft voor het eerst de opname van twee
modelstoffen in zowel bloed als CSV na nasale en intraveneuze toediening
in dezelfde patiënt. In neurochirurgiepatiënten waarbij een afvoerbuisje
was aangebracht om CSV af  te tappen, was het mogelijk om de neus-
CSV transportroute voor twee modelstoffen te onderzoeken: de
laagmoleculaire en lipofiele stof melatonine (M
w
 = 232 Da) en het
hoogmoleculaire en hydrofiele (in water oplosbare) molecuul
hydroxocobalamine (M
w
 = 1346 Da) (Merkus et al., 2003). In deze hu-
mane studies werd de CSV ratio (Vergelijking 2) gebruikt om te bepalen
of  er direct neus-CSV transport heeft plaatsgevonden. Als de CSV ratio









De hydroxocobalamine studie bij de mens leverde een extra complicatie
op doordat de concentraties hiervan in de CSV in de buurt van de
detectielimiet lagen. Om de resultaten van deze humane studie te
onderbouwen zijn in dit proefschrift dezelfde melatonine en
hydroxocobalamine formuleringen onderzocht in ratten en ook in een
vergelijkbare experimentele opzet.
Melatonine (Hoofdstuk 5) wordt in ratten snel geabsorbeerd in plasma na
nasale toediening; de tijd die nodig is om de maximale plasmaconcentratie
te bereiken (T
max
) is 2,5 minuut. In CSV is een vertraagde opname van
melatonine (T
max
 = 15 min) waargenomen na nasale toediening. De
concentratie/tijd profielen van melatonine in plasma en CSV zijn
vergelijkbaar met die na intraveneuze toediening. De CSV/plasma ratio
na nasale toediening (32,7 ± 6,3 %) is niet significant verschillend van die
194
9 Summary & Samenvatting
na intraveneuze injectie (46,0 ± 10,4 %), hetgeen ook wordt aangetoond
door de CSV ratio (zie Vergelijking 2): 0,76 ± 0,31. Dit geeft aan dat
melatonine in de CSV terecht komt door vanuit de bloedbaan de BHB te
passeren en niet via de neus-CSV route. Deze resultaten komen overeen
met de eerder genoemde humane studie die ook een snelle absorptie
(T
max
 = 5 min) van melatonine liet zien en een CSV ratio van 0,71 ± 0,30.
Voor hydroxocobalamine (Hoofdstuk 6) verschilt de CSV/plasma ratio na
nasale toediening (0,5 ± 0,2 %) niet van die na intraveneus infuus (0,6 ±
0,4 %) in ratten. Dat wijst op een opname van hydroxocobalamine in de
CSV na absorptie in de bloedbaan en passage van de BHB. Dit komt
overeen met de resultaten die gevonden zijn in de patiëntenstudie (CSV/
plasma ratio = 0,5 % voor beide toedieningswegen). Deze transportroute
wordt bevestigd door de cumulatieve AUC/tijd profielen in de CSV en
plasma. Deze profielen laten namelijk zien dat zowel in ratten als in mensen
hydroxocobalamine ongeveer 30 minuten later wordt opgenomen in de
CSV dan geabsorbeerd in plasma. Deze resultaten geven aan dat er in
mensen en in ratten geen additioneel hydroxocobalamine transport is
naar de CSV na nasale toediening in vergelijking met intraveneuze
toediening.
Zowel de melatonine als de hydroxocobalamine studies geven aan dat het
gebruikte rattenmodel een voorspellende waarde kan hebben voor de
humane situatie bij het bestuderen van neus-CSV transport van
geneesmiddelen (Hoofdstuk 5 en 6).
4. FITC-gelabeld dextraan (M
w
 = 3000 Da):
     Een hydrofiele en hoogmoleculaire modelstof
De hydrofiele en hoogmoleculaire stof  FD3 (fluoresceïne isothiocyanaat-
gelabeld dextraan met een molecuulgewicht van 3000 Da), werd
onderzocht op neus-CSV transport in ratten (Hoofdstuk 7). Na nasale en
intraveneuze toediening zijn vergelijkbare concentratie/tijd profielen van
FD3 gevonden in de CSV. Er zijn evenwel geen significante verschillen
waargenomen tussen de CSV/plasma ratios van FD3 na nasale toediening
(1,33 ± 0,40 %) en na intraveneus infuus (1,03 ± 0,56 %). Dit geeft aan
dat er in ratten geen direct FD3-transport plaatsvindt vanuit de neusholte
naar de CSV (Hoofdstuk 7).
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5. Concluderende opmerkingen
In dit proefschrift is aangetoond dat voor alle onderzochte lipofiele en
hydrofiele stoffen de opname in de CSV na nasale toediening geheel
afhankelijk is van de hoeveelheid stof  die zich in het bloed bevindt.
Een aantal studies in de literatuur claimen een direct transport van
geneesmiddelen via het gebied waar de reukzenuwen zich bevinden in de
neus naar de hersenen/CSV te hebben aangetoond, maar in het merendeel
van deze dierstudies worden extreme experimentele condities gebruikt.
Deze condities zijn niet te vergelijken met de omstandigheden waaronder
bij mensen een neusspray of  neusdruppels worden toegediend. De
onderzoekers, die geloven in direct neus-hersen/CSV transport worden
hierbij aangemoedigd om dit aan te tonen in mensen, aangezien uit de
resultaten van dit proefschrift blijkt dat de waargenomen
geneesmiddelopname in CSV zo goed als volledig wordt veroorzaakt door
transport via de bloed-hersen en bloed-CSV barrière en niet via een directe
nasale route.
196
9 Summary & Samenvatting
Nawoord
Aan het eind van het promotietraject begint het samenbundelen van het
gedane onderzoek in de vorm van een boekje. Dit boekje kon echter
alleen tot stand komen door de medewerking van verschillende mensen
die ik hier wil noemen.
Ten eerste de medewerkers van de subsectie Farmaceutische Technologie
en Biofarmacie en met name Stefan Romeijn die altijd klaar stond met
praktische hulp en oplossingen. Een heel prettige samenwerking, die zeer
veel heeft bijgedragen aan het slagen van de experimenten. Aangezien
deze vakgroep klein is, mocht ik gelukkig ook deel uitmaken van een
‘sociale vakgroep’: Farmaceutische Technologie. Op deze manier heb ik
ruim 4 jaar lang een zeer gevarieerde groep aan kamer- en pauzegenootjes
gehad, altijd gekleurd door een grote variëteit aan nationaliteiten wat een
bijzondere ervaring was. Dit heeft bijgedragen aan een heel prettige
werksfeer.
In de beginfase van mijn onderzoek heb ik veel geleerd van Marc Fluttert
en Wout Meelis van de afdeling Medische Farmacologie bij het opzetten
van mijn rattenmodel. Ook onmisbaar was de hulp van Henk de Vries
van de afdeling Farmacochemie bij de stalling van de proefdieren op het
Gorlaeus, dat heeft heel wat ritjes naar het Sylvius gespaard. In mijn laatste
jaar heb ik nog de luxe van een ‘echte’ dierstal kunnen meemaken met
Johan Pragt en Fred Kokkedee als dierverzorgers, die het niet erg vonden
om ook met kleine praktische problemen even bij te springen.
Heel blij ben ik met de samenwerking met KNO-arts Paul Merkus, ook
al was het voornamelijk ‘op afstand’. Het kunnen vergelijken van mijn
ratten studies met het onderzoek bij mensen, dat hij in het AMC te
Amsterdam uitvoerde, was een zeer waardevolle toevoeging aan mijn
proefschrift.
In mijn derde jaar kreeg ik een stage student, Joke in ’t Veen, onder mijn
hoede. Nadat ik je goed en wel had ingewerkt, werd ik 4 maanden ziek en
kon ik alleen nog aan het eind je verslag nakijken. Gelukkig werd je goed
opgevangen door onder andere Stefan Romeijn en heb je heel veel werk
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kunnen verzetten, met als resultaat een waardevolle bijdrage aan mijn
onderzoek. De samenwerking is heel prettig en gezellig geweest en werd
gelukkig voortgezet toen je mijn collega werd als AIO.
Een andere collega die ik niet wil vergeten is Arno Hazekamp van de
afdeling Farmacognosie; niets fijner dan even opgefrist te worden met
een aanstekelijke dosis enthousiasme als je het even niet meer ziet zitten.
Dat bleef  gelukkig niet bij ‘even kletsen in de kantine’, inmiddels heb je
me helemaal overtuigd van het plezier dat wandelen biedt!
Tijdens de laatste fase van het promoveren kwam steeds vaker de hulp
van de secretaresses om de hoek kijken. In het bijzonder wil ik Anka
Schoordijk noemen die voor mij grote delen van de algemene inleiding
en discussie heeft overgetypt vanwege RSI problemen aan mijn rechterarm.
Buiten de werkkring om heb ik heel veel hulp en steun gehad van vele
mensen. Ten eerste mijn huisgenoten op de Maredijk. Ik heb in ruim 5
jaar veel huisgenootjes voorbij zien komen, maar de gezelligheid en opvang
van Marjan, Annet, Mira en Ilse zal ik niet vergeten. Wat natuurlijk niet
mag ontbreken is de ‘BFW-club’: Aukje, Ciska, Heidi, Ine, Marieke, Roos
en Suus. Ondanks de weer toenemende afstand blijven we elkaar volgen
en met elkaar meeleven, heel fijn zo’n vertrouwd clubje!
Gedurende het hele traject had ik op maandagavond altijd even een
uitlaatklep: de repetities van Collegium Musicum. Een heel gezellige
vereniging waar je eigenlijk niet weg wilt, maar ja je moet een keer
ophouden. Met name wil ik Marleen noemen voor haar kritische blik op
de Nederlandse samenvatting (ik begin nooit meer een Nederlandse zin
met ‘Echter’) en Sander voor het leveren van het programma Pagemaker.
En last but not least: mijn ouders! Omdat ik niet beter weet, is het zo
gewoon dat ik altijd terug kan vallen op jullie en jullie altijd voor me klaar
staan wat er ook gebeurt. Maar nu ik er even bij stil sta vind ik het toch
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